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ABSTRACT
Interferon (IFN) and phosphatidylinositol 3-kinase (PI3K) are apoptosis regulators
that are targeted by viruses to promote survival of infected cells. Significant crosstalk
exists between IFN and PI3K, and this study sought to investigate the relationships
between IFN, PI3K and apoptosis during virus infection. Parainfluenza virus 5 (PIV5)
and influenza A virus (IAV) are both negative-sense single-stranded RNA viruses
that encode multifunctional proteins in order to maximise their genome coding
capacity. The PIV5 V and IAV NS1 proteins are well-studied as IFN antagonists and,
in addition, both are reported to modulate PI3K signalling. Less well-studied is the
role of these proteins in apoptosis regulation; the ability of V and NS1 to inhibit
apoptosis was therefore investigated. PIV5/V was found to limit cell death in
response to a number of apoptosis inducers in a manner that required its STAT1-
degradative activity and also inhibited activation of the PI3K downstream target, Akt.
IAV/NS1 binds directly to PI3K to stimulate its activity, and this is reported to mediate
anti-apoptotic signalling during IAV infection. However, a virus expressing an NS1
unable to bind PI3K did not induce more apoptosis than wt virus. NS1 expression,
either in a stable cell-line or during virus infection, was also unable to protect cells
from pro-apoptotic stimuli. NS1-mediated PI3K activation similarly had no effect on
IFN production or ISG expression in infected cells. In contrast, other NS1 mutant
viruses induced large amounts of apoptosis. These viruses also induced significant
levels of IFN and were unable to cause apoptosis in IFN-deficient cells, indicating
that NS1 limits apoptosis induction through its IFN antagonist functions. The
implications of this work for anti-cancer and anti-viral therapies are discussed.
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11 INTRODUCTION
Limiting virus replication and spread is of major importance to the host cell. Prior to
activation of the adaptive immune response, innate antiviral mechanisms can
severely impair virus replication and are often sufficient to clear a viral infection. Virus
adsorption and entry to the host cell can be prevented by circulating neutralising
antibodies which bind to the viral capsid or envelope. These include ‘natural’ or
spontaneous antibodies present in the sera of non-immunised humans which
significantly reduce viral titre in peripheral organs (Ochsenbein et al., 1999,
Ochsenbein and Zinkernagel, 2000, Gobet et al., 1988). In addition, the complement
cascade can result in the direct coating of virions with complement components,
thereby preventing virus entry and promoting phagocytosis or even lysis of the virus
(Lachmann and Davies, 1997). If these first defenses fail (or the virus is able to
overcome them) and the virus enters the cell, a whole host of intracellular and
humoral pathways are activated that restrict virus replication. Detection of viral
components by the cell rapidly stimulates the interferon (IFN) response and induction
of apoptosis; viral replication is subsequently inhibited and virus-infected cells are
effectively cleared by phagocytic immune cells, limiting virus spread. Both IFN and
apoptosis are so efficient at hampering virus infections that many (if not all) viruses
express viral inhibitors of these responses. In the following sections, induction of IFN
in response to infection, IFN signal transduction and the establishment of the IFN-
induced antiviral state will be examined. The role of apoptosis as an essential arm of
the antiviral response and apoptosis regulation by IFN and phosphatidylinositol 3-
kinase (PI3K) will be discussed. Finally the mechanisms by which viruses (in
particular parainfluenza virus 5 [PIV5] and influenza A virus [IAV]) inhibit IFN and
apoptosis are described.
1.1 The IFN response
The IFN family of cytokines are secreted in response to virus infection and elicit an
‘antiviral state’ in cells by upregulating expression of many genes, including those
involved in inhibiting protein synthesis, inhibiting cell growth and promoting
apoptosis. As a result, the host cell becomes a highly unfavourable environment for
virus replication. Three groups of IFNs exist. In humans, type I IFNs are a large
group of molecules that are further split into five classes: IFN-α (of which there are
twelve different subtypes), IFN-β, and the more recently characterised IFN-ε, IFN-κ 
and IFN-ω. Type II IFNs comprise IFN-γ only, and type III IFNs include IFN-λ1 (IL-
229), IFN-λ2 (IL-28A) and IFN-λ3 (IL-28B). Virus infection induces expression of IFN-
α, IFN-β and IFN-ω, with the ratio and absolute levels of production of these classes 
varying with cell type and viral stimuli (Pestka et al., 2004), while IFN-γ is produced 
by activated T-lymphocytes and natural killer (NK) cells.
1.1.1 Induction of the IFN-β gene
Given the huge variety in virus modes of entry and replication, there exist a number
of different ways by which the host cell can detect a virus infection. IFN can be
induced in response to a number of viral stimuli, including viral proteins and nucleic
acids. Production of IFN-β in fibroblasts following virus infection or treatment with
synthetic double-stranded RNA (dsRNA) has been intensively studied. This is
considered to be the best model of IFN-induction and will be described here. The
different virus detection pathways co-ordinate assembly of several transcription
factors at the IFN-β promoter to stimulate IFN-β transcription; IFN-β induction
therefore occurs without the need for de novo protein synthesis. The minimal events
required for IFN-β transcription are activation of the IFN regulatory factor 3 (IRF3)
and nuclear factor kappa B (NF-kB) transcription factors, recognition sites for which
exist in the IFN-β promoter. Latent IRF3 exists in the cytoplasm as a monomer but
dimerises and translocates to the nucleus upon its activation by virus infection (Lin et
al., 1998b, Dragan et al., 2007). Similarly, inactive NF-kB is retained in the cytoplasm
by its inhibitor, inhibitor of NF-kB (IkB). Following the appropriate signal, IkB
becomes phosphorylated by IKK (IkB kinase), leading to its ubiquitination and
subsequent degradation. Removal of IkB-mediated inhibition allows NF-kB to
translocate to the nucleus and regulate transcription from NF-kB-responsive
promoters. An additional transcription factor, activator protein 1 (AP-1), is required for
maximal induction of the IFN-β gene (Wathelet et al., 1998). IRF3, NF-kB and AP-1,
in the presence of high mobility group (HMG1) proteins, together form the
‘enhanceosome’ (Thanos and Maniatis, 1995). The enhanceosome recruits the co-
activator cAMP-responsive-element binding protein (CREB)-binding protein
(CBP)/p300 to initiate IFN-β transcription (Merika et al., 1998).
Type I IFNs have been divided into two classes (‘primary’ and ‘secondary’) according
to their temporal expression during virus infection. As detailed above, the IFN-β gene
is a primary IFN gene that requires no new protein synthesis for its expression in
response to viral stimuli. IFN-β stimulates expression of IRF7, a transcription factor
that is essential for transcription of secondary IFN-α genes, in the continual presence
3of viral stimuli (Sato et al., 1998, Marie et al., 1998). In most cell-types, IRF7 is
expressed at very low or undetectable levels; as a result, in these cells, IFN-β is
required for induction of IRF7 and IFN-α (Erlandsson et al., 1998, Yeow et al., 2000).
IRF7 can additionally bind to the IFN-β promoter to upregulate transcription in a
positive feedback mechanism (Wathelet et al., 1998, Panne et al., 2007). In
plasmocytoid dendritic cells (pDCs) however, massive amounts of IFN-α are
produced early in virus infection: this is due to constitutive IRF7 expression in these
cells (Prakash et al., 2005).
1.1.2 Detection of virus infection by the host cell
1.1.2.1 The Toll-like receptors
Toll-like receptors (TLRs) are membrane-bound glycoproteins: they comprise
extracellular leucine-rich repeats that mediate recognition of pathogen-associated
molecular patterns (PAMPs) and an intracellular TIR (Toll/Interleukin-1 resistance)
domain that mediates recruitment of downstream signalling proteins (Akira and
Takeda, 2004). Binding of PAMPs to the TLR promotes receptor dimerisation and
subsequent changes in receptor conformation. This permits the TIR domain to recruit
adaptor proteins (the nature of which varies with the TLR) and initiate downstream
signalling.
Detection of extracellular or endosomal viral dsRNA
dsRNA, produced during replication of positive-stranded RNA viruses and DNA
viruses (Weber et al., 2006), is exceptionally efficient at inducing IFN (Marcus, 1983).
Cells can rapidly respond to extracellular dsRNA (present in the culture medium) or
dsRNA internalised by the cell via the endosomal pathway. The cellular dsRNA
receptor responsible for this was identified as TLR3 (Alexopoulou et al., 2001), which
is essential for defence against certain viruses (Tabeta et al., 2004, Zhang et al.,
2007). TLR3 is expressed in endosomes (and also at the cell surface in fibroblasts)
(Matsumoto et al., 2003, Johnsen et al., 2006); presence of TLR3 in these
compartments allows detection of extracellular viral dsRNA or endosomal dsRNA
(formed following virus uncoating) without the requirement for virus replication.
Downstream of TLR3 stimulation, NF-kB and IRF3 activation occurs via the TRIF
(TIR domain-containing adaptor inducing IFN-β) adaptor protein and members of the
4TNF receptor-associated factor (TRAF) family (Figure 1.1A, Yamamoto et al., 2002,
Yamamoto et al., 2003, Hoebe et al., 2003, Jiang et al., 2004, Hacker et al., 2006).
TRIF binds TLR3 and recruits the E3 ligase TRAF6 and the receptor-interacting
protein RIP1 (Sato et al., 2003, Cusson-Hermance et al., 2005, Meylan et al., 2004);
TRAF6 subsequently catalyses the Lys63 polyubiquitination of itself and RIP1. These
polyubiquitin chains mediate association of TRAF6 and RIP1 with the TAK1 binding
proteins TAB2 and TAB3 (Kanayama et al., 2004, Chen, 2005, Deng et al., 2000).
TAK1 (transforming growth factor β-associated kinase 1) and IKK are recruited to this
protein complex through their interactions with TAB2/TAB3 and polyubiquitinated
RIP1 respectively (Wang et al., 2001a, Ea et al., 2006, Li et al., 2006a, Wu et al.,
2006). IKK is heterotrimeric and comprises the catalytic subunits IKKα and IKKβ, and
the regulatory subunit IKKγ/NEMO (DiDonato et al., 1997, Mercurio et al., 1997,
Zandi et al., 1998, Rothwarf et al., 1998). The IKK complex is activated through
TAK1-dependent phosphorylation of IKKβ (Wang et al., 2001a) which results
indirectly in NF-kB activation through inactivation of IkB. TRIF activates IRF3 through
its association with TRAF3 (Hacker et al., 2006, Oganesyan et al., 2006). A TRAF3-
dependent protein complex forms, comprising the TRAF-associated NF-kB activator,
TANK (Li et al., 2002), TANK-binding kinase 1 (TBK1) and IKKε (Sharma et al.,
2003, Fitzgerald et al., 2003, Hemmi et al., 2004). TBK1 and IKKε catalyse IRF3
phosphorylation to promote its nuclear translocation, and in this respect these two
kinases appear to be functionally redundant (Hemmi et al., 2004). In addition to their
effects on IRF3, TBK-1 and IKKε can also phosphorylate and activate IRF7 (Sharma
et al., 2003).
Detection of endosomal viral ssRNA and DNA
pDCs secrete large amounts of IFN in response to viral nucleic acids (Colonna et al.,
2004), but they do not express TLR3 (Kadowaki et al., 2001). They do, however,
express an abundance of TLR7 and TLR9 in their endosomal compartments (Diebold
et al., 2004, Kadowaki et al., 2001, Jarrossay et al., 2001). Studies involving virus-
derived or synthetic single-stranded RNA (ssRNA) have revealed that TLR7 is
required for ssRNA-induced IFN production (Heil et al., 2004, Diebold et al., 2004)
and for recognition of ssRNA viruses such as IAV and vesicular stomatitis virus
(VSV) (Lund et al., 2004). In contrast, TLR9 recognises unmethylated CpG motifs
present in viral DNA (Hemmi et al., 2000, Rutz et al., 2004, Abe et al., 2005) and is
required for recognition of DNA viruses including herpes simplex virus-1 (HSV-1) and
human cytomegalovirus (HCMV) (Krug et al., 2004a, Krug et al., 2004b).
AP-1
AP-1
(A)
(B)
TRADD
AP-1
Figure 1.1: Induction of IFN-b by viral nucleic acid.
Pathways of TLR3 (A), TLR 7 and 9 (B), and RIG-I/mda-5 (C) signalling in response 
to viral nucleic acids are shown. Downstream signalling from these receptors 
requires TRIF, MAVS or MAVS adaptor proteins respectively. TRAFs bind these 
adaptors to orchestrate the assembly of multi-protein complexes that activate the 
IRF3 (or IRF7) and NF-kB transcription factors. Once activated, IRFs and NF-kB 
translocate to the nucleus where they stimulate transcription of the IFN-b gene.
Modified from Randall and Goodbourn, 2008. 
(C)
5Observations that TLR7 and TLR9 are absent from the pDC cell surface (Kawai and
Akira, 2006) and that intact endocytic pathways are required for TLR7-mediated IFN-
induction (Lund et al., 2004, Lund et al., 2003) indicate that virus internalisation is
required before viral nucleic acid can be detected by TLR7/9. Viral genomes possess
characteristics, for example the CpG motifs recognised by TLR9, that distinguish
them from cellular nucleic acids. Even so, host RNA and DNA have been reported to
activate TLRs (Diebold et al., 2004, Kariko et al., 2004). Consequently, it is thought
that nucleoside modifications and/or subcellular localisation play a critical role in
distinguishing host and viral nucleic acids (Kariko et al., 2005, Crozat and Beutler,
2004, Ishii and Akira, 2005).
TLR7 and TLR9 activate downstream signalling through the adaptor myeloid
differentiation primary-response protein 88 (MyD88; Figure 1.1B) (Krug et al., 2004b,
Lund et al., 2004). MyD88 recruits a protein complex consisting of IRAK1 and IRAK4
(IL-1 receptor-associated kinases) and TRAF6 to the TLR. TRAF6 mediates
activation of IKK by a TAB2/3 and TAK1-dependent mechanism similar to signalling
downstream of TLR3. In pDCs, IRF7 is the predominant IRF activated early in
infection (Prakash et al., 2005); IRF7, not IRF3, is activated by TLR7 and TLR9 in
these cells. The MyD88/IRAK1/IRAK4/TRAF6 complex directly binds to IRF7 (Honda
et al., 2004, Uematsu et al., 2005) through a process that may also be dependent on
ubiquitinated RIP1 (Huye et al., 2007). IRF7 becomes ubiquitinated by the E3 ligase
activity of TRAF6 (Kawai et al., 2004); subsequent phosphorylation by IRAK1 allows
IRF7 to translocate to the nucleus to stimulate transcription (Uematsu et al., 2005).
1.1.2.2 Cytoplasmic nucleic acid receptors
Detection of cytoplasmic RNA
TLR3 appears to play a dispensable role in the antiviral response to certain dsRNA,
ssRNA and DNA viruses (Edelmann et al., 2004) and mice lacking either TLR9 or
MyD88 are still able to control local HSV-1 infection (Krug et al., 2004b). These data
indicate that virus infection can be detected by additional, TLR-independent
mechanisms. The IFN-inducible RNA helicases RIG-I (retinoic acid-inducible gene
product I) and mda-5 (melanoma differentiation-associated gene-5) have been
identified as two such TLR-independent viral nucleic acid detectors (Yoneyama et al.,
2004, Andrejeva et al., 2004), and disruption of RIG-I or mda-5 genes prevents virus-
induced IFN expression (Yoneyama et al., 2005). These proteins carry a C-terminal
6helicase domain with ATPase activity and two caspase-recruitment domains
(CARDs) at their N-terminus. Activation of RIG-I and mda-5 by viral nucleic acid
induces a conformational change that exposes the CARDs so they can mediate
downstream protein-protein interactions (Yoneyama et al., 2004). The CARDs of
both proteins bind the mitochondrial antiviral signalling protein, MAVS. MAVS, which
is anchored to the outer mitochondrial membrane, acts as an adaptor to recruit
signalling molecules that lead to NF-kB and IRF3 activation and resultant IFN-β gene
transcription (Figure 1.1C, Seth et al., 2005, Kawai et al., 2005, Meylan et al., 2005).
NF-kB activation occurs through an association between MAVS and tumour necrosis
factor receptor (TNFR1)-associated death domain protein (TRADD). TRADD
orchestrates formation of a complex containing TRAF3, TRAF6, TANK, RIP1 and
FADD (Balachandran et al., 2004, Kawai et al., 2005, Michallet et al., 2008, Xu et al.,
2005). IKKγ/NEMO is recruited to this complex to activate IRF3 by a TBK1/IKKε-
dependent pathway and NF-kB through activation of IKK (Zhao et al., 2007). MAVS
can also stimulate a non-canonical pathway of NF-kB activation (see later, Section
1.1.3.4): the RIG-I:MAVS complex interacts with IKKα and NF-kB-inducing kinase
(NIK) to stimulate the processing of p100/ NF-kB2 to p52 (Liu et al., 2008b).
The RIG-I:MAVS interaction requires Lys63-ubiquitination of the RIG-I CARD by the
E3 ligase TRIM25; TRIM25 knockout cells are subsequently unable to produce IFN-β
in response to Sendai virus (SeV) infection (Gack et al., 2007). The same
modification is not required for signalling downstream of mda-5 (Gack et al., 2007),
however mda-5 may be subject to negative regulation by dihydroxyacetone kinase
(DAK) in quiescent cells (Diao et al., 2007). Signalling from both RIG-I and mda-5 is
also negatively regulated by the RIG-I-related IFN-inducible helicase LGP2. This
protein lacks the CARDs required for downstream signalling so it was suggested that
LGP2 antagonism of IFN-induction occurred through RNA sequestration (Yoneyama
et al., 2005, Rothenfusser et al., 2005). However, LGP2-mediated inhibition may be
more complex, as LGP2-deficient mice are more sensitive to viruses that activate
mda-5 than those that activate RIG-I signalling (Venkataraman et al., 2007).
Ubiquitination by the E3 ligase RNF125 and subsequent degradation of RIG-I, mda-5
and MAVS has also been demonstrated, resulting in suppression of IFN-induction in
response to dsRNA or SeV infection (Arimoto et al., 2007). RNF125 is itself an
interferon-stimulated gene (ISG) product, indicating that this ubiquitination represents
a negative feedback regulation loop. MAVS activity is negatively regulated by NLRX1
which co-localises with MAVS at the mitochondrial membrane and prevents its
interaction with RIG-I and mda-5 (Moore et al., 2008).
7While both RIG-I and mda-5 are activated by synthetic dsRNA [poly(I:C)] (Andrejeva
et al., 2004, Yoneyama et al., 2004), their activities are not redundant. Studies using
mda-5-knockout mice revealed that mda-5 recognises poly(I:C) while RIG-I detects in
vitro transcribed dsRNAs (Kato et al., 2006), suggesting RIG-I and mda-5 may
recognise different dsRNA structures. It has since been shown that RIG-I recognises
viral genomic RNA bearing uncapped 5’-triphosphates (Hornung et al., 2006,
Pichlmair et al., 2006). Since cellular RNAs are 5’-capped during post-transcriptional
processing, they are not recognised by RIG-I whereas in vitro transcribed RNAs do
carry a 5’-phosphate, and therefore activate RIG-I signalling (Hornung et al., 2006).
In support of their differential roles in viral RNA detection, RIG-I and mda-5 mediate
detection of different types of viruses to different extents. For instance, RIG-I, but not
mda-5, signalling is activated following infection with paramyxoviruses and IAV while
mda-5, but not RIG-I, is required for detection of picornavirus infection (Gitlin et al.,
2006, Loo et al., 2008, Pichlmair et al., 2006, Berghall et al., 2006, Kato et al., 2006).
Viruses recognised by RIG-I transiently produce uncapped 5’-triphosphorylated
mRNAs during their replication (Hornung et al., 2006), while picornavirus infection
does not activate RIG-I as the 5’ ends of picornavirus RNAs are covalently linked to
the VPg protein throughout the virus life cycle (Lee et al., 1977). Infection with
reoviruses and flaviviruses however, trigger both RIG-I and mda-5-mediated innate
immune responses (Loo et al., 2008), indicating either a degree of overlap in
recognised structures or the production of different RNA species during the life cycle
of these viruses.
Recently, an additional pathway of NF-kB and IRF3 activation has been identified;
this pathway requires stimulator of interferon genes (STING) which localises to the
ER membrane and associates with the translocon. STING is required for induction of
type I IFN genes in response to the negative-stranded RNA virus VSV and co-
precipitates with RIG-I (Ishikawa and Barber, 2008). RIG-I and STING may therefore
function to detect viral RNAs that are being translated by the host translational
machinery. The signalling molecules downstream of STING that lead to NF-kB and
IRF3 activation have yet to be identified.
Detection of cytoplasmic DNA
Evidence is mounting that a cytoplasmic DNA sensor exists to activate IFN
expression by a TLR9-independent pathway: direct introduction of dsDNA into the
cytoplasm triggers expression of IFN in a TBK-1/IKKε/IRF3-dependent manner (Ishii
8et al., 2006, Stetson and Medzhitov, 2006). The IFN-inducible Z-DNA-binding protein
1 (ZBP1) is a candidate for this DNA sensor. ZBP1 binding to dsDNA promotes its
dimerisation and enhances its interactions with TBK1 and IRF3 to activate IFN-β
transcription (Takaoka et al., 2007, Wang et al., 2008). Additionally, siRNA-mediated
knockdown of ZBP1 impairs antiviral responses to the DNA virus HSV-1 but not the
RNA virus Newcastle disease virus (NDV) (Takaoka et al., 2007). The downstream
signalling molecules involved in the activation of IFN expression by DNA remain to
be fully elucidated, but it has been suggested that dsDNA activates antiviral
signalling through a RIG-I/MAVS-dependent pathway (Cheng et al., 2007). Indeed,
STING (see above) has also been implicated in the recognition of intracellular DNA
and DNA virus infection (Ishikawa and Barber, 2008).
1.1.3 Signalling pathways activated by IFN
Cytokines, growth factors and hormones exert their intracellular effects through
interaction with, and activation of, membrane-bound receptors. Following binding of
the appropriate ligand, these receptors undergo rapid tyrosine phosphorylation.
While growth factor receptors contain intrinsic tyrosine kinase activity, most cytokine
receptors do not and require receptor-associated protein tyrosine kinases (PTKs) for
their phosphorylation. The Janus kinase (JAK) family of PTKs are responsible for
downstream signalling from a wide variety of cytokines, including IFNs and
interleukins (Burfoot et al., 1997, Johnston et al., 1995, Platanias et al., 1996, Darnell
et al., 1994). In quiescent cells, JAKs are associated with cytokine receptors in an
enzymatically inactive form. Regions in the N-terminus of JAKs are essential for both
receptor association and downstream signalling (Chen et al., 1997, Gauzzi et al.,
1997, Frank et al., 1995). Several features of JAKs distinguish them from other
classes of PTKs. Firstly, they possess two kinase-like domains at their C-terminus,
JAK homology 1 (JH1) and JH2. Only the JH1 domain appears to have functional
tyrosine kinase activity, while JH2, which lacks certain residues critical for enzymatic
activity, negatively regulates JAK activity and prevents its activation in the absence of
ligand stimulation (Luo et al., 1997, Saharinen et al., 2000). Following ligand-binding,
oligomerisation of receptors causes local aggregation of JAKs at the intracellular
membrane surface, and results in their activation through auto- or trans-
phosphorylation (Rane and Reddy, 2000). Active JAKs subsequently phosphorylate
the receptors at specific tyrosine residues; these phosphotyrosines recruit
downstream Src-homology 2 (SH2) domain-containing signalling molecules, such as
the signal transducers and activators of transcription (STATs) and
9phosphatidylinositol 3-kinase (PI3K). IFN stimulation can therefore trigger a number
of intracellular signalling pathways through its activation of JAKs (reviewed in
Takaoka and Yanai, 2006).
1.1.3.1 STAT signalling
The STATs
In humans, the STAT family comprises seven members, STAT1-4, STAT5a, STAT5b
and STAT6, which can homo- or heterodimerise and activate transcription in
response to cytokine stimulation (reviewed by Schindler and Plumlee, 2008). Each
STAT protein contains seven conserved domains, including a DNA-binding domain,
a coiled-coil domain that mediates interactions with regulatory proteins, an SH2
domain that mediates receptor association and dimerisation, a tyrosine activation
motif and a transcriptional activation domain containing serine phosphorylation sites
that facilitate coactivator recruitment. The STATs most critical for IFN signalling are
STAT1 and STAT2.
STAT activation by type I IFNs
STATs are the best characterised JAK substrates and JAK/STAT signalling is known
as the ‘classical’ pathway of IFN signal transduction (Du et al., 2007). Activation of
classical STAT signalling is depicted in Figure 1.2. Type I IFNs (IFN-α and IFN-β)
bind to the IFN-α/β receptor (IFNAR), which comprises two subunits, IFNAR1 and
IFNAR2 (Novick et al., 1994). Prior to receptor stimulation, the intracellular domains
of IFNAR1 and IFNAR2 are physically associated with the cytoplasmic JAKs Tyk2
and JAK1 respectively (Novick et al., 1994, Abramovich et al., 1994, Muller et al.,
1993, Colamonici et al., 1994). IFNAR2 additionally associates with STAT2 prior to
activation by IFN, and STAT1 is also recruited to IFNAR through a weak interaction
with STAT2 (Stancato et al., 1996, Precious et al., 2005a). IFN-α/β binding to IFNAR
induces receptor dimerisation and conformational change that results in tyrosine
phosphorylation of IFNAR1 (at Tyr466) by Tyk2. This phosphotyrosine enables a
strong association between IFNAR1 and STAT2, and STAT2 is subsequently
phosphorylated by Tyk2 at Tyr690. STAT2 phosphorylation is required for
subsequent STAT1 phosphorylation by JAK1 at Tyr701 (Leung et al., 1995). STAT1
and STAT2 are now able to form stable heterodimers and expose a non-classical
nuclear localisation signal (NLS) that promotes their nuclear import (Melen et al.,
Figure 1.2: Classical JAK/STAT signalling activated by type I IFN.
Binding of IFN-a/b to IFNAR activates the tyrosine kinases JAK1 and Tyk2, which 
phosphorylate tyrosine residues in STAT1 and STAT2. STAT1 and STAT2 then 
strongly associate through their SH2 domains and associate with IRF9 to form the 
ISGF3 transcription factor. In the nucleus, ISGF3 stimulates transcription from ISRE 
elements in the promoters of IFN-stimulated genes.
From Randall and Goodbourn, 2008. 
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2003, Fagerlund et al., 2002). STAT1 and STAT2 remain in the nucleus until their
dephosphorylation leads to the exposure of nuclear export signals (NESs) and their
export to the cytoplasm (McBride et al., 2000, Banninger and Reich, 2004). Through
a direct interaction with STAT2, IRF9 is recruited to the STAT1/STAT2 heterodimer
to form the interferon-stimulated gene factor 3 (ISGF3) (Martinez-Moczygemba et al.,
1997, Veals et al., 1992). Reports that IRF9 can directly bind to IFNAR2 and that
STAT2 and IRF9 associate even in the absence of IFN-stimulation indicate that
ISGF3 formation may occur at the IFNAR (Tang et al., 2007b, Martinez-Moczygemba
et al., 1997). Once in the nucleus, ISGF3 binds to, and activates transcription from,
interferon-stimulated response elements (ISREs) that occur upstream of IFN-α/β-
responsive genes (Kessler et al., 1990, Levy et al., 1989).
The formation of additional STAT dimers in response to type I IFN, such as STAT1,
STAT3, STAT4 or STAT6 homodimers, or STAT1/3, STAT1/4, STAT1/5, STAT2/3 or
STAT5/6 heterodimers, has also been described (Darnell, 1997, Stark et al., 1998,
Meinke et al., 1996, Platanias, 2005, Farrar et al., 2000, Torpey et al., 2004,
Matikainen et al., 1999, Fasler-Kan et al., 1998). These dimers bind to gamma-
activated sequence (GAS) elements in the promoters of ISGs to activate their
transcription (Figure 1.3). Formation of these different STAT dimers allows for
differential regulation of ISG subsets. Some ISG promoters contain ISREs, some
contain GAS elements and some contain both; as a result, combinations of STAT
dimers may be required for the maximal expression of an ISG (Platanias, 2005).
Different STAT dimers appear to display divergent biological activities which may
account for the wide range of biological activities induced by IFN. For example,
during virus infection both in vitro and in vivo, IFN-α-induced secretion of IFN-γ is 
negatively regulated by STAT1 but activated by STAT4. (Nguyen et al., 2002b).
STAT activation by type II IFNs
Type II IFN (IFN-γ) induction of JAK/STAT signalling shares many common features 
with type I IFN stimulation. Like IFNAR, the IFN-γ receptor (IFNGR) is composed of 
two distinct subunits, IFNGR1 and IFNGR2. Similarly, the cytoplasmic domains of
the receptor associate with JAKs: IFNGR1 and IFNGR2 bind to JAK1 and JAK2
respectively (Igarashi et al., 1994). IFN-γ stimulation causes receptor dimerisation 
which results in the sequential activation of JAK2 and JAK1. The JAKs mediate
phosphorylation of IFNGR1 to form two binding sites for STAT1, which subsequently
recruit two molecules of STAT1 through their SH2 domains. STAT1 is activated by
Figure 1.3: Signalling downstream of the IFN receptors.
Signalling pathways activated downstream of the type I IFN (IFN a/b), type II IFN (IFN-g) and type III IFN (IFN-l) receptors are shown. All of them 
activate ‘classical’ STAT signalling but additional ‘non-classical’ pathways can also be activated. Stimulation with type I IFN recruits Crk/CrkL to the 
IFN receptor, where it becomes phosphorylated by Tyk2 and forms a heterodimer with phosphorylated STAT5. STAT5/Crk translocates to the nucleus 
to stimulate GAS-dependent gene transcription. Additinal STAT dimers can also form; for example, STAT4 homodimers are induced by certain 
subtypes of IFN-a in T-cells. PI3K signalling is activated downstream of the type I IFN receptor through phosphorylated IRS proteins (with a possible 
role for STAT3; see text for details). Active PI3K stimulates Akt and PKC-d activity. In addition, ERK2 and p38 MAPK signalling can be activated, 
promoting STAT1 serine phosphorylation; MAPK signalling is not discussed in this thesis, but is reviewed in Li et al., 2007.
From Takaoka and Yanai, 2006.
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phosphorylation at Tyr701, resulting in its dissociation from the receptor. SH2
domains then mediate STAT1 homodimerisation and STAT1/STAT1 dimers (also
called GAF; gamma-activated factor) translocate to the nucleus and activate
transcription from GAS elements in the promoters of IFN-γ-responsive genes.
STAT regulation
IFN-induced tyrosine phosphorylation of STATs is required for their homo- and
heterodimerisation and subsequent nuclear translocation. However, for maximal
transcriptional activity, STATs also require additional biochemical modifications and
recruitment of additional cellular proteins. The STATs are also negatively regulated
through the activities of protein phosphatases and the suppressor of cytokine
signalling (SOCS) family.
Serine phosphorylation
Treatment with both type I and type II IFNs induces the serine phosphorylation of
STAT1 at Ser727, near its C-terminus (Wen et al., 1995). Serine phosphorylation of
STAT1 has been attributed to several kinases, including PKC-δ, PKC-ε,
calcium/calmodulin-dependent protein kinase II (CaMKII) and the ERK2 and p38
MAP kinases (MAPKs), depending on the cell-type (Uddin et al., 2002, Deb et al.,
2003, Choudhury, 2004, Nair et al., 2002, David et al., 1995, Gollob et al., 1999).
This modification is independent of tyrosine phosphorylation and has no effect on
STAT1 dimerisation, nuclear translocation or DNA binding affinity, but enhances
transcriptional activity at a subsequent stage (Wen and Darnell, 1997, Decker and
Kovarik, 2000). Ser727 phosphorylation allows STAT1 to more efficiently recruit the
transcriptional coactivators p300, CBP, and minichromosome maintenance protein 5
(MCM5) (Varinou et al., 2003, Zhang et al., 1998). p300/CBP enhances transcription
from ISGs by causing local chromatin remodelling (Zhang et al., 1998) while MCM5
possesses helicase activity (Shuai, 2000). Expression of IFN-γ-induced genes is
strongly reduced in macrophages expressing a STAT1 mutant that is unable to
undergo Ser727 phosphorylation; this suggests serine phosphorylation is required for
IFN-γ-dependent innate immunity (Varinou et al., 2003). A recent study revealed that
Ser727 phosphorylation is required for the subsequent SUMOylation of STAT1 and
therefore plays a role in the co-ordination of STAT1 cellular responses (Vanhatupa et
al., 2008).
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ISGylation
STAT1 can be conjugated to ISG15, a small, ubiquitin-like protein that is upregulated
by IFN (Malakhov et al., 2003). Stabilising ISGylation by knocking out UBP43, the
protease responsible for removing ISG15 from ISGylated proteins, renders mice
hypersensitive to IFN-β. This was found to be due to prolonged STAT1 tyrosine
phosphorylation and enhanced ISG expression, indicating that STAT1 ISGylation is
required for regulation of JAK/STAT signalling (Malakhova et al., 2003). However,
more recent studies have concluded that STAT1 ISGylation is not essential for
STAT1 signalling responses to IFN or virus infection. The IFN hypersensitivity of
UBP43 (-/-) mice was shown to be ISG15-independent and ISG15 (-/-) mice
displayed no obvious alterations in phenotype (Osiak et al., 2005, Knobeloch et al.,
2005, Kim et al., 2006). The biological implications of STAT1 ISGylation therefore
remain to be fully elucidated.
SUMOylation
SUMOylation of STAT1 at Lys703 by members of the protein inhibitors of activated
STAT (PIAS) family, which are known to inhibit STAT1 activity, has also been
reported (Ungureanu et al., 2003, Rogers et al., 2003). PIAS1 interacts with STAT1
to inhibit STAT1-dependent gene expression (Liu et al., 1998). Ungureanu et al.
reported that IFN-γ-treatment induces STAT1 SUMO conjugation through PIAS1 and
that mutation of Lys703 enhances transcription from GAS elements, implicating
SUMO modification in the negative regulation of STAT signalling (Ungureanu et al.,
2003, Ungureanu et al., 2005). However, Rogers et al. implicate PIAS-α, not PIAS1,
STAT1-SUMO conjugation, and demonstrate that SUMOylation has no effect on the
ability of STAT1 to activate transcription (Rogers et al., 2003). Further studies are
therefore required to clarify the role of SUMO modification in STAT signalling.
Ubiquitination
Polyubiquitination of STAT1 has been reported in HeLa cells (Kim and Maniatis,
1996) and leads to its degradation by the proteasome. Ubiquitinated STAT1 is
targeted to the proteasome by the E3 ligase SLIM (STAT1-interacting LIM protein),
the overexpression of which leads to a reduction in STAT1 activity due to enhanced
STAT1 degradation (Tanaka et al., 2005b). However, STAT1 ubiquitination is not
thought to play a significant role in IFN signalling.
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Methylation
STAT1 can be methylated by the protein arginine methyl-transferase PRMT1 at
Arg31 and methylation at this site enhances the DNA binding activity of STAT1
(Mowen et al., 2001). This has, however, been refuted by subsequent studies and
the validity of the experimental methods utilised by Mowen et al. brought into
question (Meissner et al., 2004, Komyod et al., 2005).
Acetylation
Acetylation/deacetylation of histones by p300/CBP enhances IFN-dependent
transcription by STATs (see above). Additionally, histone acetyltransferases (HATs)
can directly acetylate STAT1 at Lys410 and Lys413 (Kramer et al., 2006). This
modification functions as a molecular switch that promotes the association of STAT1
with the p65 subunit of NF-kB to inhibit NF-kB nuclear translocation, DNA binding
and the expression of NF-kB-responsive genes. In the absence of deacetylase
activity, innate antiviral responses are impaired, indicating that
acetylation/deacetylation, either of histones or of the STAT1 protein, plays a pivotal
role in the IFN response (Nusinzon and Horvath, 2003); indeed, IFN-α has been
reported to induce STAT1 acetylation (Kramer et al., 2006). Inhibition of histone
deacetylases (HDACs) reduces IFN-α-induced transcription without affecting STAT1
tyrosine phosphorylation, ISGF3 formation, nuclear translocation or DNA binding
activity (Nusinzon and Horvath, 2003). Similarly, HDAC inhibitors inhibit IFN-β
expression in response to virus infection or dsRNA (Nusinzon and Horvath, 2006).
The role of HDAC in type II IFN signalling may differ to type I IFN signalling: while
HDAC activity is also required for gene expression in response to type II IFN, HDAC
inhibitors prevented JAK1 activation and subsequent STAT1 tyrosine
phosphorylation and nuclear translocation (Klampfer et al., 2004).
A degree of crosstalk exists between the different modifications of STAT1. For
example, methylation at Arg31 inhibits association of STAT1 with PIAS1, which may
inhibit its SUMOylation (Mowen et al., 2001). Similarly, Ser727 phosphorylation of
STAT1 has been shown to promote its SUMOylation (Vanhatupa et al., 2008).
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Interaction with Crk proteins
Crk proteins are a family of adapters that are homologous to an oncogene encoded
by the CT10 avian sarcoma virus (Mayer et al., 1988). These proteins contain both
SH2 and Src-homology 3 (SH3) domains that mediate associations with a wide
range of signalling components (Feller, 2001). Crk proteins were first implicated in
the regulation of IFN signalling in a study by Ahmad et al., which demonstrated that
type I IFN treatment induced an association between CrkL (Crk-like protein) and
Tyk2, resulting in the rapid tyrosine phosphorylation of CrkL (Ahmad et al., 1997). A
later study reported a similar phosphorylation event following IFN-γ treatment 
(Alsayed et al., 2000). CrkL couples the IFN receptors to the guanine-nucleotide-
exchange factor (GEF) C3G, with which it interacts through its SH3 domain (Ingham
et al., 1996, Sawasdikosol et al., 1995, Smit et al., 1996). C3G is a GEF for Rap1, a
G-protein that possesses tumour suppressor activity (Gotoh et al., 1995, Kitayama et
al., 1989, Hattori and Minato, 2003). IFN-stimulation can therefore activate growth
inhibitory pathways through CrkL-dependent activation of Rap1 (Lekmine et al.,
2002, Platanias et al., 1999, Alsayed et al., 2000).
CrkL also has Rap1-independent effects on IFN-α/β-signalling. Type I IFN treatment
induces formation of a complex between CrkL and tyrosine-phosphorylated STAT5, a
complex which translocates to the nucleus, binds to GAS elements and enhances
ISG expression (Figure 1.3, Lekmine et al., 2002, Fish et al., 1999); indeed,
activation of STAT5 has been shown to be necessary for maximal transcription of
GAS-regulated genes (Uddin et al., 2003). One such gene is the promyelocytic
leukaemia (PML) protein that is involved in IFN-induced growth inhibition (Grumbach
et al., 2001, Takahashi et al., 2004).
SOCS
The SOCS proteins antagonise STAT function through direct inhibition of JAK activity
(Yasukawa et al., 1999, Sasaki et al., 1999) or by targeting signalling proteins, such
as JAKs or insulin receptor substrate (IRS) proteins, for degradation by the
proteasome (Frantsve et al., 2001, Kamizono et al., 2001, Rui et al., 2002). Their
expression is induced by IFNs; SOCS regulation of IFN therefore constitutes a
negative feedback loop.
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Protein tyrosine phosphatases
Since tyrosine phosphorylation of STATs plays such a critical role in their ability to
activate transcription, it comes as no surprise that protein tyrosine phosphatases can
negatively regulate STAT signalling by dephosphorylating tyrosine residues. The
SH2 domain-containing protein tyrosine phosphatases SHP1 and SHP2, among
others, have been implicated in returning both STATs and cytokine receptors to their
basal, unphosphorylated state (reviewed by Mustelin et al., 2005).
1.1.3.2 PI3K signalling
The PI3Ks
Although the JAK/STAT pathway has become synonymous with signalling
downstream of IFNs, it is now becoming clear that PI3K also plays an important role
in the IFN response. PI3Ks are involved in signal transduction from many cell surface
receptors, and consequently regulate many intracellular events including cell
survival, cell proliferation, metabolism, and cell movement (reviewed by Hawkins et
al., 2006). PI3K activation by IFN appears to counter many functions of STAT
signalling; for example JAK/STAT signalling upregulates many genes involved in
apoptosis while PI3K signalling promotes cell survival. The way in which cells
respond to IFN therefore appears to be subject to complex regulation, with PI3K and
STAT pathways (and perhaps other signalling pathways) competing to dictate the
outcome of the IFN response.
Three classes of PI3Ks exist which are further divided into subclasses, each with
different tissue distributions, substrate specificity and modes of activation (Fruman et
al., 1998). The primary function of the class IA PI3Ks is to catalyse phosphorylation
of the inositol ring (at position D3) of phosphatidylinositol lipids in response to
cytokines, growth factors and certain hormones (Cantley, 2002). The
phosphatidylinositol-3,4,5-trisphosphate (PIP3) product of this reaction functions as
an important second messenger that regulates multiple effector proteins (reviewed
by Hawkins et al., 2006, Rameh and Cantley, 1999, Cantley, 2002). Class I PI3Ks
are also reported to possess serine/threonine kinase activity and regulate
downstream proteins directly (Rameh and Cantley, 1999, Platanias et al., 1996,
Vanhaesebroeck et al., 1999, Stoyanova et al., 1997, Dhand et al., 1994). While this
protein kinase activity was initially thought to be a distinct kinase tightly associated
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with PI3K (Carpenter et al., 1993b), subsequent studies have shown it may be an
intrinsic activity to PI3K (Foukas et al., 2004, Dhand et al., 1994).
Regulation of PI3K activity
Class 1A PI3Ks are heterodimers made up of a p110 catalytic subunit and a
regulatory subunit (Wymann and Pirola, 1998). Three isoforms of the catalytic
subunit have been identified; p110α, p110β, and p110δ. The regulatory subunit is
encoded by one of three genes, p85α, p85β and p55γ, but splice variants of these 
gene products also exist. The regulatory subunit contains a B-cell receptor homology
(BH) domain, an SH3 domain and two SH2 domains that promote interactions with
signalling proteins and the catalytic subunit of PI3K. The p85 regulatory subunit
inhibits the lipid kinase activity of the catalytic subunit in quiescent cells and plays a
role in promoting conformational stability (Yu et al., 1998b). The importance of this
negative regulation is demonstrated by studies that show mutations in the p85-
binding site of p110 result in potent activation of PI3K and high oncogenicity (Zhao et
al., 2005b, Kang et al., 2005). Binding of p85 SH2 domains to phosphotyrosines (in a
consensus YXXM motif) within activated receptors or receptor-associated adaptor
proteins relieves its restraint on p110 catalytic activity (Carpenter et al., 1993a,
Rordorf-Nikolic et al., 1995, Yu et al., 1998a). p85-mediated recruitment of PI3K to
cell membrane receptors may itself affect p110 activation by increasing the effective
concentration of p110 phosphatidylinositol substrates (Vanhaesebroeck et al., 2005).
It has also been suggested that monomeric p85 can sequester SH2-binding protein
away from PI3K: free p85 competes with p85/p110 heterodimer for IRS-1 binding,
preventing PI3K activation downstream of the insulin receptor (Luo and Cantley,
2005). However, other reports indicate PI3K exists as an obligate heterodimer and
that monomeric p85 is unstable (Geering et al., 2007a, Geering et al., 2007b), so
p110 inhibition through sequestration may not occur in vivo.
p110 catalytic activity can also be modulated through post-translational modification
of p85. Src kinase mediates phosphorylation of p85 at Tyr688 which relieves its
inhibitory effect on p110 and activates PI3K (Cuevas et al., 2001). In contrast, serine
phosphorylation of p85 negatively regulates p110 catalytic activity (Foukas et al.,
2004). Furthermore, p110 is reported to mediate PI3K autoregulation by directly
phosphorylating p85 at Ser608 (Dhand et al., 1994, Vanhaesebroeck et al., 1999).
Ser608 phosphorylation is observed both in vitro and in vivo, and mutation of Ser608
affects PI3K heterodimerisation and enzymatic activity (Foukas et al., 2004).
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Moreover, defective p85 Ser608 phosphorylation, which leads to constitutive PI3K
activation, may be involved in the development of human colon and ovarian tumours
(Foukas et al., 2004, Philp et al., 2001).
Protein interactions that occur independently of the SH2 domains can also modulate
PI3K activity. Rho GTPases such as Rac1 and Cdc42 can bind p85 through its BH
domain to activate p110 (Tolias et al., 1995, Zheng et al., 1994b). Also important for
PI3K activation is binding of the active form (GTP-bound) of the Ras GTPase to a
Ras-binding domain in p110 (Rodriguez-Viciana et al., 1994). This interaction
elevates basal PI3K activity, indicating that Ras-binding has a direct effect on
catalytic activity (Rodriguez-Viciana et al., 1996).
The PTEN (phosphatase and tensin homologue deleted on chromosome ten) and
SHIP (SH2 domain-containing inositol 5’-phosphatases) phosphatases oppose PI3K
action by dephosphorylating PIP3 at the 3-position and the 5-position respectively.
The PIP2 products of this reaction can themselves signal to downstream pathways to
regulate cellular processes (reviewed by Hawkins et al., 2006). PTEN is well-
characterised as a tumour-suppressor and its mutation or silencing is implicated in a
number of human cancers (Li et al., 1997, Sansal and Sellers, 2004). In addition to
its negative regulation of the p110 catalytic subunit, p85α has been shown to
upregulate PTEN activity, thus negatively regulating the PI3K pathway (Taniguchi et
al., 2006).
PI3K activation by IFN
IRS-dependent activation
Like IFNAR and IFNGR-mediated activation of STATs, IFN receptors use PTKs as
mediators to signal to PI3K (Figure 1.3). Following type I IFN treatment, IFNAR-
associated Tyk2 recruits IRS-1 and IRS-2 through their pleckstrin homology (PH)
domains, resulting in their rapid phosphorylation at certain tyrosine residues
(Platanias et al., 1996, Uddin et al., 1995). Phosphotyrosines on IRS-1 and IRS-2
form docking sites for the SH2 domains of the p85 regulatory subunit of PI3K,
allowing for activation of p110 (Platanias et al., 1996, Uddin et al., 1995). Both
protein and phospholipid kinase activities of PI3K are activated by IFN-α treatment
(Uddin et al., 1995, Uddin et al., 1997).
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IRS-independent activation
IRS-independent activation of PI3K by IFN has also been reported. Type I IFN-
stimulated tyrosine phosphorylation of IFNAR1 was found to recruit STAT3 to the IFN
receptor. STAT3 acts as an adaptor that, through two phosphotyrosine residues,
provides a docking site for p85. Once bound to the receptor through STAT3, p85
itself undergoes tyrosine phosphorylation (Pfeffer et al., 1997), a modification that
activates PI3K catalytic activity (Cuevas et al., 2001). However, the involvement of
STAT3 in PI3K activation has been disputed by subsequent studies: PI3K has been
reported to associate with IFNAR1 in a ligand- and STAT3-independent manner
(Uddin et al., 2000, Rani et al., 1999). IFN-γ treatment also activates PI3K
independently of IRS proteins (Platanias et al., 1996, Uddin et al., 2000) indicating
that other adaptor proteins must recruit PI3K to the type II IFN receptor. The proto-
oncogene product CBL is a candidate for such an adaptor since it is activated by
IFN-γ and can bind p85 through its SH3 domain (Panchamoorthy et al., 1996, Soltoff
and Cantley, 1996). Several pathways of PI3K activation by IFN may therefore exist,
and the contribution of each pathway to activation of PI3K may be cell-type, and/or
IFN-type-specific.
Downstream effectors of PI3K
Membrane-associated PIP3 is thought to be the major signal generated in response
to PI3K activation. PIP3 recruits a large number (at least 20, Krugmann et al., 2002)
of PH domain-containing effector proteins to the cell membrane. Through PIP3
therefore, PI3K can regulate a large number of signalling pathways (reviewed by
Hawkins et al., 2006). The way these effector proteins become activated by PIP3
binding is unclear, but several mechanisms have been suggested and these may
contribute to different extents in the activation of different proteins. Recruitment of
PH-domain-containing proteins to the cell membrane alters the subcellular
localisation of effector proteins and may itself be considered ‘activating’ due to an
increase in the effective substrate/binding partner concentration. Additionally, the
effector may be brought into close proximity with activating kinases (Hawkins et al.,
2006). In some proteins, the PH domain mediates inhibition of other domains.
Binding of PIP3 to the PH domain relieves this inhibition, increasing catalytic activity
or altering affinity for binding partners. For example, a PH domain restricts the
catalytic activity of the GEF Dbl domain: PIP3 binding to the PH domain relieves
inhibition of the Dbl domain and restores GEF catalytic activity (Das et al., 2000).
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There is emerging evidence that the serine/threonine kinase activity of PI3K may
also activate downstream protein kinase cascades. Wymann and colleagues
demonstrated that a PI3K with disrupted lipid kinase activity but intact protein kinase
activity activated MAPK signalling (Bondeva et al., 1998).
Perhaps the best-studied of the PH-domain-containing effector proteins is the
serine/threonine kinase Akt, also called protein kinase B (Brazil et al., 2004); the
mechanism of Akt activation by PI3K is shown in Figure 1.4. Akt is recruited to the
cell membrane through PIP3:PH domain interactions where it undergoes
phosphorylation at Thr308 and Ser473 by PDK1 (phosphoinositide-dependent-kinase
1) and mammalian target of rapamycin (mTOR) complex 2 (mTORC2) respectively
(Sarbassov et al., 2005, Alessi et al., 1997). Although PDK1 is constitutively active,
its phosphorylation of Akt is PI3K-dependent as PIP3 binding to the Akt PH domain is
required to make the Thr308 residue available for PDK1-dependent phosphorylation
(McManus et al., 2004). In addition, PDK1 recruitment to the membrane is dependent
on PIP3:PH domain interaction. Phosphorylation of Ser473 is also PI3K-dependent
(Bayascas and Alessi, 2005) but the mechanism of mTORC2 activation by PI3K has
not yet been determined. Phosphorylation at both sites leads to an increase in the
catalytic activity of Akt, resulting in phosphorylation of a variety of downstream
effectors (Figure 1.5, reviewed by Manning and Cantley, 2007).
PI3K and regulation of the IFN response
PI3K can regulate signalling from TLR3 in response to dsRNA stimulation. TLR3 and
PI3K directly associate, resulting in PI3K and Akt activation (Sarkar et al., 2004).
Although active PI3K does not affect IRF3 dimerisation and nuclear translocation,
PI3K is required for complete IRF3 phosphorylation and therefore its maximal DNA
binding activity (Ehrhardt et al., 2006, Sarkar et al., 2004). PI3K can also regulate
NF-kB signalling downstream of TLR3 in response to poly(I:C). In DCs, the PI3K
inhibitors wortmannin and LY294002 enhance IFN-β expression: PI3K physically
interacts with TRIF to selectively inhibit NF-kB (but not IRF3) activation and IFN-β
production (Aksoy et al., 2005).
Since serine phosphorylation of STATs is required for their maximal activity and PI3K
serine kinase activity is activated by type I IFN treatment (Platanias et al., 1996), it
was postulated that PI3K activity may be required for maximal transcription from
ISRE/GAS elements (Platanias and Fish, 1999). While PI3K inhibitors are reported to
Figure: 1.4: Activation of PI3K and Akt downstream of growth factor receptors.
PI3K is recruited to the intracellular domains of growth factor receptors through receptor phosphotyrosine residues. 
Active PI3K generates phosphatidylinositol (3,4,5) triphosphate which recruits inactive Akt to the plasma membrane. 
Ser473 (in the regualatory loop) and Thr308 (in the kinase domain) of Akt are subsequently phosphorylated by 
mTORC2 (labelled as S473K in the diagram) and PDK1 respectively. Active Akt can then phosphorylate its downstream 
substrates. PI3K activation is regulated by PTEN, while Akt is inactivated by protein phosphatase 2A (PP2A). 
Modified from Brazil et al., 2004.
Akt
Akt
Figure: 1.5: Cellular functions of Akt.
Phosphorylation of target proteins by Akt leads to their activation (arrows) or 
inhibition (blocked arrows). Through modulation of the activity of these substrates, 
Akt can regulate a number of cellular process, including cell survival, cell growth 
and proliferation, metabolism, glucose uptake and angiogenesis. Some of these 
substrates exert multiple functions; for example, GSK3 has a role in cell survival, 
proliferation and metabolism regulation. From Manning and Cantley, 2007. 
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have no effect on type I IFN-induced gene transcription (Thyrell et al., 2004,
Hjortsberg et al., 2007, Uddin et al., 1997), a recent study demonstrated that ISG
transcription is impaired in PI3K knockout cells (Kaur et al., 2008b). The same results
were not observed in Akt knockout cells (Kaur et al., 2008a), indicating that PI3K
exerted its effects on ISG transcription by an Akt-independent mechanism. The PI3K
substrates responsible for this effect have yet to be identified, but may include the
PKC or Tec protein families, both of which are PI3K targets and are known to
regulate gene transcription by phosphorylating STATs (Uddin et al., 2002, Deb et al.,
2003, Choudhury, 2004, Saharinen et al., 1997, Jiang et al., 2007). However, STAT1
serine phosphorylation and STAT1-dependent transcription following type II IFN
treatment appears to require both PI3K and Akt activation (Nguyen et al., 2001):
PKC-δ is activated by IFN-γ in a PI3K-dependent manner and its inhibition blocks
STAT1 Ser727 phosphorylation (Deb et al., 2003, Uddin et al., 2002).
Akt is activated downstream of PI3K in response to IFN in a range of cell lines (Yang
et al., 2001, Nguyen et al., 2001, Lei et al., 2005, Kaur et al., 2008a). PI3K/Akt
activation appears to play a key role in regulation of ISG translation. Treatment with
type I and type II IFNs results in activation of p70 S6 kinase (p70 S6K), which causes
downstream phosphorylation of the S6 protein of the ribosomal 40s subunit to
stimulate mRNA translation. This pathway is dependent on PI3K, Akt and the mTOR
complex 1 (mTORC1) (Kaur et al., 2008b, Lekmine et al., 2003, Kaur et al., 2008a).
Additionally, PI3K activation leads to phosphorylation and negative regulation of
translational repressor eukaryotic initiation factor 4E-binding protein (4E-BP1) and
subsequent activation of the translation initiation factor eIF4E (Lekmine et al., 2003,
Kaur et al., 2008b). Expression of the ISGs ISG15 and CXCL10 in response to IFN-
α and IFN-γ is significantly reduced in p85 and Akt knockout cells; these cells are
subsequently much less sensitive to the antiviral effects of IFN-α than wildtype cells
(Kaur et al., 2008a). This indicates that PI3K selectively increases ISG translation to
generate an antiviral state.
1.1.3.4 NF-kB signalling
NF-kB binding sites are present in the promoters of certain ISGs (Du et al., 2007)
and type I IFN activates NF-kB DNA-binding and transcriptional activity in a wide
range of cell types (Figure 1.6). Type I IFNs promote phosphorylation and
degradation of the NF-kB inhibitor IkB (Yang et al., 2000) through a pathway that
requires STAT3, PI3K and Akt (Yang et al., 2001). PI3K-dependent NF-kB activation
Figure 1.6: Activation of classical and alternative NF-kB signalling downstream of the type I IFN receptor.
The JAK/STAT pathway activated by type IFNs is shown. Type I IFNs also activate classical NF-kB signalling through 
recruitment of STAT3, PI3K and Akt to IFNAR. This pathway promotes degradation of IkB to release NF-kB, which 
subsequently undergoes nuclear translocation to regulate gene expression. In addition, an alternative, non-canonical 
pathway of NF-kB activation occurs through TRAF2 and NIK: NIK processes the NF-kB2 p100 precursor to form p52, 
which translocates to the nucleus and regulates ISG transcription.
From Du et al., 2007.
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has no effect on transcription from the ISRE, indicating that NF-kB activation may
represent a distinct mechanism by which IFN can regulate gene expression (Du et
al., 2007). The CXCL11 chemokine gene, an ISG that is selectively induced by IFN-β
but not IFN-α (Rani et al., 1996), requires both ISGF3 and NF-kB for its expression
(Rani et al., 2001). CXCL11 induction is also STAT3- and PI3K/Akt-dependent (Yang
et al., 2007a, Rani et al., 2002), providing further evidence that type I IFN activates
NF-kB in a STAT3/PI3K/Akt-dependent manner to stimulate ISG transcription.
An alternative, non-canonical pathway of IFN-induced NF-kB activation also exists
that occurs independently of PI3K activation and IkB proteolysis (Figure 1.6,
Pomerantz and Baltimore, 2002, Du et al., 2007). This pathway requires TRAF2 and
its downstream effector NIK (Xiao et al., 2001, Yang et al., 2005, Senftleben et al.,
2001). NIK processes the NF-kB2/p100 precursor to remove its IkB-like C-terminus;
the resulting p52 product then heterodimerises, translocates to the nucleus and
regulates gene transcription (Pomerantz and Baltimore, 2002). p52 can be detected
in IFN-α/β-treated cells, and generation of this product is not affected by PI3K
inhibitors (Yang et al., 2005). Type I IFN can therefore stimulate both classical, PI3K-
dependent, and non-canonical, TRAF2/NIK-dependent pathways of NF-kB activation;
activation of both of these pathways generates survival signals that protect cells from
the pro-apoptotic effects of IFN (Yang et al., 2001, Yang et al., 2005). Studies using
NF-kB knockout cells revealed that there is a subset of ISGs that are either positively
or negatively regulated by NF-kB, and these gene products include ISG15 and
components of antigen-presentation machinery (Pfeffer et al., 2004, Wei et al.,
2006).
1.1.4 The IFN-induced antiviral state
IFNs induce an ‘antiviral state’ in cells through induction of ISGs. More than 300
ISGs have been identified; they perform roles in a vast range of biological processes
including transcriptional and translational regulation of gene expression, cell cycle
modulation, apoptosis, and stimulation of immune cells (de Veer et al., 2001). The
combined effects of these ISGs make the cell an exceptionally hostile environment
for virus replication and spread; consequently, recombinant IFNs are frequently used
to clinically treat infections with certain viruses (for example, chronic hepatitis C virus
[HCV] infection). The critical role of IFNs in defending the cell against virus infection
has been demonstrated by studies in mice with targeted disruption of the IFNAR or
IFNGR genes. These mice are highly sensitive to virus infection, despite being able
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to mount normal T-cell responses, and virus titres in internal organs are much higher
than in wildtype mice (Hwang et al., 1995b, Huang et al., 1993, Muller et al., 1994).
The roles of the best-studied ISGs in the antiviral state are described below.
1.1.4.1 Antiviral ISGs and their functions
PKR
The IFN-inducible double-stranded RNA-activated protein kinase (PKR) is
constitutively expressed at low levels in quiescent cells. PKR exists in an inactive
form through steric interference between its N-terminus and its catalytic domain
(Gelev et al., 2006). Binding of viral dsRNA to binding sites in the N-terminus induces
a conformational change that relieves this inhibition of the kinase domain (Nanduri et
al., 2000). Catalytic activity requires PKR homodimerisation and subsequent
autophosphorylation at a number of residues (Dar et al., 2005, Dey et al., 2005,
Romano et al., 1998, Taylor et al., 1996). Active PKR phosphorylates eIF2α to halt
cellular translation. PKR additionally plays a role in promoting apoptosis, and this will
be discussed in a later, in Section 1.2.5.1.
OAS/RNaseL
The IFN-inducible 2’-5’-oligoadenylate synthase (OAS) proteins become activated by
dsRNA and catalyse the conversion of ATP into 2’-5’-linked adenosine oligomers
(Rebouillat and Hovanessian, 1999). These oligomers subsequently activate RNaseL
(itself IFN-upregulated), an endonuclease that is constitutively expressed in an
inactive form (Zhou et al., 1993, Slattery et al., 1979). Active RNaseL degrades both
viral and cellular RNAs into short fragments, a process that inhibits virus replication
by inhibiting protein synthesis (Zhou et al., 1998, Scherbik et al., 2006, Silverman,
2007). RNaseL overexpression has been shown to suppress the replication of
encephalomyocarditis virus (EMCV), parainfluenza virus 3 (hPIV3), VSV and
vaccinia virus (VACV) (Zhou et al., 1998). Nucleotide fragments produced by
RNaseL can also enhance IFN-β expression by binding to RIG-I and mda-5 to
activate MAVS-dependent signalling (Malathi et al., 2007). Effects of OAS/RNaseL
on apoptosis induction will be discussed in Section 1.2.5.1.
23
ISG15
ISG15 is a ubiquitin homologue that is conjugated to cellular proteins (Loeb and
Haas, 1992). This process (ISGylation), like ubiquitination, requires the activities of
an E1 activating enzyme, an E2 conjugating enzyme and an E3 ligase (Takeuchi et
al., 2005, Yuan and Krug, 2001, Zhao et al., 2004, Kim et al., 2004, Wong et al.,
2006, Zou and Zhang, 2006); these enzymes are also upregulated by IFN (Kang et
al., 2001a, Nyman et al., 2000). While ubiquitination of proteins generally leads to
their degradation by the proteasome, ISGylation results in protein translocation (Loeb
and Haas, 1994), stabilisation (Lu et al., 2006b) or non-degradative negative
regulation (Zou et al., 2007b, Kim et al., 2008). ISG15-deficient mice are hyper-
sensitive to infection with a number of viruses, including IAV and HSV-1 (Lenschow
et al., 2007), and in mice unable to respond to IFN, ISG15 expression offered
protection against Sindbis virus (Lenschow et al., 2005). Knockout of UBP43, the
protein required for ISG15-deconjugation, renders mice more sensitive to IFN and
poly(I:C) treatment than wildtype mice (Malakhova et al., 2003, Zou et al., 2007a).
These mice are also resistant to infection with VSV and lymphocytic choriomeningitis
virus (LCMV) (Ritchie et al., 2004). Similarly, siRNA knockdown of UBP43
potentiates the inhibitory effect of IFN on HCV replication (Randall et al., 2006),
indicating that ISG15-conjugation may be required to mount an efficient IFN
response. Indeed, many proteins involved in IFN pathways, including STAT1, Jak1,
Erk1, PKR and MxA, undergo ISG-conjugation (Zhao et al., 2005a, Malakhov et al.,
2003): the role of ISGylation in STAT1 regulation is described in Section 1.1.3.1.
The ISG15-conjugation system may also perform a negative regulatory role in the
IFN response, as ISGylation of RIG-I has been reported to inhibit stimulation of the
IFN-β promoter during infection with NDV (Kim et al., 2008).
Mx GTPases
The Mx group of guanine-hydrolysing enzymes were first identified as antiviral during
studies which revealed mice carrying mutations in the Mx gene are sensitive to
orthomyxovirus infection (Lindenmann, 1962). The human genome encodes two Mx
proteins, MxA and MxB, both IFN-inducible and cytoplasmic (Aebi et al., 1989), of
which only MxA demonstrates antiviral activity. Mx proteins contain an N-terminal
GTPase domain and a C-terminal leucine zipper domain, both of which are required
to bind virus structures (Kochs and Haller, 1999). By recognising virus
nucleocapsids, MxA can inhibit replication of Thogoto virus (THOV) by preventing
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nuclear import of the virus genome (Kochs and Haller, 1999, Weber et al., 2000).
Additionally, MxA that is artificially given a nuclear localisation can directly bind and
inhibit viral polymerase activity in THOV and IAV-infected cells (Turan et al., 2004,
Weber et al., 2000, Pavlovic et al., 1992). Replication of a wide range of viruses is
inhibited by MxA expression, including paramyxoviruses, orthomyxoviruses,
bunyaviruses, rhabdoviruses and picornaviruses (Sadler and Williams, 2008).
PML
The IFN-inducible PML protein displays antiviral activity against a number of viruses
including VSV and IAV (Chelbi-Alix et al., 1998, Djavani et al., 2001, Everett, 2001,
Regad et al., 2001). PML localises to nuclear bodies (NBs) that also contain many
other proteins; some, like Sp100 and PA28, are also IFN-inducible. Many NB
components are involved in chromatin remodelling, transcription, DNA repair or
elimination of mis-folded protein aggregates (reviewed by Everett and Chelbi-Alix,
2007). PML NBs may also play a key role in IFN-induced apoptosis, and the
evidence for this will be presented in Section 1.2.5.1.
Immunomodulation
Both type I and type II IFNs upregulate a number of components involved in class I
antigen presentation to cytotoxic T-lymphocytes (CTLs) (Der et al., 1998a). These
include MHC class I molecules, proteasome subunits and transporters required for
MHC expression at the cell surface (Der et al., 1998a, Schroder et al., 2004,
Epperson et al., 1992). Type I IFNs can additionally promote DC maturation (Le Bon
et al., 2003), stimulation of NK cell cytotoxicity (Nguyen et al., 2002a) and CTL
proliferation (Tough et al., 1996, Marrack et al., 1999, Kolumam et al., 2005).
IFN-γ is secreted by activated type I helper T (Th1) cells and, in addition to promoting
an antiviral state in non-immune cells, performs a number of roles to co-ordinate an
antiviral response from immune cells (reviewed by Schroder et al., 2004). Briefly,
these include upregulation of MHC class II components and proteases involved in
production of antigenic peptides in macrophages and DCs, promotion of NK cell
activity and enhancement of lysosome activity in macrophages.
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Apoptosis
Induction of a cellular pro-apoptotic state is an important function of IFNs, and the
IFN-inducible PKR, PML and the OAS/RNaseL systems all play roles in the
establishment of such a state. Similarly, apoptosis regulation is a major function of
PI3K/Akt activation. The role of apoptosis in the IFN-induced antiviral state and the
mechanisms by which PI3K/Akt regulates apoptosis will be dealt with in Sections
1.2.5 and 1.2.6.
Cell cycle regulation
Treatment with type I IFNs causes cells to spend prolonged periods in the G1, S and
G2 phases of the cell cycle (Balkwill and Taylor-Papadimitriou, 1978), which may
lead to induction of apoptosis. IFN modulates cell-cycle progression through
upregulation of a number of cyclin-dependent kinase (CDK) inhibitors (Sangfelt et al.,
1999, Sangfelt et al., 1997b, Mandal et al., 1998) and the p200 family of proteins
(Asefa et al., 2004). For instance, the CDK inhibitor p21Waf1 is upregulated by type I
and II IFNs and is linked with cell cycle arrest and apoptosis (Subramaniam et al.,
1998, Mandal et al., 1998, Urashima et al., 1997, Chin et al., 1996).
1.1.4.2 PI3K regulation of the IFN-induced antiviral state
A small subset of IFN-α-induced genes that are regulated by PI3K have been
identified by microarray (Hjortsberg et al., 2007). PI3K and Akt activation by IFN may
function to negatively regulate the antiviral state, since PI3K/Akt activates many
pathways that IFN inhibits, and vice versa. Seemingly in contradiction to the pro-
apoptotic state induced by IFN, a major function of PI3K/Akt activation is the
prevention of apoptosis and promotion of cell survival. The mechanisms by which
PI3K/Akt regulate apoptosis will be dealt with in Section 1.2.6. Inhibition of 4E-BP1
and p70 S6K by Akt promotes mRNA translation (see above), in contrast to PKR-
mediated translation inhibition stimulated by IFN. In addition, Akt may enhance
membrane biosynthesis (a requirement for cell growth and proliferation) through
regulation of ATP citrate lyase, an enzyme that catalyses formation of acetyl-CoA
required for fatty acid synthesis (Berwick et al., 2002). PI3K/Akt promotes cell growth
through its effects on protein and membrane synthesis. The IFN-stimulated CDK
inhibitors p21Waf1 and p27Kip1 are also Akt target proteins. Akt-mediated
phosphorylation of these proteins inhibits their nuclear translocation, thereby
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promoting cell proliferation (Shin et al., 2002, Viglietto et al., 2002, Zhou et al., 2001,
Liang et al., 2002). Expression of p21Waf1 and p27Kip1 is also reduced through the
effects of Akt on p53 and FOXO transcription factors (see Section 1.2.6) (Collado et
al., 2000, Dijkers et al., 2000b, Medema et al., 2000). In addition, the downstream
Akt effector glycogen synthase kinase 3β (GSK3β) usually promotes rapid turnover
of the G1 cyclins D and E, and the transcription factors c-jun and c-myc (Diehl et al.,
1998), (Wei et al., 2005, Welcker et al., 2003, Yeh et al., 2004). Inhibition of GSK3β
by Akt elevates expression of these proteins, which are all important for G1/S phase
transition.
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1.2 Apoptosis
Apoptosis is a tightly controlled process whereby cells activate pathways leading to
their self-destruction in response to a wide range of stimuli, including virus infection,
DNA damage and signals from immune cells. These death pathways culminate in
engulfment of apoptotic cell fragments by neighbouring and phagocytic cells,
preventing leakage of cell contents into the extracellular environment. This is in
contrast to necrosis, where cells swell and burst, leading to activation of the
inflammatory response. Apoptotic cells exhibit characteristic morphological and
biochemical features, including chromosome condensation, DNA fragmentation,
membrane ‘blebbing’, collapse of the mitochondrial membrane potential and loss of
membrane phospholipid asymmetry. Different pathways of apoptosis induction are
activated depending on the nature of the apoptotic stimulus. However, these
pathways converge at the point of the protease effectors of apoptosis that are
responsible for dismantling the cell.
1.2.1 Protease effectors of apoptosis
Caspases
The role of the caspase family of cysteine proteases in apoptosis has been
extensively researched, so much so that current models of apoptosis induction have
been described as ‘caspase-centric’ (Hail et al., 2006). Caspases are highly
conserved among multicellular organisms and cleave a large number of cellular
proteins in response to apoptotic stimuli. They are synthesised as inactive
precursors, procaspases, that require activation allosterically or by proteolytic
cleavage (Saikumar et al., 2007, Ayala et al., 1994). Caspases-8 and -9 are activated
by the death-receptor pathway and the mitochondrial pathways of apoptosis
respectively (Figure 1.7). These caspases are often called ‘initiator’ caspases
because once activated, they cleave and activate a downstream ‘caspase cascade’.
The cascade culminates in activation of ‘effector’ caspases-3 and -7: effector
caspases represent a point of convergence between the mitochondrial and death
receptor pathways. Caspases cleave an array of downstream targets including
nuclear lamins and cytoskeletal proteins, cleavage of which brings about the
morphological changes associated with apoptosis. Caspase cleavage inactivates the
inhibitor of caspase-activated DNase (ICAD), releasing the DNase responsible for
Figure 1.7: The death receptor and mitochodrial pathways of apoptosis.
In response to ligand binding, the TNFR, Fas and TRAILR death receptors recruit specific 
adaptor proteins to form the DISC (FADD and procaspase-8) via their intracellular 
death domains. TNFR1 requires TRADD to recruit FADD and procaspase-8, while Fas 
and TRAILR directly bind these DISC components. The DISC cleaves procaspase-8 to 
form active caspase-8, which subsequently activates downstream caspases. Caspase-8 
can also signal to the mitochondrial pathway of apoptosis by promoting BID cleavage. 
Truncated tBID translocates to the mitochondria and interacts with BAX and BAD results 
to stimulate cytochrome c and APAF-1 release from the mitochondria. APAF1, cytochrome 
c and procaspase-9 form the apoptosome, which activates caspase-9 and the caspase 
cascade. These pathways are negatively regulated at the level of the DISC by cIAP and 
cFLIP and at the mitochondrial level by BCL-2 and BCL-XL. These inhibitory proteins 
themselves are counteracted by mitochondrial proteins such as Smac/Diablo. 
From Schutze et al., 2008.
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nucleosomal DNA fragmentation, CAD (Sakahira et al., 1998). Additionally,
caspases cleave and inactivate a number of cell signalling proteins, including STAT1
(King and Goodbourn, 1998), IkB (Barkett et al., 1997) and NF-kB (Kang et al.,
2001b) and the anti-apoptotic Bcl-2 family members Bcl-2 (Cheng et al., 1997) and
Bcl-XL (Clem et al., 1998). Conversely, cleavage of Bid by caspase-8 augments its
pro-apoptotic properties, resulting in transduction of the apoptotic signal from the
cytoplasm to the mitochondria (Li et al., 1998a).
Cathepsins
The cathepsin family can be divided into cysteine, aspartate and serine proteases,
and, like the caspases, are synthesised as inactive precursors that require
proteolysis for activation. The roles of the cysteine proteases cathepsins B and L,
and of cathepsin D, an aspartate protease, in apoptosis have been the most studied.
These cathepsins are found in lysosomes and endosomes, but are secreted into the
cytoplasm during apoptosis (Li et al., 1998b, Roberg and Ollinger, 1998). Here, they
cleave and activate pro-apoptotic Bid and procaspases and degrade anti-apoptotic
Bcl-2, Bcl-XL, XIAP (X-linked inhibitor of apoptosis) and Mcl-1 (myeloid leukaemia
cell differentiation protein) (Stoka et al., 2001, Droga-Mazovec et al., 2008, Ishisaka
et al., 1999, Zhou and Salvesen, 1997, Vancompernolle et al., 1998). Cathepsins are
additionally involved in p53-dependent apoptosis, as two p53 binding sites exist in
the cathepsin D promoter and cathepsin D inhibitors suppress p53-induced cell death
(Wu et al., 1998).
Calpains
Calpains are a group of cytosolic cysteine proteases that are activated by increases
in the levels of intracellular free Ca2+. Studies have shown calpains to become
activated during apoptosis in a variety of cell types (Squier et al., 1994, Debiasi et al.,
1999, Knepper-Nicolai et al., 1998), and calpain inhibitors have an inhibitory effect on
cell death in response to some stimuli but not others (Squier et al., 1999, Gressner et
al., 1997). A large number of calpain substrates have been identified, including p53
(Kubbutat and Vousden, 1997), Bax (Wood et al., 1998), and procaspases-3 and -9
(Wolf et al., 1999). Calpain also cleaves several elements of the cytoskeleton,
suggesting it may play a role in destruction of the cellular architecture during
apoptosis (Knepper-Nicolai et al., 1998). The nature of crosstalk between calpain
and caspases remains to be elucidated (and may be dependent on cell type and the
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nature of the stimulus), with some studies placing calpain upstream of caspase
activation (Waterhouse et al., 1998), some placing it downstream (Wood and
Newcomb, 1999, Porn-Ares et al., 1998), and some indicating that caspases are not
required for calpain activation (Wolf et al., 1999).
Granzymes
CTLs and NK cells induce apoptosis in target cells by expressing death receptor
ligands on their surface (Montel et al., 1995, Suda et al., 1995) to activate the death
receptor pathway of apoptosis in target cells. CTLs and NK cells can also induce
apoptosis through ‘granule exocytosis’ which involves secretion of perforins and
granzymes into the extracellular environment. Perforins insert into the target cell
membrane and form pores, leading to cell permeabilisation and possibly aiding entry
of granzymes (Masson and Tschopp, 1985, Young et al., 1986). Granzyme B
cleaves and activates pro-caspases-3, -7, and -9 through its serine protease activity
(Gu et al., 1996, Quan et al., 1996, Duan et al., 1996). In addition, granzyme B
regulates Bcl-2 proteins through cleavage of pro-apoptotic Bid (Heibein et al., 2000)
and by degrading anti-apoptotic Mcl-1 (Han et al., 2004). Caspase-independent
cleavage of ICAD by granzyme B has also been reported, triggering apoptotic DNA
fragmentation (Thomas et al., 2000, Sharif-Askari et al., 2001).
The proteasome
An increase in the abundance of proteasomal subunits and proteasomal activity have
been observed during apoptosis (Dawson et al., 1995, Jones et al., 1995), and
proteasome inhibitors can inhibit or activate apoptosis depending on the cell type and
apoptosis inducer (Grimm et al., 1996, Meriin et al., 1998, Imajoh-Ohmi et al., 1995).
Proteasome inhibitors can increase caspase-3 activity, suggesting that the
proteasome protects cells from apoptosis by degrading caspase-3 or its upstream
proteases (Fujita et al., 1996a, Drexler, 1997). The proteasome also plays an
important role in p53 and NF-kB signalling pathways. Mdm2 and IkB, which
negatively regulate p53 and NF-kB respectively, are degraded by the proteasome
following their ubiquitination (Chang et al., 1998, Chen et al., 1995). Bax, the
proapoptotic Bcl-2 protein, is also degraded by the proteasome (Chang et al., 1998).
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1.2.2 Death receptor-mediated apoptosis
1.2.2.1 Death receptors and their ligands
The tumour necrosis factor (TNF) superfamily of death receptor (DR) ligands
contains 19 proteins that are involved in the control of the immune and inflammatory
responses (reviewed in Bodmer et al., 2002). They are expressed on the surfaces of
cells of the immune system, while their receptors are widely expressed across
different cell types. Activation of the TNF receptors therefore occurs during contact
between immune cells and other cell types. Activation can also occur in the absence
of cell to cell contact, as soluble ligands (particularly TNF-α) can be formed following
their cleavage from the cell surface (McGeehan et al., 1994, Mohler et al., 1994). The
best characterised of these ligands are the prototypical member TNF-α, Fas ligand
(FasL) and TNF-related apoptosis inducing ligand (TRAIL). TNF-α is secreted by
activated T cells and macrophages in response to infection, while FasL is expressed
on the surface of CTLs and NK cells to mediate destruction of virus-infected cells.
TNF-α, FasL and TRAIL all contain a conserved TNF homology domain (THD) which
is responsible for binding the appropriate DR (TNFR1, Fas [or CD95] and DR4/DR5
respectively). The receptors are required to oligomerise prior to ligand binding in
order to function (Chan et al., 2000); their cytoplasmic domains can then form
platforms for the binding of one of two classes of signalling molecules; the TRAFs or
the ‘death domain’ (DD) containing proteins (Locksley et al., 2001).
1.2.2.2 Signalling downstream of death receptors
Following ligand-binding, DRs promote apoptosis through the formation of the multi-
protein death-inducing signalling complex (DISC), which comprises Fas-associated
DD-containing protein (FADD) and procaspase-8 (Figure 1.7, reviewed by Peter and
Krammer, 2003). The receptors recruit FADD through its DD: while Fas and
DR4/DR5 can associate directly with FADD, TNFR1 requires TRADD as an
intermediate adaptor for FADD recruitment. Procaspase-8 is activated by its
association with the DISC (Kischkel et al., 1995, Medema et al., 1997) and activates
the caspase cascade through downstream cleavage of caspase-3 and other pro-
apoptotic proteins (Li et al., 1998a, Scaffidi et al., 1998). Caspase-10 can also be
recruited to the DISC and can initiate apoptosis, even in the absence of caspase-8
(Kischkel et al., 2001, Wang et al., 2001b). While one study indicates caspase-10
cannot substitute functionally for caspase-8 (Sprick et al., 2002), caspase-10 still
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appears to play an important role in apoptosis since defective caspase-10 has been
implicated in apoptosis abnormalities seen in certain autoimmune diseases (Wang et
al., 1999b).
In addition to inducing apoptosis, DR stimulation can also activate anti-apoptotic NF-
kB signalling. TNF-α and FasL promote NF-kB activation by distinct mechanisms:
TNFR1-mediated activation requires TRADD and RIP1, while Fas-mediated
activation requires FADD and caspase-8 (Imamura et al., 2004). TNFR1 is thought
to promote sequential assembly of two distinct complexes at its cytoplasmic tail
(Micheau and Tschopp, 2003). Immediately following TNF-α-binding, TNFR1 recruits
TRADD, RIP1, and TRAF2 (Figure 1.8A): TRAF2 ubiquitinates RIP1, a modification
that recruits the NEMO subunit of the IKK complex, leading to NF-kB activation. It is
worth noting that this complex exhibits many similarities to the NF-kB-activating
complex formed downstream of RIG-I/mda-5 activation by viral RNA (Section
1.1.2.2). At later times (at least 2h (Muppidi et al., 2004)) following receptor
activation, TRADD, RIP1 and TRAF2 dissociate from TNFR1, and recruit FADD and
procaspase-8 to form the DISC. The temporal delay between the formation of these
complexes allows sufficient time for the expression of NF-kB-induced anti-apoptotic
proteins cFLIP (cellular FLICE inhibitory protein), cellular inhibitor of apoptosis 1
(cIAP-1), cIAP-2, TRAF 1 and TRAF2 that prevent induction of apoptosis by the
DISC (Wang et al., 1998a). If NF-kB signals are absent, these anti-apoptotic proteins
are not upregulated and DISC formation results in cell death. The sequential
formation of these two complexes is thought to be achieved through receptor
internalisation (Figure 1.8, reviewed by Schutze et al., 2008). While TNFR1 is
present at the cell-surface, it mediates anti-apoptotic NF-kB signalling; following
clathrin-dependent endocytosis of the receptor however, RIP1 is degraded and
TRADD recruits DISC components to mediate pro-apoptotic signalling (Figure 1.8A).
Fas is unable to bind TRADD, so Fas-activation of NF-kB occurs in a TRADD-
independent manner. Following Fas activation, low amounts of FADD and
procaspase-8 are recruited to the receptor and activate NF-kB; however, following
clathrin-dependent receptor internalisation, higher levels of these DISC components
bind the receptor to promote apoptosis (Figure 1.8B).
1.2.2.3 Regulation of death receptor-mediated apoptosis
Caspase-8 activity is negatively regulated at the level of the DISC by cFLIP which is
recruited to these complexes through its death effector domains (DEDs) (Irmler et al.,
(A)
(B)
Figure 1.8: Activation of cell survival and apoptotic pathways downstream of 
death receptors.
(A) TNFR1 activates NF-kB through recruitment of TRADD, RIP1 and TRAF2. Soon after 
ligand binding, TNFR1 is internalized via clathrin-dependent endocytosis. NF-kB signalling 
is terminated by the recruitment of CARP2 and A20, leading to RIP1 degradation. TRADD 
then recruits FADD and procaspase-8 to TNFR1 to form the DISC. Activated caspase-8 
is subsequently released, resulting in activation of the caspase cascade and induction of 
apoptosis. Further along the endocytic pathway, TNF-receptosomes form multivesicular 
bodies that can mediate apoptosis through cleavage of BID and activation of caspase-9.
(B) Soon after activation of Fas/CD95, low levels of FADD and procaspase-8 are recruited to 
the receptor. Signalling protein oligomerization transduction structures (SPOTS) are formed, 
resulting in Fas/CD95 clustering (a process known as ‘capping’) which depends on active 
caspase-8. This leads to the formation of large lipid-raft platforms. At this stage, Fas/CD95 can 
promotes cell survival through NF-kB and MAPK activation, but not apoptosis. 5-15 minutes 
after receptor activation, Fas/CD95 is internalized by clathrin-mediated endocytosis. During 
endosomal trafficking, high levels of DISC components FADD and caspase‑8 are recruited, 
resulting in significant caspase‑8 activation and apoptosis. From Schutze et al., 2008.
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1997, Sharp et al., 2005, Micheau and Tschopp, 2003). Several mRNA splicing
variants of cFLIP exist, however, only two have been detected at the protein level;
cFLIPL and the shorter cFLIPS. cFLIPS is an enzymatically inactive homologue of
caspase-8 and is well-characterised as a caspase-8 inhibitor (Krueger et al., 2001,
Scaffidi et al., 1999). Although the cFLIPL variant is also regarded as a caspase-8
inhibitor (Irmler et al., 1997, Sharp et al., 2005), it has been suggested that cFLIPL
can act as either an inhibitor or an activator depending on its expression levels
(Chang et al., 2002). cFLIP can also activate both NF-kB and ERK signalling
pathways in human T lymphocytes through its interaction with components of these
pathways (Kataoka et al., 2000). cIAP-1 negatively regulates apoptosis by forming
part of an anti-apoptotic protein complex that assembles at DRs and prevents
caspase-8 activation (Figure 1.7, Sun et al., 2008b). The IAPs can also antagonise
DR signalling by inhibiting effector caspase activity (see below).
1.2.3 Mitochondria-mediated apoptosis
Intracellular stresses such as DNA damage, reactive oxygen species and treatment
with certain drugs affect the integrity of the mitochondria. If these stresses are
sufficient, permeabilisation of the mitochondrial membrane occurs. Cytochrome c is
subsequently released from the mitochondrial intermembrane space into the cytosol
(Liu et al., 1996). Here, cytochrome c combines with APAF-1 (apoptotic protease
activating factor-1), procaspase-9 and dATP to form a pro-apoptotic complex, the
‘apoptosome’ (Figure 1.7). Active caspase-9 is released from this complex and can
activate downstream caspases (Zou et al., 1999).
1.2.3.1 Regulation of mitochondria-mediated apoptosis
The Bcl-2 proteins
The apoptosome is regulated by the B cell lymphoma 2 (Bcl-2) family of proteins.
There are over 20 different Bcl-2 proteins, each containing a conserved Bcl-2
homology (BH) domain, which have either pro- or anti-apoptotic properties. Anti-
apoptotic family members include Bcl-2 proper, Bcl-XL, Bcl-w, A1 and Mcl1, while the
pro-apoptotic members can be further subdivided into the multi-domain Bax family
and the BH3-only proteins (Cory and Adams, 2002).
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Anti-apoptotic Bcl-2 proteins are associated with intracellular membranes, including
those of the mitochondria, nucleus and endoplasmic reticulum (ER). Bcl-2 is an
integral membrane protein (Janiak et al., 1994), while Bcl-w and Bcl-XL only
associate with the membrane in response to apoptotic signals (Cory and Adams,
2002). Studies in Caenorhabditis elegans have shown that in normal cells, CED-9, a
Bcl-2 homologue, sequesters CED-4 (the APAF-1 homologue), anchors it to the
mitochondrial membrane and prevents it from activating the caspase CED-3 (Spector
et al., 1997). In apoptotic cells however, CED-4 is displaced from CED-9 by the BH3-
only protein EGL-1, and CED-4 adopts a perinuclear localisation (Chen et al., 2000).
The Bax family of pro-apoptotic Bcl2 proteins include the widely expressed Bak and
Bax. Disruption of Bak or Bax alone has a negligible effect on apoptosis, but
disruption of both proteins dramatically impairs apoptosis (Lindsten et al., 2000).
During apoptosis, Bax, normally present as a monomer in the cytosol, becomes
inserted in the outer mitochondrial membrane, where it oligomerises (Nechushtan et
al., 2001, Antonsson et al., 2001). In quiescent cells, Bak exists in the mitochondrial
membrane as an oligomer, but during apoptosis it changes conformation (Griffiths et
al., 1999). These Bax and Bak oligomers affect mitochondrial membrane
permeability and promote cytochrome c release (Pastorino et al., 1998, Gross et al.,
1998). This is thought to occur in one of two ways; either by forming pores
themselves (Antonsson et al., 2001, Saito et al., 2000, Pavlov et al., 2001) or by
interacting with and enlarging existing mitochondrial permeability transition pores
(Tsujimoto and Shimizu, 2000).
Eight or more BH3-only proteins exist, each containing a BH3 domain which is
responsible for the ability of these proteins to bind to and inactivate anti-apoptotic
proteins such as Bcl-2 (Chittenden et al., 1995). In addition, the BH3 domain of Bid is
able to bind and activate pro-apoptotic Bax and Bak (Wang et al., 1996). It has been
suggested that Bid acts by promoting Bax and Bak oligmerisation, forming pores in
the mitochondrial membrane and releasing cytochrome c into the cytosol (Korsmeyer
et al., 2000).
IAPs
The IAP family of apoptosis regulators inhibit apoptosis in a number of distinct ways
(reviewed by Liston et al.). The IAP BIR (baculoviral IAP repeat) domain mediates
associations with the initiator caspase-9 and the effector caspases-3 and -7 (Roy et
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al., 1997, Takahashi et al., 1998, Maier et al., 2002) and inhibits caspase activity by
either precluding substrate entry to the caspase active site (Huang et al., 2001, Chai
et al., 2001) or by stabilising the inactive form of the enzyme (Shiozaki et al., 2003).
The ring zinc finger (RZF) motif of IAPs has also been implicated in apoptosis
inhibition: the RZFs of cIAP2 and XIAP promote ubiquitination and degradation of
caspase-3 and caspase-7 (Huang et al., 2000, Suzuki et al., 2001).
1.2.4 Endoplasmic reticulum-mediated apoptosis
The presence of Bcl-2 family members in ER membranes (Krajewski et al., 1993) led
to the suggestion that they may modulate Ca2+ release from the ER (Baffy et al.,
1993, Lim et al., 2008). Ca2+ is a versatile second messenger that mediates both
cell survival and cell death (Rong and Distelhorst, 2008). Proapoptotic Ca2+ signals
are enhanced by Bax, Bak and the BH3-only proteins. Bax and Bak stimulate the
rearrangement of calcium stores from the ER to the mitochondria (Nutt et al., 2002).
The BH3-only protein Bik enhances Ca2+ release from the ER (Mathai et al., 2005),
while Bid increases the uptake of Ca2+ by the mitochondria (Csordas et al., 2002). In
contrast, the anti-apoptotic Bcl-2 proteins inhibit calcium release from the ER
(Distelhorst et al., 1996, Pinton et al., 2001, Der et al., 1998b) through interaction
with IP3 receptor calcium channels to prevent their opening (Chen et al., 2004).
Interestingly, Bcl-2 also inhibits the uptake of Ca2+ by the nucleus, suggesting a role
for the nucleus in apoptosis induction (Marin et al., 1996).
1.2.5 Regulation of apoptosis by IFN and STAT1
Apoptosis plays a critical role in the IFN-induced antiviral state. Induction of cell
death during the early stages of virus infection significantly limits viral replication, and
reduces or eliminates the spread of progeny virus (Clem and Miller, 1993). Type I
and type II IFNs can induce apoptosis in a wide range of cell-lines (Chawla-Sarkar et
al., 2001, Morrison et al., 2001, Chen et al., 2001a, Dai and Krantz, 1999, Thyrell et
al., 2002, Sangfelt et al., 1997a) and as a consequence, treatment with IFN is used
in the clinic to treat certain cancers (Pestka et al., 2004). Selective induction of
apoptosis in virus-infected cells (while leaving uninfected cells viable) is IFN-
dependent (Tanaka et al., 1998, Sedger et al., 1999). The mechanism by which IFN
induces apoptosis is similar to the death-receptor-mediated pathway and involves
FADD and caspase-8: in the presence of caspase-8 inhibitors or knockdown of
FADD, IFN treatment has no effect on cell viability (Balachandran et al., 2000). Many
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cell-lines are resistant to apoptosis induced by IFN alone, but IFN pre-treatment
sensitises these cells to apoptosis in response to other stimuli, such as Fas agonist
antibody (Ahn et al., 2002, Kurdi and Booz, 2007), TNF-α (Kulkarni et al., 2006),
dsRNA (Stewart et al., 1973, Stewart et al., 1972) or IAV infection (Balachandran et
al., 2000). Additionally, EMCV, VSV and HSV-induced apoptosis can be inhibited by
making cells unable to respond to IFN (Tanaka et al., 1998). Together, these studies
indicate that the IFN-induced antiviral state can stimulate apoptosis in the presence
of additional stimuli (Barber, 2001). While IFN can promote apoptosis in response to
infection with IAV, IFNs inhibit apoptosis induced by VSV and Sindbis virus
(Balachandran et al., 2000), presumably through inhibition of viral protein synthesis
and replication early in infection (Harrell et al., 1982, Julkunen et al., 1982, Despres
et al., 1995). The antiviral state can therefore promote either cell survival or
apoptosis depending on the viral stimulus (Balachandran et al., 2000).
As a component of the ISGF3 and GAF transcription factors, STAT1 plays an integral
role in IFN-dependent ISG induction. Many of these ISGs are involved in apoptosis
regulation; as a result, constitutive STAT1 activation enhances IFN-induced pro-
apoptotic signalling (Sironi and Ouchi, 2004). At least 15 ISGs with pro-apoptotic
functions have been identified by microarray (Der et al., 1998b, de Veer et al., 2001),
including STAT1 itself (Der et al., 1998b), procaspases (Refaeli et al., 2002, Chin et
al., 1997), DRs (Meng and El-Deiry, 2001, Lee et al., 2000b, Xu et al., 1998) and DR
ligands (Xu et al., 1998). In addition, STAT1 has been implicated in regulation of
apoptosis in response to DNA damage or stress stimuli such as heat or ischaemia
(Janjua et al., 2002, Stephanou et al., 2000b, Stephanou et al., 2001, Townsend et
al., 2004). STAT1-null cells are resistant to TNF-α-induced apoptosis (Kumar et al.,
1997); interestingly, apoptosis sensitivity could be restored by expression of a STAT1
variant that is unable to undergo tyrosine phosphorylation and dimerisation. Similarly,
STAT1 promotion of IFN-γ-induced apoptosis in lymphocytes is only partially
dependent on IFN-γ signalling (Lee et al., 2000a). These data indicate STAT1 can
additionally regulate transcription of a number of genes independently of ISGF3/GAF
formation. STAT1 can also interact with a number of cellular signalling proteins to
modulate apoptosis by transcription-independent mechanisms. The different
mechanisms by which STAT1 promotes apoptosis are summarised in Figure 1.9.
Figure 1.9: Regulation of cell death by STAT1.
STAT1 activates or suppresses transcription of a number of genes encoding 
apoptosis regulators, including procaspases, death receptors and their ligands, and 
Bcl-2 proteins. In addition, STAT1 can modulate apoptosis through transcription-
independent mechanisms: STAT1 interacts with TRADD and p53 to enhance 
apoptosis. Inhibition of the interaction between HDAC and STAT1 by HDAC inhibitor 
or IFN-a promotes STAT1 acetylation and a direct interaction with the p65 subunit 
of NF-kB to inhibit NF-kB signalling. From Kim and Lee, 2007. 
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1.2.5.1 Pro-apoptotic ISGs regulated by ISGF3/GAF
Death receptors and their ligands
Pre-treatment with type I or type II IFNs sensitises a variety of cell types to Fas-
mediated apoptosis by enhancing Fas expression (Xu et al., 1998, Spets et al., 1998,
Ahn et al., 2002). However, increasing Fas expression alone is not always sufficient
to sensitise cells to Fas-mediated apoptosis, as Fas expression can be detected on
the surface of resistant cells (Ugurel et al., 1999). It is likely then that the
sensitisation effect of IFN is due to the combined upregulation of pro-apoptotic ISGs
and downregulation of anti-apoptotic genes. In addition to upregulating the
expression of Fas, IFN-γ has also been reported to stimulate relocation of the Fas 
receptor from intracellular vesicles to the surface of vascular smooth muscle cells by
a PI3K/Akt-dependent mechanism (Rosner et al., 2006). TNFR expression on the
surface of certain cancer cells is similarly elevated following treatment with IFN-γ 
(Ossina et al., 1997, Aggarwal et al., 1985). This regulation is indirect as production
of TNFR mRNA requires protein synthesis, and likely requires the expression of an
IFN-γ-responsive transcription factor, such as IRF1 (Ossina et al., 1997). The role of
IFN in regulation of TNFR expression is unclear however, as both IFN-α and IFN-γ 
inhibit lipopolysaccharide (LPS)-induced transcription of the TNFR gene
(Tannenbaum et al., 1993). Enhancement of DR expression by IFNs presumably
increases the sensitivity of infected target cells to TNF-α and FasL-mediated CTL
and NK cell cytotoxicity.
IFNs upregulate TRAIL expression to induce apoptosis (Chen et al., 2001a, Kayagaki
et al., 1999). Expression of dominant-negative TRAIL receptors, or neutralising
antibody to TRAIL therefore inhibits the pro-apoptotic effect of IFN (Chawla-Sarkar et
al., 2001, Chen et al., 2001a). FasL expression can also be enhanced by IFN-γ in 
colon adenocarcinoma cells (Xu et al., 1998) while IFN-α stimulates FasL
transcription and surface expression in peripheral blood mononuclear cells (Kirou et
al., 2000, Kaser et al., 1999).
Procaspases
Expression of procaspases-4 and -8 is increased by type I and type II IFNs (de Veer
et al., 2001); IFN-γ additionally induces transcription of procaspase-1, -3 and -12
genes, and may also modulate procaspase-7 and procaspase-10 expression (Kalai
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et al., 2003, Chin et al., 1997, Tamura et al., 1996, Dai and Krantz, 1999, Ossina et
al., 1997).
Bcl-2 proteins
The pro-apoptotic Bcl-2 family members Bak and Bax are upregulated by IFN-γ
(Soond et al., 2007, Der et al., 1998b, Ossina et al., 1997) while anti-apoptotic Bcl-2
is down regulated (Zhou et al., 2008).
PKR
In addition to its inhibitory effects on translation (see Section 1.1.4.1), PKR also
plays an important role in apoptosis regulation. Studies into the effects of PKR on
translation demonstrated a growth suppressive phenotype in cells overexpressing
PKR which was reversed by the expression of PKR with a defective catalytic domain
(Barber et al., 1993, Chong et al., 1992). In other studies, expression of a dominant-
negative mutant of PKR caused malignant transformation of murine fibroblasts
(Balachandran et al., 1998, Koromilas et al., 1992, Meurs et al., 1993). The tumour-
suppressive effect of PKR was later shown to be due to the induction of apoptosis
(Lee and Esteban, 1994). Knockout of PKR or expression of kinase inactive variants
inhibited apoptosis induction by dsRNA (Balachandran et al., 1998, Der et al., 1997),
TNF-α (Der et al., 1997, Yeung et al., 1996) and IAV (Takizawa et al., 1996). The
mechanisms by which PKR causes apoptosis have not been fully elucidated, but it
appears PKR may perform multiple roles. It has been suggested that inhibition of
protein synthesis may be important for PKR-induced apoptosis: inhibition of the
translational machinery by PKR may suppress expression of anti-apoptotic proteins.
In support of this, PKR-induced apoptosis was blocked by expression of eIF2α that
cannot undergo PKR-mediated phosphorylation (Gil et al., 1999), and expression of
an eIF2α variant that mimics phosphorylated eIF2α was sufficient to induce
apoptosis (Srivastava et al., 1998). Inducible expression of a dominant-negative PKR
also reduced transcription of several pro-apoptotic genes, including Fas, TNFR-1,
FADD, caspase-8, Bax and Bad, in response to dsRNA treatment (Balachandran et
al., 1998). A substrate of PKR is the NF-kB inhibitor IkB, which is degraded following
PKR-mediated phosphorylation to activate NF-kB (Kumar et al., 1994). Expression of
an unphosphorylatable IkB variant suppresses activation of NF-kB by PKR and
inhibits PKR-induced apoptosis (Gil et al., 1999). Several pro-apoptotic proteins are
NF-kB-responsive, including Fas (Chan et al., 1999, Kuhnel et al., 2000), the TNFR-
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related DR6 (Kasof et al., 2001) and the TRAIL receptor (Ravi et al., 2001), so PKR
could exert its pro-apoptotic effects through enhanced DR expression. However, NF-
kB additionally up-regulates a number of anti-apoptotic proteins including cIAPs
(Hong et al., 2000, Wang et al., 1998b) and cFLIP (Kreuz et al., 2001). p53 may also
be required for PKR-induced apoptosis. PKR and p53 can directly associate to
mediate p53 activation (Cuddihy et al., 1999b) and p53 activity is inhibited in PKR
knockout cells as evidenced by a reduction in p21Waf1 and Mdm2 expression
(Cuddihy et al., 1999a). PKR may therefore function as a dsRNA receptor that
triggers induction of pro-apoptotic genes and apoptosis (see Section 1.2.7).
2’-5’-OAS/RNaseL
Transient transfection of OAS into cancer cell-lines reduces colony growth by
inducing apoptosis and IFN-γ-induced apoptosis requires OAS induction (Mullan et
al., 2005). Pro-apoptotic OAS activity appears to be limited to one splice variant of
OAS1, termed the 9-2 isozyme, which promotes apoptosis in mammalian cells,
possibly through interactions with Bcl-2 and Bcl-XL (Ghosh et al., 2001). In addition,
activation of RNase L by OAS-synthesised oligoadenylates induced apoptosis in
fibroblasts, while expression of a dominant-negative form of RNaseL rendered cells
resistant to apoptosis induced by dsRNA, staurosporine or poliovirus infection
(Castelli et al., 1997, Castelli et al., 1998). Additionally, spontaneous apoptosis
occurs at a reduced rate in the thymus and spleen of RNaseL-null mice (Zhou et al.,
1997) and mutations in the RNaseL gene have been linked to the development of
prostate cancer in several studies (Carpten et al., 2002, Rokman et al., 2002, Wang
et al., 2002b, Rennert et al., 2002, Casey et al., 2002).
PML
Overexpression of PML leads to rapid induction of cell death (Quignon et al., 1998)
and PML expression is essential for apoptotic responses to agonist Fas antibody,
TNF-α, ceramide and type I and II IFNs (Wang et al., 1998c). More recent studies
implicate p53 in PML-induced apoptosis. p53 is recruited to PML NBs where it
undergoes PML-mediated acetylation, which is essential for p53 activation and p53-
induced apoptosis (Pearson et al., 2000, Fogal et al., 2000, Guo et al., 2000, Bischof
et al., 2002). Additionally, PML bodies recruit a number of proteins involved in p53
activation or stabilisation, leading to the suggestion that PML NBs act as a scaffold
for p53 recruitment and regulation (Takahashi et al., 2004). PML NBs have also been
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linked to regulation of DR-mediated apoptosis through recruitment of CASP8AP2
(caspase-8 associated protein 2) and Daxx (reviewed in Krieghoff-Henning and
Hofmann, 2008). A caspase-independent pathway of PML-mediated apoptosis
activation has additionally been described that is independent of de novo
transcription (Quignon et al., 1998).
XAF-1
The IFN-stimulated XIAP-associated factor (XAF-1) is an interactor of XIAP (Leaman
et al., 2002, Liston et al., 2001). One of the human IAPs, XIAP directly binds and
inhibits caspases-3, 7 and 9 (Deveraux et al., 1998, Deveraux et al., 1997).
Additionally, XIAP promotes cell-survival through activation of NF-kB and JNK1
(Hofer-Warbinek et al., 2000). XAF-1 overexpression prevents inhibition of caspase
activity by XIAP (Liston et al., 2001), and the XAF-1/XIAP complex promotes the
degradation of an additional IAP family member, survivin, by a ubiquitin/proteasome-
mediated pathway (Arora et al., 2007).
IRFs
The role of IRF3 in apoptosis induction will be discussed in Section 1.2.7. Additional
members of the IRF family have been linked to apoptosis regulation. Inactivation of
IRF1 leads to accelerated cell transformation (Taniguchi et al., 1998) while
overexpression of IRF1 leads to caspase-1 activation and sensitises cells to
radiation-induced apoptosis in T lymphocytes (Tamura et al., 1995). IRF1 may
additionally be required for IFN-induced upregulation of TNFR (Ossina et al., 1997).
IFN-γ-inducible IRF8 is expressed only in lymphoid cells and macrophages and
appears to be required for DNA-damage and IFN-γ-induced apoptosis, possibly
through upregulation of Fas expression (Yang et al., 2007b) and downregulation of
Bcl-XL (Gabriele et al., 1999).
p53
Expression of p53 is enhanced by type I IFNs (Takaoka et al., 2003). While IFN
treatment does not activate p53, subsequent infection with VSV, NDV or HSV does,
and induces an apoptotic response that is independent of IFN (Takaoka et al., 2003).
Although the mechanism of p53 activation by virus infection is unknown, current
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evidence indicates an involvement for PKR, which can directly bind p53 to enhance
its transcriptional activity (Cuddihy et al., 1999a, Cuddihy et al., 1999b).
1.2.5.2 ISGF3/GAF-independent STAT1 transcription
In addition to its role in ISG expression in response to IFN, STAT1 can also regulate
ISG transcription independently of IFN. For example, while several procaspases are
upregulated by IFN, procaspase expression can also be stimulated by STAT1 in an
IFN-independent manner. STAT1 is required for constitutive expression of
procaspases-1, 2 and 3 in human fibroblasts (Kumar et al., 1997) and expression of
procaspases-1 and 11 in murine lymphocytes (Lee et al., 2000a): tyrosine
phosphorylation and dimerisation is not required for this role of STAT1 (Kumar et al.,
1997). Instead, constitutive procaspase expression and induction of cell death by
STAT1 appears to require Ser727 phosphorylation (Kumar et al., 1997), suggesting a
role for serine-phosphorylated, STAT1 monomers in pro-apoptotic gene transcription.
Indeed, serine-phosphorylated STAT1 plays a critical role in the pathogenesis of the
kidney cancer Wilms’ tumour (Timofeeva et al., 2006). PKCδ, the enzyme thought to
mediate STAT1 serine phosphorylation (Uddin et al., 2002), is required for
mitochondria-mediated apoptosis (Matassa et al., 2001); DNA-damage induces
apoptosis through PKCδ-dependent STAT1 serine phosphorylation and nuclear
translocation (DeVries et al., 2004). Non-tyrosine phosphorylated, serine-
phosphorylated STAT1 can also up- or downregulate constitutive expression of a
number of additional ISGs: upregulated genes include those involved in MHC-
mediated antigen presentation and the CDK inhibitor p21Waf1, while downregulated
genes include Bcl-2, Bcl-XL and cell cycle regulators (Chatterjee-Kishore et al., 2000,
Agrawal et al., 2002, Chin et al., 1996, Stephanou et al., 2000a). Additionally,
constitutive expression of the 20S proteasome subunit LMP2 is regulated by binding
of a complex consisting of non-tyrosine-phosphorylated STAT1 and IRF1 to a GAS
element (Chatterjee-Kishore et al., 2000).
1.2.5.3 Transcription-independent apoptosis regulation by STAT1
STAT1 can also modulate apoptosis independently of transcription, through its
interactions with signalling proteins. STAT1 directly binds both TNFR1 and TRADD
to inhibit formation of the TRADD/RIP/TRAF2 complex and suppress NF-kB
activation. Although STAT1 appears to interact with TRADD in quiescent cells
(Wesemann and Benveniste, 2003, Pajak and Orzechowski, 2007), treatment of
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HeLa cells with TNF-α increases the STAT1:TRADD association, leading to inhibition
of NF-kB activity and TNF-α-induced apoptosis (Wang et al., 2000b). In contrast,
IFN-α treatment diminishes the STAT1:TRADD interaction by shunting STAT1 into
the JAK/STAT signalling pathway; consequently, in cells which are resistant to the
cytotoxic effects of IFNs, IFN-α activates NF-kB and cell survival (Pajak and
Orzechowski, 2007). In support of this, TNF-α-treatment of STAT1-deficient cells
leads to enhanced NF-kB activation (Wesemann and Benveniste, 2003). Similarly,
IFN-γ treatment abrogates recruitment of STAT1 to TNFR in macrophages by 
promoting STAT1 translocation to the nucleus. It appears then that IFN and TNF-α
receptors compete for STAT1 to regulate NF-kB activation.
Acetylation of STAT1 at Lys410 and Lys413 is also implicated in regulation of NF-kB
and cell death. Acetylated STAT1 interacts with the p65 subunit of NF-kB to inhibit
NF-kB nuclear localisation and DNA binding activity (Figure 1.9, Kramer et al.,
2006). Consequently, STAT1 acetylation diminishes expression of anti-apoptotic NF-
kB-responsive genes to enhance the rate of apoptosis (Kramer et al., 2006). Thus,
inhibition of HDAC activity sensitises colon cancer cells to IFN-γ-induced apoptosis,
at least in part due to down-regulation of anti-apoptotic Bcl-XL and survivin (Klampfer
et al., 2004, Kramer et al., 2006).
STAT1 also appears to play an important role in p53 regulation. STAT1 directly
interacts with p53, an association that is enhanced in response to DNA damage, and
functions as a p53 coactivator to stimulate transcription of p53-responsive genes
such as Bax, Noxa and Fas (Townsend et al., 2004). In addition, STAT1 negatively
regulates expression of the p53 inhibitor Mdm2 (Townsend et al., 2004). The
importance of STAT1 in p53-mediated apoptosis is demonstrated by a decreased
susceptibility to apoptosis following DNA damage in STAT1-deficient cells
(Townsend et al., 2004). p53 has also been implicated in the activation of STAT1: in
response to genotoxic drugs, STAT1 becomes activated by p53 by a mechanism that
does not require p53-transcriptional activity but that is dependent on association of
p53:STAT1 with the proto-oncogene product c-Abl1 (Youlyouz-Marfak et al., 2008).
Interestingly, PIAS1, an E3 ligase that binds and SUMOylates STAT1 (Liu et al.,
1998, Ungureanu et al., 2003), also catalyses SUMO-conjugation of p53 (Kahyo et
al., 2001, Schmidt and Muller, 2002). These data suggest that STAT1:p53
complexes may associate with different cellular proteins (PIAS1 or c-Abl1) to
regulate either p53 or STAT1 activity, depending on other cellular signals.
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1.2.6 Regulation of apoptosis by PI3K
While IFN upregulates many pro-apoptotic genes through activation of STATs, IFN
also activates PI3K signalling, which promotes cell survival. Indeed, PI3K activation
by IFN is able to protect against virus-induced cell death (Prejean et al., 2001). The
activation of both pro- and anti-apoptotic pathways by IFN indicates that IFN-induced
apoptosis is subject to complex regulation: IFN may cause either cell death or cell
survival, depending on the extent of STAT and PI3K activation.
Many of the anti-apoptotic effects of PI3K are mediated by Akt, which phosphorylates
a number of known apoptosis regulators (Figure 1.5). Indeed, Akt was first identified
as an oncogene expressed by the mouse leukaemia virus (Bellacosa et al., 1991).
Akt activation in response to IFN is thought to determine the sensitivity of cells to
IFN-induced apoptosis. Colorectal cancer cells that are most resistant to IFN-induced
apoptosis displayed induction of Akt activity following IFN-β treatment, while Akt
activity was reduced in the most sensitive cells (Lei et al., 2005). PI3K/Akt is involved
in NF-kB activation downstream of the type I IFN receptor (Section 1.1.3.4, Du et al.,
2007, Yang et al., 2001), so in cells resistant to IFN-induced apoptosis, IFN
presumably stimulates NF-kB survival pathways rather than apoptosis.
Akt can negatively regulate a number of pro-apoptotic BH3-only proteins at both the
transcriptional level, through its effects on the transcription factors p53 and Forkhead
box protein O (FOXO), and post-transcriptionally through their direct phosphorylation.
Expression of constitutively active Akt stabilises Mdm2 by mediating its
phosphorylation at two sites (Feng et al., 2004) and promotes its nuclear
translocation, where it targets p53 for degradation and reduces its transcriptional
activity (Mayo and Donner, 2001, Ogawara et al., 2002). Downstream transcriptional
targets of p53 are involved in cell senescence, cell-cycle arrest and apoptosis.
Transcription of two BH3-only proteins, PUMA and Noxa, is regulated by p53 and
these proteins are important mediators of p53-regulated apoptosis in response to
DNA damage (Villunger et al., 2003). Inhibition of PI3K by LY294002 upregulates the
number of p53 and PUMA mRNA transcripts, leading to apoptosis in gastric cancer
cells (Chun-gen Xing, 2008). Additionally, it has been shown that PI3K prevents p53
activation by inhibiting its phosphorylation at Ser6 (Filiz et al., 2008). Akt also
negatively regulates the FOXO family of transcription factors (Tang et al., 1999) by
promoting their phosphorylation at three sites. This impairs their DNA-binding activity
and causes their nuclear export (Kops et al., 1999, Rena et al., 1999, Biggs et al.,
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1999, Brownawell et al., 2001). Expression of FOXO-dependent genes, including the
pro-apoptotic BH3-only proteins BIM and bNIP3 (Behzad et al., 2007, Tran et al.,
2002, Dijkers et al., 2000a, Stahl et al., 2002) and the death-receptor ligands FasL
and TRAIL (Modur et al., 2002, Ciechomska et al., 2003, Behzad et al., 2007), is
subsequently inhibited. Transcription of anti-apoptotic Bcl-XL is also indirectly
suppressed by FOXO4 through its upregulation of the transcriptional repressor Bcl-6
(Tang et al., 2002). In addition, another PI3K-activated serine/threonine kinase,
serum- and glucocorticoid-inducible kinase (SGK), phosphorylates FOXO3a and
prevents apoptosis (Brunet et al., 2001).
In the absence of cell survival signals, pro-apoptotic BAD is found in association with
the anti-apoptotic Bcl-XL at the outer mitochondrial membrane. In response to cell
survival signals, Akt directly phosphorylates BAD at Ser136 (Datta et al., 1997),
resulting in the release of Bcl-XL and activation of cell survival pathways in a number
of cell types (Datta et al., 2000, Datta et al., 2002). Akt phosphorylates and inhibits
GSK3, a serine-threonine kinase that regulates many physiological processes,
including glucose and protein synthesis (Cross et al., 1995). A GSK3 substrate is the
anti-apoptotic Bcl-2 protein Mcl-1, which becomes ubiquitinated and subsequently
degraded following GSK3 phosphorylation, leading to apoptosis (Maurer et al.,
2006). PI3K/Akt can also upregulate Bcl-2 and Mcl-1 at the transcriptional level to
inhibit the mitochondrial apoptosis pathway. This is mediated by CREB (Skorski et
al., 1997, Pugazhenthi et al., 2000, Wang et al., 1999c), which becomes directly
phosphorylated by Akt. The ability of CREB to recruit its coactivator CBP is
enhanced (Du and Montminy, 1998), enabling the activation of cAMP-responsive-
elements (CREs) in the Bcl-2 promoter. In addition, Akt can directly phosphorylate
caspase-9 at Ser196, inactivating it and offering partial resistance to mitochondrial
apoptosis (Cardone et al., 1998).
The three main MAPK cascades, JNK, p38 and ERK, have all been implicated in
apoptosis induction. Akt inhibits apoptosis activated by JNK and p38 through direct
interaction with the apoptosis signal-regulating kinase (ASK) 1. ASK1 is a MAPK
kinase kinase (MAPKKK) that acts upstream of JNK and p38 and interaction with Akt
leads its phosphorylation and negative regulation (Kim et al., 2001). Akt also inhibits
Raf/MEK/ERK signalling through direct interaction with, and phosphorylation of, Raf,
which results in cell survival (Zimmermann and Moelling, 1999).
Activation of Akt protects cells from apoptosis in response to a number of stimuli,
including TRAIL and TNF-α through activation of the NF-κB pathway (Bortul et al.,
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2003, Suzuki et al., 2008, Reddy et al., 2000). Conversely, inhibition of PI3K/Akt by
PTEN inhibits TNF-α-induced NF-κB activation and enhances apoptosis (Koul et al.,
2006). A proposed mechanism of NF-κB activation is the direct phosphorylation of
IKKα by Akt at Thr23 (Ozes et al., 1999). By activating NF-κB, Akt upregulates NF-
κB-responsive genes, including anti-apoptotic cFLIP (Micheau et al., 2001, Bortul et
al., 2003), TRAF1 and 2, A1/Bfl-1 (Wang et al., 1999a), cIAP1 and cIAP2 (Wang et
al., 1998a, Deveraux et al., 1998) and A20, a negative regulator of NF-κB that has
also been implicated in apoptosis inhibition (Sarma et al., 1995, Beyaert et al., 2000).
PI3K/Akt may also be able to act pro-apoptotically. Inhibition of PI3K/Akt can protect
epidermal cells from FasL-mediated apoptosis (Lu et al., 2006a), and IFN-α-induced
and IFN-γ-induced apoptosis have been shown to require PI3K and mTOR (Thyrell
et al., 2004, Fang et al., 2006, Lekmine et al., 2003, Nguyen et al., 2001, Wen et al.,
1995). It has recently been reported that GSK3 forms an anti-apoptotic protein
complex DDX3 and cIAP1. This complex associates with DRs and inhibits DISC
formation and caspase-8 activation; inhibitors of GSK3 (including PI3K/Akt) can
therefore potentiate DR-stimulated apoptosis (Sun et al., 2008b). PI3K/Akt also
promotes Fas receptor trafficking to the cell membrane (Rosner et al., 2006).
Interestingly, in TNF-α-treated neutrophils, PI3K directly binds the TNFR and triggers
the secretion of microbicidal oxygen radicals (Korchak and Kilpatrick, 2001).
1.2.7 Viral RNA induces apoptosis independently of IFN
Viral dsRNA exhibits potent cytotoxic activity that is independent of de novo protein
synthesis (Cordell-Stewart and Taylor, 1973), indicating that dsRNA can cause
apoptosis independently of IFN production. Indeed, virus infection induces apoptosis
even in cells that are non-responsive to IFN (Weaver et al., 2001). Detection of
cytoplasmic dsRNA or IAV infection by RIG-I in human keratinocytes and
macrophages induces caspase-1 and -3 activation and subsequent apoptosis in a
pathway that is dependent on MAVS (Rintahaka et al., 2008). Pro-apoptotic
signalling by RIG-I/MAVS requires downstream activation of IRF3 (McAllister and
Samuel, 2008, Holm et al., 2007) to stimulate transcription from a distinct subset of
proapoptotic ISGs (Heylbroeck et al., 2000, Weaver et al., 2001, Weaver et al., 1998,
McAllister and Samuel, 2008, Holm et al., 2007). Consequently, IRF3 is an absolute
requirement for apoptosis induction of during infection with reovirus (Holm et al.,
2007), Bunyamwera virus (Kohl et al., 2003), NDV (Weaver et al., 2001), and SeV
(Heylbroeck et al., 2000, Peters et al., 2008). Constitutive expression of IRF3 is toxic
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to cells and its inducible expression and activation is sufficient to cause apoptosis in
a number of cell types (Heylbroeck et al., 2000, Weaver et al., 2001). IRF3-mediated
apoptosis requires formation of the dsRNA activated factor DRAF-1 (composed of
IRF3 and CBP/p300) to mediate gene transcription (Heylbroeck et al., 2000, Weaver
et al., 2001, Weaver et al., 1998): DRAF-1 binds to promoter sequences containing
the ISRE and several flanking adenine residues (Daly and Reich, 1993, Daly and
Reich, 1995) to regulate expression of a subset of ISGs. Caspase-8 appears to be
the predominant caspase involved in IRF3-mediated death, indicating the
involvement of extrinsic apoptosis pathways (Heylbroeck et al., 2000). PKR also
appears to be involved in this pathway: PKR activation by 5’-triphosphate RNA leads
to apoptosis induction, and RNA-induced apoptosis is significantly reduced in PKR
knockdown cells (McAllister and Samuel, 2008). Removal of 5’-triphosphate from the
RNA stimulus decreases apoptosis without affecting PKR activation, while
knockdown of MAVS further inhibits apoptosis in PKR-deficient cells (Zhang and
Samuel, 2008, McAllister and Samuel, 2008), perhaps suggesting that PKR acts
downstream of RIG-I but upstream of MAVS. Although the role of PKR in RIG-
I/MAVS-mediated IRF3 activation is unclear, the reported interaction between TRAF3
and PKR (Oganesyan et al., 2006) makes it easy to speculate that PKR regulates
IRF3 activation downstream of RIG-I through TRAF3 (Zhang and Samuel, 2008). In
conclusion, viral nucleic acid stimulates both an IFN-mediated antiviral state and an
IRF3-dependent pro-apoptotic program; these two pathways appear to involve many
of the same molecules.
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1.3 Viral inhibition of intracellular antiviral responses
The IFN and apoptosis responses are incredibly efficient at limiting virus replication.
In order to establish infection in vivo therefore, viruses must evade these responses;
consequently, many (if not all) viruses encode factors that antagonise IFN and/or
apoptosis. The ways in which viruses antagonise IFN and apoptosis will be outlined
in the following section.
1.3.1 IFN antagonism
The IFN response can be counteracted at a number of different stages, and the
mechanisms by which viruses antagonise IFN have been the subject of several
comprehensive reviews (Randall and Goodbourn, 2008, Goodbourn et al., 2000,
Weber et al., 2004). Many viruses interfere with induction of IFN in response to viral
stimuli (Figure 1.10), IFN signalling (Figure 1.11) or the functions of IFN-induced
antiviral proteins. Additionally, global inhibition of transcription or translation is a
common viral strategy for preventing IFN and ISG expression. The mechanisms by
which viral IFN antagonists function vary extensively, and viruses often encode more
than one antagonist activity to allow more efficient evasion of the IFN response. In
some cases, these distinct inhibitory activities may be encoded by the same viral
protein, particularly in the case of small RNA viruses where many proteins are multi-
functional in order to maximise the coding capacity of the genome.
1.3.1.1 Inhibition of IFN induction
The mechanisms by which viruses interfere with IFN-α/β induction are summarised in
Figure 1.10. Restricting the production of PAMPs or preventing their recognition by
the IFN-induction machinery is of primary importance to the virus in vivo. Many
viruses encode dsRNA-binding proteins that sequester dsRNA away from viral
nucleic acid sensors. In addition, these proteins also prevent dsRNA-mediated
activation of PKR and OAS. The dsRNA-binding affinity of the ς3 protein of
reoviruses has been linked to strain-specific differences in IFN production (Bergeron
et al., 1998). The vaccinia virus (VACV) E3L (Deng et al., 2008, Xiang et al., 2002)
and Ebola virus (EBOV) VP35 (Cardenas et al., 2006, Hartman et al., 2006) proteins
also bind intracellular dsRNA to antagonise IFN production. An alternative method for
preventing IFN induction by dsRNA is employed by bovine viral diarrhoea virus
(BVDV). The BVDV Erns glycoprotein is secreted out of the cell, where it binds and
Figure 1.10: Viral antagonists of IFN-a/b induction.
The signalling scheme presented shows IFN-b induction by both TLR3- and RIG-I/mda-5-dependent pathways. The sites of intervention by 
several antagonists are indicated. Note that some antagonists, such as BVDV/NPro, are extremely effective at blocking IFN-a/b induction 
from a variety of PAMPs, because they target signalling molecules (IRF3) that are common to TLR3 and RIG-I/mda-5 pathways of IFN-
induction. Others, such as the V proteins of paramyxoviruses, may block only one arm of the induction pathway (mda-5). Also note that 
other IFN antagonists, such as HCV/NS3/4A, have more than one cellular target. From Randall and Goodbourn, 2008.
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degrades dsRNA through its dsRNA-binding and RNase activity respectively (Iqbal et
al., 2004); as a result, extracellular dsRNA is unable to bind TLR3 and IFN is not
induced.
Some viruses interfere with TLR and RIG-I/mda-5/ZBP-1 signalling. The V proteins of
most paramyxoviruses bind and inhibit mda-5 (Andrejeva et al., 2004, Childs et al.,
2007), while RIG-I activity is inhibited by the NS1 protein of IAV (discussed in
Section 1.3.4). The NS3/4A protease of HCV prevents signalling downstream of
TLR3 through cleavage of TRIF (Li et al., 2005a), while the VACV A46R and A52R
proteins prevent signalling downstream of multiple TLR pathways through inhibition
of TRIF and MyD88 (Stack et al., 2005, Harte et al., 2003). HCV NS3/4A, in addition
to its effects on TRIF, also targets MAVS, the mda-5/RIG-I adaptor protein. NS3/4A
mediates MAVS cleavage away from the mitochondrion, preventing its activation of
TBK1 and IKKε (Li et al., 2005b, Meylan et al., 2005, Cheng et al., 2006, Kaukinen et
al., 2006, Lin et al., 2006a, Loo et al., 2006).
Downstream of MAVS and TRIF, viruses can inhibit NF-kB activation in a number of
ways. The human papillomavirus (HPV) E7 (Spitkovsky et al., 2002), HCV core (Joo
et al., 2005), adenovirus (AdV) E3 (Friedman and Horwitz, 2002) and VACV N1
(DiPerna et al., 2004) proteins associate directly with the IKK complex to inhibit its
kinase activity, impairing IkB phosphorylation and degradation. VACV can
additionally inhibit IkB degradation through its K1 protein (Shisler and Jin, 2004). The
A238L gene product of African swine fever virus (ASFV) is an IkB homologue that
interacts with NF-kB to prevent its transcriptional activity (Powell et al., 1996, Revilla
et al., 1998, Tait et al., 2000); MNF from myxoma virus may also function in a similar
manner since it co-localises with NF-kB and inhibits NF-kB signalling (Camus-
Bouclainville et al., 2004).
Inhibition of IRF3 expression or activation is also a common viral strategy. Rotavirus
NSP1, bovine herpesvirus-1 (BHV-1) bICP0 and the NPro proteases of BVDV and
classical swine fever virus (CSFV) target IRF3 for degradation by the proteasome
(Saira et al., 2007, Ruggli et al., 2005, Bauhofer et al., 2005, Bauhofer et al., 2007,
La Rocca et al., 2005, Hilton et al., 2006, Graff et al., 2007). The E6 protein of HPV-
16 binds and sequesters IRF3 (Ronco et al., 1998), while HSV-1 ICP0 recruits IRF3
and CBP/p300 to nuclear structures, away from host chromatin (Melroe et al., 2004,
Lin et al., 2004a, Melroe et al., 2007). IRF3 dimerisation and activity are inhibited by
the E1 protein of human herpesvirus 6 (HHV-6)(Jaworska et al., 2007) and the Ml
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protein of THOV (Hagmaier et al., 2004, Jennings et al., 2005) while IRF3
phosphorylation by TBK-1 is inhibited by rabies virus (RABV) P (Brzozka et al.,
2005), hantavirus (HTNV) G1 (Alff et al., 2006), Borna disease virus (BDV) P
(Unterstab et al., 2005) and VACV N1 proteins (DiPerna et al., 2004). Both bovine
and human respiratory syncytial virus (RSV) NS1 and NS2 proteins interfere with
IRF3 function by uncharacterised mechanisms (Spann et al., 2005, Bossert et al.,
2003).
1.3.1.2 Inhibition of IFN signalling
The mechanisms by which viruses interfere with IFN signalling are summarised in
Figure 1.11. Like viral inhibition of IFN induction, viruses antagonise IFN signalling at
different stages by a diverse range of mechanisms. Transduction of type I and IFN
signals can be inhibited prior to IFN:receptor binding. Poxviruses secrete soluble
IFN-α- and IFN-γ-binding proteins that sequester extracellular IFN and prevents its
activation of the receptor (Colamonici et al., 1995, Symons et al., 1995, Upton et al.,
1992, Alcami and Smith, 1995, Mossman et al., 1995). Additionally, these proteins
can bind the surface of neighbouring cells and prevent them responding to IFNs
(Alcami et al., 2000). The K3 and K5 proteins of Kaposi’s sarcoma-associated
herpesvirus downregulate expression of IFNGR1 subunit of the IFN-γ receptor by
targeting it for endocytosis and degradation (Li et al., 2007).
Activation of the IFN receptor and associated JAKs can also be inhibited. Dengue
virus infection, HPV-18 E6 protein and the Japanese encephalitis virus (JEV) NS5
protein block Tyk2 activation (Li et al., 1999, Ho et al., 2005, Lin et al., 2004b, Lin et
al., 2006b). Several viruses target JAK1, a component of both type I and type II IFN
signalling, thereby inhibiting both pathways. HCMV enhances JAK1 degradation by
the proteasome (Miller et al., 1998, Miller et al., 1999) and HSV-1 infection also
decreases JAK1 expression (Chee and Roizman, 2004). The large T antigen of
murine polyoma virus (MPyV) binds to JAK1 to inactivate signalling from the IFN
receptors (Weihua et al., 1998) while the paramyxoviruses mumps virus (MuV) and
measles virus (MeV) prevent JAK1 phosphorylation (Yokota et al., 2003, Kubota et
al., 2002). The NS5 of Langat virus (LGTV) antagonises both type I and type II IFN
signalling through association with IFNAR and IFNGR and preventing JAK1 and
Tyk2 phosphorylation (Best et al., 2005).
Figure 1.11: Viral antagonists of IFN-a/b signalling.
The ‘classical’ JAK/STAT signalling pathway activated by type I IFNs is shown. Sites of intervention of 
several viral antagonists are indicated. Note that many, but not all, of these IFN antagonists also inhibit 
IFN-g signalling. For example, the V protein of PIV5 targets STAT1 for degradation and thus blocks IFN-
a/b, IFN-g and type III IFN signalling, whilst the V protein of hPIV2 targets STAT2 for degradation (in 
human cells) and thus does not block IFN-g signalling. See text for details. 
From Randall and Goodbourn, 2008. 
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Given the critical role of STATs in IFN signalling, it comes as no surprise that they
are targeted by many viral IFN antagonists. The V proteins of some paramyxoviruses
target STATs for proteasomal degradation: MuV targets STAT1 and STAT3, NDV,
PIV5 and simian virus 41 (SV41) target STAT1 while parainfluenza virus type 2
(PIV2) targets STAT2 (Ulane et al., 2003, Kubota et al., 2001, Nishio et al., 2001,
Didcock et al., 1999b, Huang et al., 2003, Young et al., 2000, Andrejeva et al.,
2002b, Precious et al., 2005b, Parisien et al., 2001). The STAT-degradative function
of SeV is attributed to the C protein, which promotes STAT1 ubiquitination (Garcin et
al., 2002, Garcin et al., 1999). RSV targets STAT2 through the activities of the NS1
and NS2 proteins (Ramaswamy et al., 2006, Ramaswamy et al., 2004, Elliott et al.,
2007). Viruses from other families also increase STAT turnover: STAT2 levels
decrease significantly during HSV-1 infection (Chee and Roizman, 2004). Viruses
can also target STAT proteins without enhancing their degradation. For example, the
paramyxovirus MeV, Mapuera virus (MPRV), Rinderpest virus (RPV), Hendra virus
(HeV) and Nipah virus (NiV) V proteins sequester STATs to prevent their
translocation to the nucleus (Nanda and Baron, 2006, Rodriguez et al., 2002,
Rodriguez et al., 2003, Palosaari et al., 2003, Hagmaier et al., 2007). STAT nuclear
translocation can be actively inhibited by EBOV VP24 and severe acute respiratory
syndrome coronavirus (SARS Co-V) ORF6 proteins which bind the karyopherin
nuclear import proteins to inhibit STAT nuclear accumulation (Reid et al., 2006,
Frieman et al., 2007). The P protein of RABV binds to tyrosine-phosphorylated
STAT1 and STAT2, inhibiting both their nuclear translocation and DNA binding
activity (Vidy et al., 2007, Brzozka et al., 2006). The HCMV IE1 protein associates
with STAT1 and STAT2 in the nuclei of infected cells and prevents association of
ISGF3 with the ISRE (Paulus et al., 2006). HBV precore/core proteins interact
directly with the ISRE in the MxA promoter, downregulating MxA transcription
(Fernandez et al., 2003). Viruses can also affect the phosphorylation states of
STATs. SeV C inhibits STAT1 phosphorylation in addition to its effects on total
STAT1 levels (Garcin et al., 2003, Saito et al., 2002, Komatsu et al., 2002, Young et
al., 2000). HCV core protein also reduces STAT1 phosphorylation to prevent its
association with STAT2 and inhibit ISGF3 formation (Lin et al., 2006c). VACV
encodes a viral phosphatase, VH1, responsible for dephosphorylation and
deactivation of STAT1 (Najarro et al., 2001). HBV and HCV upregulate protein
phosphatase 2A (PP2A)(Christen et al., 2007, Duong et al., 2004) which leads to a
decrease in STAT1 transcriptional activity due to STAT1 hypomethylation and an
increased association between STAT1 and PIAS1, the protein responsible for
SUMO-modification of STAT1 (Duong et al., 2004, Duong et al., 2005, Christen et al.,
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2007). SOCS, a cellular inhibitor of STAT signalling, is upregulated by HCV core
protein (Bode et al., 2003) and by HSV-1 infection (Yokota et al., 2004). In addition to
STATs, IRF9 is also a viral target due to its role in the ISGF3 transcription factor.
HPV-16 E7 binds IRF9 directly, preventing ISGF3 formation (Barnard and McMillan,
1999), while AdV E1A decreases IRF9 expression to inhibit IFN-α signalling (Leonard
and Sen, 1997).
1.3.1.3 Inhibition of ISG products
Viral dsRNA-binding proteins, in addition to preventing induction of IFN, sequester
dsRNA away from the antiviral proteins that require dsRNA for their activation.
Consequently, the dsRNA-binding activities of VACV E3L, Epstein-Barr virus (EBV)
SM and HSV-1 Us11 are required to inhibit PKR and OAS activation (Sanchez and
Mohr, 2007, Poppers et al., 2003, Chang et al., 1992, Rivas et al., 1998, Poppers et
al., 2000). In addition, some viruses encode RNA species, such as the AdV virus
associated RNA I (VAI RNA), that complex with PKR to inhibit its
autophosphorylation and activation of downstream signalling (Katze et al., 1987).
Because dsRNA-independent activation of PKR can also occur through PKR
activator PACT, viruses have evolved additional mechanisms of PKR inhibition. HCV
NS5A directly binds PKR to inhibit its activity (Gale et al., 1997). A similar function
has been attributed to the HSV-1 Us11 protein (Peters et al., 2002) indicating that
this viral protein inhibits PKR activation by two distinct mechanisms. An as yet
unidentified protease encoded by poliovirus specifically degrades PKR (Black et al.,
1989, Black et al., 1993) while VACV K3L shares a number of conserved residues
with the PKR substrate eIF2α and acts as a pseudosubstrate PKR inhibitor
(Kawagishi-Kobayashi et al., 1997). dsRNA-independent viral inhibition of the
OAS/RNaseL system has also been reported: EMCV and human immunodeficiency
virus HIV-1 upregulate expression of a cellular RNaseL inhibitor (Martinand et al.,
1998, Martinand et al., 1999) while HCV NS5A directly binds OAS to inhibit its
activity (Taguchi et al., 2004).
1.3.1.4 Inhibition of global protein synthesis and secretion
A large number of viruses affect cellular protein expression through inhibition of
global transcription or mRNA processing, nuclear export or translation. A major
function of host protein synthesis shut-off is thought to be the reduction of IFN and
ISG expression. In support of this, the NSs protein of Bunyamwera virus, which
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interferes with mRNA transcription (Thomas et al., 2004), prevents IFN induction. An
NSs deletion mutant is a much stronger inducer of IFN than wt and displays
attenuated growth characteristics (Weber et al., 2002); a phenotype similar to wt
virus can be restored in cells that are unresponsive to IFN (Young et al., 2003). Viral
inhibition of global protein secretion, for instance by the 3A protein of several
picornaviruses (Choe et al., 2005), may also play a role in preventing IFN release
into the extracellular fluid.
1.3.2 Viral inhibition of apoptosis
One of the first studies into the effects of apoptosis on virus replication demonstrated
that apoptosis decreased multiplication of an insect virus by about 50-fold (Clem and
Miller, 1993). Subsequent studies, however, have shown that viruses (including HSV-
1, VSV and poliovirus) can replicate considerably in apoptotic cells and that
apoptosis induction only slightly reduces viral titres (Koyama et al., 1998). It has
been suggested that apoptosis may play a more predominant role in limiting in vivo
infections, as phagocytosis of virus-infected, apoptotic cells completely abrogates
virus multiplication (Fujimoto et al., 2000, Nakanishi et al., 2008). The primary reason
that many viruses block apoptosis then may be to prevent apoptotic cell clearance by
macrophages (Koyama et al., 2000). The benefits to the virus of limiting
phagocytosis in vivo may be two-fold: to increase virus multiplication and to suppress
cell-mediated immunity.
Apoptosis inhibition by DNA and RNA tumour viruses has been studied in depth due
to its implications for cancer research. These studies dominate the literature and will
only be summarised here as they have been comprehensively reviewed elsewhere
(Benedict, 2003, Benedict et al., 2002, White, 2006). Since DNA viruses and
retroviruses hijack host transcriptional and translational machinery, they require
continued cell survival for efficient virus replication. Consequently, these viruses
encode viral apoptosis inhibitors to prolong the life of the cell; these inhibitors can act
at a number of different stages of apoptosis and often are homologous to cellular
inhibitors. Many viruses antagonise mitochondrial apoptosis by encoding Bcl-2
mimics or through post-translational modification of the Bcl-2 proteins. For example,
the AdV E1B-19K protein is similar in both sequence and function to the Bcl-2 family
members and binds to Bax, preventing its oligomerisation and subsequent
cytochrome c release (Sundararajan et al., 2001, Sundararajan and White, 2001).
The HIV-1 NEF protein stimulates Bad phosphorylation, abrogating its pro-apoptotic
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activity and suppressing apoptosis (Wolf et al., 2001) while the human T-cell
leukaemia virus type I (HTLV-1) Tax protein increases transcription from the Bcl-XL
promoter (Tsukahara et al., 1999). The DR-mediated pathway of apoptosis is also
targeted by viral proteins. In a similar manner to their antagonism of the IFN
response, poxviruses secret soluble TNF-α receptors (Smith et al., 1990, Reading et
al., 2002). In contrast, AdV E3 proteins decrease Fas and TRAIL receptor expression
on the cell surface, reducing cell sensitivity to DR ligands (Shisler et al., 1997,
Tollefson et al., 1998, Benedict et al., 2001). The EBV LMP1 engages TRAFs and
TRADD in a similar manner to TNFR and subsequently activates anti-apoptotic NF-
kB signalling (Uchida et al., 1999, Cahir McFarland et al., 1999, Izumi et al., 1999).
Modulation of caspase activity is also a function of many viral apoptosis inhibitors:
the viral caspase-8 inhibitors, vFLIPs, encoded by herpesviruses and poxviruses,
block caspase-8 activation by the DISC (Bertin et al., 1997) whilst baculoviruses
encode IAP orthologues that inhibit caspase activity (Seshagiri and Miller, 1997,
Clem and Miller, 1994). Viruses can additionally disrupt apoptosis through
inactivation of p53. The large T antigen of SV40 sequesters p53 into an inactive
complex (Linzer and Levine, 1979, Zheng et al., 1994a, Yanai and Obinata, 1994),
and the AdV E1B-55K and E4orf6 proteins promote p53 ubiquitination and
degradation (Steegenga et al., 1998, Querido et al., 2001).
Given the importance of the IFN response in promoting a pro-apoptotic state in cells,
viral IFN antagonists can also antagonise apoptosis through inhibition of pro-
apoptotic ISG expression and/or function. In addition, dsRNA can induce apoptosis
through RIG-I/MAVS and PKR to activate IRF3-dependent transcription from a
distinct subset of pro-apoptotic ISGs (see Section 1.2.7). Viruses that encode
dsRNA-binding proteins or inhibitors of RIG-I, PKR, MAVS or IRF3 can therefore
prevent both the induction of IFN and the induction of apoptosis. In support of this,
several viral dsRNA-binding proteins, including VACV E3L and IAV NS1 (see below),
are oncogenic (Garcia et al., 2002) and the PKR-binding function of NS5A has been
linked to the disruption of apoptosis (Gale et al., 1999). Degradation of IRF3 by
CSFV NPro limits both IFN and apoptosis induction (Ruggli et al., 2005, La Rocca et
al., 2005, Bauhofer et al., 2007). BVDV infection inhibits dsRNA-induced IFN
production and apoptosis (Schweizer and Peterhans, 2001), and although inhibition
of apoptosis by BVDV has not yet been attributed to NPro activity, CSFV and BVDV
NPro target IRF3 by a conserved mechanism (Hilton et al., 2006, Seago et al., 2007).
Similarly, the NSs of Bunyamwera virus inhibits IFN and apoptosis by interfering with
IRF3 transcription (Kohl et al., 2003, Leonard et al., 2006, Weber et al., 2001). Some
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viruses limit apoptosis through activation of NF-kB pro-survival pathways: HCV core
protein inhibits TNF-α-induced apoptosis (Ray et al., 1998) through enhancement of
NF-kB activation and upregulation of cFLIP (Saito et al., 2006, You et al., 1999,
Marusawa et al., 1999).
Many viruses have evolved ways of activating PI3K or Akt in order to block or delay
virus-induced apoptosis. For some viruses, PI3K/Akt activation contributes to latent
infection. For example, EBV LMP1 binds the p85 subunit of PI3K to mediate the
activation of PI3K and downstream Akt phosphorylation (Dawson et al., 2003).
Inhibition of EBV-induced PI3K activity decreases cell viability, suggesting PI3K/Akt
is essential for promoting the survival of infected cells (Dawson et al., 2003). HPV-
16, also a virus associated with prolonged periods of latency, encodes the E5 protein
which associates with the epidermal growth factor receptor (EGFR) resulting in its
stimulation (Hwang et al., 1995a, Crusius et al., 1998). PI3K is subsequently
recruited to the receptor and PI3K/Akt cell survival pathways are activated (Zhang et
al., 2002). PI3K/Akt also plays a role during chronic viral infection, particularly with
hepatitis B virus (HBV) and HCV. The HBx protein of HBV blocks apoptosis by
activating a PI3K/Akt/Bad-dependent pathway that has not yet been fully
characterised (Lee et al., 2001) while HCV NS5A associates directly with p85 to
enhance its tyrosine phosphorylation, promoting Akt activation and blocking
apoptosis induction by reducing FOXO1 transcriptional activity (He et al., 2002b,
Street et al., 2005, Street et al., 2004). Transient activation of PI3K/Akt also occurs
early on in infection with several small RNA viruses in order to mediate short-term
cell survival. RSV prevents premature apoptosis induction through PI3K/Akt-
dependent activation during the first few hours of infection (Thomas et al., 2002), a
function that may be due to the non-structural proteins NS1 and NS2 (Bitko et al.,
2007). A number of apoptosis regulators, including Mdm2 (Groskreutz et al., 2007),
NF-kB and GSK-3β (Thomas et al., 2002) are activated downstream of PI3K/Akt
during RSV infection. This effect on cell death is only transient however, preventing
apoptosis just long enough for the virus to complete its replication phase; later in
infection, apoptosis is induced, perhaps to facilitate virus spread.
1.3.3 Antagonism of antiviral responses by PIV5 V protein
PIV5 (also known as simian virus 5; SV5) is a prototypical member of the rubulavirus
genus of the Paramyxoviridae family (paramyxovirus taxonomy and molecular
biology are comprehensively reviewed in Lamb and Kolakofsky, 2001). PIV5 is an
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enveloped virus with a negative-sense non-segmented ssRNA genome that encodes
eight gene products from seven genes. The integral membrane proteins HN
(haemagglutinin-neuraminidase) and F (fusion) are present in the viral envelope and
are required for cell attachment and fusion respectively. Also in the envelope is the
SH (small hydrophobic) protein, which has been implicated in apoptosis inhibition
(He et al., 2001, Lin et al., 2003, Wilson et al., 2006). The P (phosphoprotein) and L
(large) proteins form the viral polymerase while M (matrix) associates with the inside
of the viral envelope and plays a role in virus assembly. Viral genome is
encapsidated within helical capsids formed from NP (nucleocapsid protein); also
found in association with NP are the viral polymerase components and the V protein.
PIV5 is a poor inducer of IFN, and IFN-α is unable to activate transcription from the
ISRE in PIV5-infected cells (Didcock et al., 1999a); PIV5 therefore efficiently
circumvents the IFN response through inhibition of both IFN production and IFN
signalling. This IFN antagonism function has been attributed to the multifunctional
PIV5 V protein (He et al., 2002a, Didcock et al., 1999b, Poole et al., 2002, Andrejeva
et al., 2004), which also plays key roles in viral RNA encapsidation (Precious et al.,
1995, Randall and Bermingham, 1996), viral RNA synthesis (Lin et al., 2005, Gainey
et al., 2008a, Nishio et al., 2008), cell cycle regulation (Lin and Lamb, 2000),
inhibition of pro-inflammatory cytokine (IL-6) expression (Lin et al., 2007) and
inhibition of apoptosis (Sun et al., 2004). V is a faithful transcript of the P/V gene,
while the P protein is generated by a shift in the reading frame caused by a viral
polymerase ‘stuttering’ mechanism (Vidal et al., 1990). Consequently, V shares a
164-residue N-terminus with P, while its cysteine-rich C-terminus is unique. This C-
terminal domain is highly conserved among all paramyxoviruses and contains a zinc-
finger domain which is thought to be involved in mediating interactions between V
and other proteins (Paterson et al., 1995, Thomas et al., 1988).
V inhibits both type I and type II IFN signalling by targeting STAT1 for degradation by
the ubiquitin/proteasome system (Andrejeva et al., 2002b, Didcock et al., 1999a,
Young et al., 2000, Didcock et al., 1999b). Critical for STAT1 degradation is an
interaction between V and DDB1, the damage-specific DNA binding protein (Leupin
et al., 2003, Lin et al., 1998a, Andrejeva et al., 2002a). The observations that DDB1
complexes with Cullin 4a to form E3 ligases (Wertz et al., 2004, Shiyanov et al.,
1999) and that there is an absolute requirement for STAT2 in V-mediated STAT1
degradation (Parisien et al., 2002) led to the suggestion that a multiprotein complex
comprising V, STAT1, STAT2, DDB1 and Cullin 4a was responsible for STAT1
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degradation (Precious et al., 2005b, Ulane and Horvath, 2002). In support of this,
studies into the molecular interactions between these proteins demonstrated that V is
unable to directly bind STAT1, but can bind STAT2 and DDB1 independently; STAT1
is recruited to this complex through its interaction with STAT2 (Precious et al.,
2005a). V therefore acts as an adaptor, bringing STAT1/STAT2 heterodimers into
close proximity to the DDB1/Cullin 4a ubiquitin ligase complex (Precious et al., 2007,
Precious et al., 2005a). Following STAT1 ubiquitination and degradation, the binding
affinity of V for STAT2 decreases and STAT2 is released from the complex, allowing
for continued rounds of STAT1 ubiquitination (Precious et al., 2007). Naturally-
occurring isolates of PIV5 exist that differ in their ability to inhibit IFN signalling
(Figure 3.11, Chatziandreou et al., 2002). The PIV5-CPI- strain was isolated from a
dog that had been experimentally infected with the PIV5-CPI+ virus (Baumgartner et
al., 1981). While PIV5-CPI+ can inhibit IFN signalling, three amino acid substitutions
in the N-terminus of the V render the PIV5-CPI- virus unable to target STAT1 for
degradation (Southern et al., 1991, Chatziandreou et al., 2002).
V can also limit IFN induction by directly binding mda-5, the cytoplasmic RNA sensor,
and inhibiting its activity (Poole et al., 2002, He et al., 2002a, Andrejeva et al., 2004).
This function of V is specific to mda-5, as RIG-I activity is unaffected by V expression
(Childs et al., 2007, Komatsu et al., 2007, Yoneyama et al., 2005). A mechanism of
mda-5 inhibition by V has recently been proposed (Childs et al., 2009). Activation of
mda-5 by dsRNA requires homo-oligomerisation through its helicase domain. Since
the V-binding site of mda-5 has been mapped to a stretch of residues (between aa
676 and 816, although additional contacts are important in the interaction) in its C-
terminal helicase domain, V competes with dsRNA for mda-5 binding to inhibit mda-5
oligomerisation (Childs et al., 2007, Childs et al., 2009).
Wildtype strains of PIV5 are relatively uncytopathic in tissue culture and can
establish persistent infections (Parks et al., 2002, Sun et al., 2004, Choppin, 1964,
Chatziandreou et al., 2002). However, a recombinant virus lacking the conserved C-
terminus of V (rPIV5-VΔC) induces large amounts of apoptosis as well as IFN (Sun
et al., 2004, He et al., 2002a). This apoptosis does not seem to require IFN-
production, since rPIV5-VΔC also caused more cell death than wt virus in Vero (IFN-
α/β-deficient) and U3A (STAT1-deficient) cells (Sun et al., 2004, He et al., 2002a).
He and colleagues demonstrated activation of caspase-12 during rPIV5-VΔC-
induced apoptosis, a caspase associated with ER-mediated apoptosis (Szegezdi et
al., 2003, Sun et al., 2004). The significance of this result is open to question
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however, since human caspase-12 genes have acquired a premature stop codon
that precludes expression of the full-length protein and a loss-of-function mutation in
a domain critical for catalytic activity (Fischer et al., 2002, Xue et al., 2006). The P/V-
CPI- virus, a recombinant PIV5 virus engineered to express the P/V gene of PIV5-
CPI-, generated by Parks and colleagues, also causes more apoptosis than wt in a
variety of cell-lines, suggesting that the three amino acids associated with the ability
to target STAT1 for degradation may also be involved in apoptosis regulation
(Wansley and Parks, 2002).
V can directly bind viral RNA through a series of basic residues in its N-terminus (Lin
et al., 1997). V also inhibits replication and translation of the viral RNA (Lin et al.,
2005, Gainey et al., 2008a), and it has been suggested that this prevents production
of aberrant RNAs that may otherwise trigger IFN and apoptosis (Dillon and Parks,
2007). In support of this, P/V-CPI- virus, a potent inducer of IFN-β and apoptosis,
also demonstrated a higher level of viral mRNA synthesis than a P/V-CPI-
expressing wild-type V (Wansley and Parks, 2002, Dillon and Parks, 2007).
Interestingly, while virus transcription was increased, the overall rate of host and viral
protein synthesis was lower in cells infected with P/V-CPI- than wt virus; this effect
correlated with PKR activation and eIF2α phosphorylation (Gainey et al., 2008a). V
therefore seems to limit induction of antiviral pathways through limiting viral RNA
production and PKR activation. The PIV5 P protein, which shares its N-terminal 164
residues with V, also exhibits these effects on RNA synthesis and translation (Gainey
et al., 2008a, Dillon and Parks, 2007), indicating the shared RNA-binding domain
may be critical for this function. Curbing aberrant viral RNA production to limit
antiviral responses may be a mechanism shared by the paramyxoviruses: the
measles virus C protein also regulates viral RNA synthesis (Reutter et al., 2001) and
its deletion leads to eIF2α phosphorylation and translation inhibition (Nakatsu et al.,
2006).
Some evidence exists for the involvement of Akt in the replication of PIV5 (and other
paramyxoviruses). Bioinformatic analysis of the V protein revealed an Akt1 binding
motif centred around Ser176, a region that appears to be well conserved among
paramyxoviruses, and a V:Akt interaction was confirmed by co-immunoprecipitation
(Sun et al., 2008a). Moreover, pharmacological inhibition of Akt reduced PIV5 titre by
three orders of magnitude, indicating that Akt plays a critical role in virus replication.
The biological function of such a V:Akt interaction was not determined, but the
authors speculated that V may exert its effects on the cell cycle, apoptosis or IL-6
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expression through an effect on Akt. A subsequent report from the same laboratory
demonstrated that the PIV5 L protein enhanced Akt phosphorylation to activate NF-
kB signalling. The authors speculated further that, due to its ability to inhibit
expression of the NF-kB-responsive IFN and IL-6 genes (Poole et al., 2002, Lin et
al., 2007), V blocks L-stimulated NF-kB signalling through inhibition of Akt (Luthra et
al., 2008), although no evidence was produced to support this.
1.3.4 Antagonism of antiviral responses by IAV NS1 protein
Influenza A viruses, members of the Orthomyxoviridae family, are enveloped viruses
with a segmented negative-sense, ssRNA genome. Eight genome segments code for
up to eleven viral proteins: segments 1,2 and 3 encode the PB2, PB1 and PA
components of the viral polymerase; segment 4, the haemagglutinin (HA)
glycoprotein; segment 5, the nucleocapsid protein NP; segment 6, neuraminidase
(NA); segment 7, the matrix proteins M1 and M2 ; segment 8 encodes the non-
structural (NS1) and nuclear export proteins (NEP). Segment 2 additionally encodes
PB1-F2 through a shift in the reading frame. The functions of these viral proteins and
their roles during the virus life cycle have been reviewed extensively (Lamb and
Krug, 2001).
A co-linear mRNA transcript of segment 8 codes for the ~26kDa NS1 protein. It
carries an RNA-binding domain (RBD) at its N-terminus (comprising the first 73
amino acid residues) that binds dsRNA and the IAV RNA genome (Hatada and
Fukuda, 1992, Chien et al., 2004, Hatada et al., 1992, Qian et al., 1995). The rest of
the protein forms the C-terminal ‘effector’ domain, which is required for interactions
with cellular proteins and stabilisation of the RBD (Wang et al., 2002c). NS1 appears
to exist as a homodimer both in vitro and in vivo, with both the RBD and the effector
domain contributing to dimerisation (Chien et al., 1997, Liu et al., 1997, Hale et al.,
2008a, Nemeroff et al., 1995, Wang et al., 2002c). The NS1 protein has been
assigned multiple functions (recently reviewed in Hale et al., 2008c). A major function
of NS1 appears to be limiting host innate antiviral responses activated during
influenza infection (Egorov et al., 1998, Garcia-Sastre et al., 1998, Kochs et al.,
2007, Zhirnov et al., 2002). It is an IFN antagonist and suppresses expression of a
large number of antiviral genes, including IFN and ISGs (Hayman et al., 2007, Geiss
et al., 2002, Hayman et al., 2006, Kochs et al., 2007, Noah et al., 2003).
Consequently, delNS1 viruses or viruses with C-terminal truncations in NS1 are
excellent inducers of IFN and are attenuated in IFN-competent cells. In Vero cells
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however, which lack IFN-α/β genes, these viruses demonstrate similar growth
kinetics to wt (Garcia-Sastre et al., 1998, Egorov et al., 1998).
NS1 prevents activation of IRF3, NF-kB and AP-1, and subsequent IFN induction, in
response to dsRNA or virus infection (Talon et al., 2000, Ludwig et al., 2002, Wang
et al., 2000a). This effect was shown to require an intact RBD: mutation of two
residues in this domain, Arg-38 and Lys-41, abrogated RNA binding and a virus
expressing these mutations was unable to block IRF3 activation or IFN induction
(Donelan et al., 2003, Talon et al., 2000, Wang et al., 1999d). As a result, it was
proposed that NS1 sequesters viral RNA away from cytoplasmic sensors such as
RIG-I (Talon et al., 2000). More recent studies however indicate that NS1 may
interact with RIG-I to inhibit its activity and limit IFN induction (Opitz et al., 2007, Guo
et al., 2007, Pichlmair et al., 2006, Mibayashi et al., 2007). Interestingly, an intact
RBD (and specifically Arg-38 and Lys-41) was also required for RIG-I binding and
inhibition (Guo et al., 2007, Pichlmair et al., 2006), hinting at a role for RNA in the
NS1:RIG-I interaction. NS1 also inhibits the function of the IFN-induced proteins PKR
and OAS. Since OAS is activated by dsRNA, NS1 is thought to sequester viral RNA
through the activity of its RBD, thereby preventing OAS activation (Min and Krug,
2006). Although it was initially thought that NS1 inhibited PKR in a similar manner
(Hatada et al., 1999, Lu et al., 1995), it has since been demonstrated that NS1 can
inhibit PKR activation by dsRNA or PACT (Li et al., 2006b). Moreover, NS1 binds
directly to PKR and residues 123-127, but not the Arg-38 residue required for RNA-
binding, are essential for this interaction (Li et al., 2006b, Min et al., 2007, Tan and
Katze, 1998). A model has been proposed based on this evidence: NS1 binds to
residues in the linker region of PKR and blocks the conformational change required
for PKR activation in response to either dsRNA or PACT (Li et al., 2006b).
NS1 can limit the IFN-induced antiviral state post-transcriptionally by blocking pre-
mRNA processing and nuclear export (Fortes et al., 1994, Qiu and Krug, 1994).
Three distinct mechanisms are utilised by NS1 to achieve this. The first involves an
interaction between NS1 and the 30kDa subunit of cleavage and polyadenylation
specificity factor (CPSF30) (Nemeroff et al., 1998, Noah et al., 2003, Twu et al.,
2006), a host protein that, in concert with poly(A)polymerase, plays a key role in the
formation of cellular pre-mRNA 3’ ends. The NS1:CPSF30 association is thought to
prevent host pre-mRNA cleavage and polyadenylation by sequestering CPSF30 and
prevent its binding to RNA substrate (Nemeroff et al., 1998). IFN-β and ISG
expression occurs earlier and in much larger amounts in IAV expressing NS1 with a
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mutated CPSF30 binding site, illustrating the importance of this function in IFN
antagonism (Noah et al., 2003). Secondly, NS1 inhibits function of the poly(A)
binding protein II (PABPII), preventing elongation of pre-mRNA 3’ poly(A) chains and
its nucleo-cytoplasmic shuttling (Chen et al., 1999). As a result of both CSPF30 and
PABPII inhibition, processing and nuclear export of cellular mRNAs can be
specifically inhibited: since polyadenylation of influenza virus mRNAs is mediated by
the viral polymerase (Poon et al., 1998), viral mRNA export is unaffected. There is
some evidence for the formation of a ternary complex comprising NS1, CPSF30 and
PABPII, indicating that these two binding functions may act in concert to inhibit host
mRNA processing (Chen et al., 1999). Additionally, NS1 downregulates expression
of the nucleoporin Nup98 and forms an inhibitory complex with NXF1/TAP, p15/NXT,
Rae1/mrnp41, and E1B-AP5 (Satterly et al., 2007). These proteins are key
components of the mRNA nuclear export machinery that direct mRNAs through the
nuclear pore complex.
Influenza A virus infection induces apoptosis in a wide range of cell types both in
vitro and in vivo (Mori et al., 1995, Hinshaw et al., 1994, Fesq et al., 1994, Takizawa
et al., 1993, Price et al., 1997). Within 2-3 days of in vivo infection, apoptosis is
induced in bronchial, bronchiolar and alveolar epithelial cells of the airways (Mori et
al., 1995) although rates of cell death differ with the virus subtype (Price et al., 1997,
Mok et al., 2007). While originally thought to be a host defence mechanism to limit
replication of the virus (Kurokawa et al., 1999), evidence is mounting that apoptosis
may play a more facilitatory role in influenza virus infection (Stray and Air, 2001):
IAV-induced caspase-3 and p53 activation, and Fas, FasL and TRAIL expression are
all required for efficient virus yield (Takizawa et al., 1999, Fujimoto et al., 1998,
Wurzer et al., 2003, Wurzer et al., 2004, Takizawa et al., 1995, Wada et al., 1995,
Turpin et al., 2005). This said however, IAV multiplication can be effectively
abrogated by phagocytosis of infected apoptotic cells, but not by apoptosis of
infected cells alone, indicating that apoptosis limitation may still be of primary
importance to the virus (Takizawa et al., 1999, Koyama et al., 2000, Fujimoto et al.,
2000, Nakanishi et al., 2008). Further support for the important role of macrophage
phagocytosis in clearing IAV infection comes from the observation that the IAV PB1-
F2 protein promotes apoptosis more readily in macrophages than in epithelial cells
(Coleman, 2007, Chen et al., 2001c, Chanturiya et al., 2004, Zamarin et al., 2005).
NS1 has been implicated in regulation of IAV-induced apoptosis, and has been
assigned both pro-apoptotic (Schultz-Cherry et al., 2001, Morris et al., 2002, Lam et
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al., 2008) and anti-apoptotic roles (Morris et al., 2002, Zhirnov et al., 2002,
Stasakova et al., 2005). Cells infected with a delNS1 virus exhibit apoptosis markers
much earlier than wt virus, a difference that was attributed to the effects of NS1 on
the IFN response since wt and delNS1 viruses induce apoptosis to similar extents in
Vero cells which lack IFN-α/β genes (Zhirnov et al., 2002). The NS1-mediated post-
transcriptional block on host gene expression has its implications for apoptosis
inhibition as well as IFN. In addition to preventing the induction of pro-apoptotic ISGs
(Geiss et al., 2002), NS1 inhibits TNF-α-induced expression of NF-kB-responsive
genes (Hayman et al., 2006) and may contribute to TNF-α sensitivity of IAV (Seo et
al., 2002). PKR and OAS/RNaseL may also play a key role in the induction of
apoptosis during IAV infection, given their pro-apoptotic functions (Section 1.2.5.1,
Takizawa et al., 1996, Mullan et al., 2005, Castelli et al., 1997, Castelli et al., 1998):
NS1-mediated inhibition of PKR and OAS may therefore function to delay both the
induction of IFN and apoptosis.
IAV also activates PI3K, possibly to promote cell survival pathways (Zhirnov and
Klenk, 2007, Shin et al., 2007a, Ehrhardt et al., 2007). The NS1 effector domain
mediates a direct interaction with the p85 subunit of PI3K to promote its activation
(Hale et al., 2006, Shin et al., 2007c, Ehrhardt et al., 2007); this interaction appears
to be specific to the p85β isoform (Li et al., 2008, Hale et al., 2006, Hale et al.,
2008b). Akt activation has been demonstrated downstream of PI3K activation by
NS1, and Akt phosphorylation occurs at an early stage (during the first 6h) of
infection (Zhirnov and Klenk, 2007, Hale et al., 2006). NS1 requires a tyrosine at
position 89 for interaction with p85: mutation of this residue to a phenylalanine
abrogates the NS1:p85 interaction and Akt activation (Hale et al., 2006). Additionally,
a recombinant virus expressing NS1-Y89F displays attenuated growth characteristics
(Hale et al., 2006) indicating that PI3K activation is required for efficient virus
propagation. Other NS1 residues implicated in NS1:PI3K interaction are Met93 (Hale
et al., 2006), Pro164/Pro167 (Shin et al., 2007a) and Leu141/Glu142 (Li et al., 2008).
NS1 is thought to activate PI3K by masking the p85β residues responsible for
regulating p110 catalytic activity (Hale et al., 2008b, Li et al., 2008). During infection
with avian IAVs, NS1 hyperactivates the PI3K/Akt pathway through additionally
interacting with Crk and CrkL proteins (Heikkinen et al., 2008). Crk/CrkL are involved
in a number of signalling pathways that regulate diverse cellular functions through
their roles as adaptor proteins. Significantly, associations between Crk/CrkL and p85
have been reported, both through a direct interaction (Gelkop et al., 2001, Gesbert et
al., 1998) and indirectly through intermediate linker proteins (Reedquist et al., 1996,
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Fukazawa et al., 1996, Husson et al., 1997). Avian NS1 may act as such a linker to
bring p85 and Crk/CrkL into close proximity, resulting in more efficient PI3K
activation.
1.4 Aims
The overall aim of this study was to explore the relationships between IFN, PI3K
signalling and apoptosis. The negative-stranded RNA viruses PIV5 and IAV both
encode the IFN antagonist proteins V and NS1 respectively; these proteins are also
reported to target PI3K/Akt signalling to enhance virus replication. This project
sought to determine whether modulation of IFN and PI3K pathways by PIV5/V and
IAV/NS1 could affect host cell apoptosis. To achieve this, a system for the study of
apoptosis in suitable (i.e. physiologically relevant) cell-lines first has to be developed.
Once this is in place, the effects of PIV5/V and IAV/NS1 protein expression, in the
context of both virus infection and stable cell-lines, on evasion of cell death will be
explored. More specifically, the effects of PIV5/V-mediated STAT1-degradation on
apoptosis will be studied. In addition, the V:Akt association between V and Akt and
its implications for modulation of Akt signalling will be examined. With regards to
IAV/NS1, reports that NS1-mediated PI3K activation promotes anti-apoptotic
signalling will be investigated. Since PI3K also plays a role in the IFN response,
effects of PI3K activation by NS1 on IFN production and ISG expression will also be
studied. NS1 modulates the activity of a number of other host cell proteins to
antagonise the IFN response; the effects of mutations in NS1 reported to abrogate
these binding activities on cell death will also be determined.
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2 MATERIALS AND METHODS
2.1 Cell-lines and tissue culture
2.1.1 Cells used in this study
1321N1: Human brain astrocytoma cell-line (from Prof. C. P. Downes,
University of Dundee).
293T: A highly transfectable derivative of the human embryonic kidney 293
cell-line, constitutively expressing the SV40 large T-antigen (provided
by Prof. R. Iggo, University of St Andrews).
A549: A human epithelial cell-line derived from a human lung carcinoma
(European Collection of Cell Cultures; ECACC).
HEp2: Human cervix carcinoma epithelial cells derived from the HeLa cell-
line (ECACC).
HFFF: Human foetal foreskin fibroblasts. Although HFFFs normally have a
limited passage number, this clone expresses telomerase reverse
transcriptase in order to increase number of cell passages achievable
before senescence (McSharry et al., 2001). Provided by Prof. G.
Wilkinson, Cardiff University.
MDCK: Canine kidney cells (ECACC).
MRC5: Untransformed human foetal lung fibroblasts with a finite life span
(ECACC).
Neutrophils: Isolated and provided by Prof. I. Dransfield, University of Edinburgh.
Vero: Fibroblast-like cells established from the kidney of an African Green
monkey (ICN Pharmaceuticals Ltd.).
In addition to the basic cell-lines mentioned above, the following permanent cell-lines
(generated by others) were also used:
A549-ISRE.Luc: A549 cells stably expressing the firefly luciferase gene under
the control of an ISRE (provided by M. Valahaus, University of
St Andrews).
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A549-NFkB.Luc: A549 cells stably expressing the firefly luciferase gene under
the control of the NFB promoter (provided by Prof. Ron Hay,
University of Dundee).
MDCK/V: MDCK cells stably expressing the V protein of PIV5 (Precious
et al., 2005b).
The following stable cell-lines were also generated using lentivirus vectors and used
as part of this study:
A549 and MRC-5 cells expressing the following proteins:
BVDV/NPro: A549 cells stably expressing the Npro protein of BVDV (Pe515
strain) with an N-terminal V5 tag.
HCV/NS3/4a: A549 cells stably expressing the NS3 and NS4a proteins of
HCV, gla1 strain- 4a. NS4a carries a C-terminal V5 tag.
PIV5/V(CPI-): A549 cells stably expressing the V protein of the CPI- strain of
PIV5.
PIV5/V(w3): A549 cells stably expressing the V protein of the w3 strain of
PIV5.
A549 and 1321N1 cells expressing the following proteins:
PR8/NS1 wt: A549 cells stably expressing the NS1 protein of IAV,
PR8 strain, with a C-terminal V5 tag.
PR8/NS1-Y89F: A549 cells stably expressing the PR8/NS1 carrying the
Y89F amino acid substitution, with a C-terminal V5 tag.
2.1.2 Cell maintenance
Cell monolayers were maintained in 25cm2 or 75cm2 tissue culture flasks (Greiner) in
DMEM (Dulbecco’s modified Eagle’s medium; Invitrogen) supplemented with 10%
(v/v) heat-inactivated foetal calf serum (FCS; Biowest) and incubated at 37oC/5%
CO2. Cells were routinely passaged using trypsin/EDTA (Becton Dickinson Ltd.), at a
frequency dictated by the rate of cell growth.
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2.1.3 Cell stock freezing and resuscitation
Adherent cells were trypsinised, resuspended in DMEM/10% FCS, and centrifuged at
~500xg for 5mins. Pelleted cells were resuspended in DMEM supplemented with
20% FCS and 10% DMSO and aliquoted into cryovials. Cell stocks were frozen at -
70oC before long-term storage in liquid nitrogen. For resuscitation of cells, cryovials
were thawed at 37oC before centrifugation at ~500xg. Pelleted cells were then
resuspended and grown in DMEM/10%FCS at 37oC/5% CO2. Medium was replaced
after 24 hours in order to remove traces of DMSO.
2.1.4 Treatment of cells
IFN treatment
Cells were treated overnight (at least 12 hours, unless where otherwise stated) with
media supplemented with Roferon recombinant human IFN-2a (Roche Diagnostics)
or IFN-γ (Invitrogen) at a concentration of 103 units/ml. To activate the ISRE
promoter for luciferase assay, cells were treated with 104 units/ml.
Apoptosis induction
To induce apoptosis, cells were treated with media supplemented with 15ng/ml TNF-
 (often in conjunction with 10 µg/ml cycloheximide; CHX, Sigma-Aldrich) or 1µg/ml
staurosporine (STS; Sigma-Aldrich). Treatment with FasL (200ng/ml; Alexis
Biochemicals) required the presence of anti-FLAG M2 antibody (2µg/ml; Sigma-
Aldrich) to promote multimerisation of FasL via its N-terminal FLAG tag.
Treatment with inhibitors
PI3K activity was inhibited by LY294002 (25µM; Calbiochem). Protein synthesis was
inhibited using CHX (10µg/ml).
Transfections with plasmid DNA
Transfection of cells with plasmid DNA was carried out using FuGENE 6 transfection
reagent (Roche) according to the manufacturer’s instructions.
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2.2 Virus infections
2.2.1 Viruses used in this study
EMCV: Encephalomyocarditis virus.
PIV5-w3: standard laboratory strain of PIV5 (Choppin, 1964).
PIV5-CPI+: canine isolate of PIV5 (Evermann et al., 1981)
PIV5-CPI-: canine isolate of PIV5, isolated from the brain tissue of a dog
infected experimentally with CPI+ (Baumgartner et al., 1987).
CPI- virus fails to block IFN signalling due to three amino-acid
changes in the N-terminal domain of the V protein
(Chatziandreou et al., 2002).
PIV5-VΔC: recombinant PIV5 that lacks the C-terminal cysteine-rich
domain of the V protein (He et al., 2002a). This virus is unable
to block IFN production or signalling.
SeV: Sendai virus strain Z, a gift from D. Kolakofsky (University of
Geneva, Switzerland).
rUd wt: recombinant wild-type IAV (A/Udorn/72; H3N2), provided by D.
Jackson, Northwestern University, USA (Hale et al., 2006).
rWSN wt: recombinant wild-type IAV (A/WSN/33; H1N1), provided by D.
Jackson (Northwestern University, USA).
The following recombinant viruses were generated and provided by D. Jackson and
C. Galloway. All viruses were isolated and subsequently grown in MDCK/V cells.
rUd-Y89F: recombinant Udorn virus expressing NS1 with the Y89F
amino-acid substitution. Generated and provided by D.
Jackson, Northwestern University, USA (Hale et al., 2006).
rWSN-Y89F: recombinant WSN virus expressing NS1 with the Y89F amino
acid substitution. Generated and provided by D. Jackson
Northwestern University, USA (Hale et al., 2006).
rUd-P164/7A: The NS1 protein carries two amino acid substitutions at
positions 164 and 167 that are reported to abrogate PI3K
binding (Shin et al., 2007a).
rUd-P162/4/7A: The NS1 protein carries three amino acid substitutions at
positions 162, 164 and 167. Virus isolation took much longer
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than for other mutants, and was initially a mixed population of
virus, also containing rUd NS1-Δ99.
rUd-Δ99: This virus encodes an NS1 protein carrying only amino acids
1-98, and was isolated during rescue of the rUd-
P162/164/167A virus.
rUd-184-8(L): At positions 184-188, five amino acids, GLEWN have been
substituted for RFLRY. This mutation eliminates the binding
site for CPSF30 (Noah et al., 2003). This virus took much
longer to rescue than other mutants, and isolated virus was
initially a mixed population, also containing rUd NS1-184-8(P).
rUd-184-8(P): Isolated during the rescue of rUd-184-8(L). rUd-184-8(P)
differs from rUd-184-8(L) at position 186, where it carries a
proline instead of a leucine residue.
rUd-103/106: The NS1 protein carries F103L and M106I amino acid
substitutions. Residues 103 and 106 are important for
stabilising the NS1:CPSF30 interaction ((Kochs et al., 2007,
Das et al., 2008).
rUd-123/4: The binding site for PKR (residues 123-127) is mutated in the
NS1 protein. Mutation of this site abrogates the ability of NS1
to inhibit PKR during virus infection (Min et al., 2007).
rUd-R38A: The NS1 protein carries an amino acid substitution at position
38. This residue is absolutely required for the dsRNA binding
activity of NS1, and replacement of arginine with alanine
abrogates this activity (Wang et al., 1999d).
2.2.2 Virus infections
To infect with paramyxovirus isolates, monolayers were inoculated with virus diluted
in DMEM supplemented with 2% FCS at an appropriate multiplicity of infection (MOI),
or DMEM only (for mock infections). For virus infections in 6-well plates, cells were
inoculated in a volume of 1ml per well and placed on a rocking platform at 37°C for
an adsorption period of 1-2 hours. Inoculations in 96-well plates were carried out
without rocking in a volume of 50µl per well. Virus inoculum was then removed and
replaced with DMEM/ 2%FCS. Cells were incubated at 37C/5% CO2 until harvested.
For investigating PI3K/Akt activation, monolayers were washed in DMEM only prior
to inoculation and infections carried out in serum-free DMEM.
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IAV infections were carried out in serum-free DMEM. Monolayers were washed in
DMEM prior to infection to remove all traces of serum. Cell monolayers were infected
with 400µl virus (per well of a 6-well plate) diluted in serum-free DMEM at an
appropriate MOI (or DMEM only for mock infections). Cells were incubated for 1hr at
37°C, with gentle agitation at regular intervals. Inoculations in 96-well plate were
carried out as for paramyxoviruses (see above). Virus inoculum was removed and
replaced with serum-free DMEM. Cells were incubated at 37C/5% CO2 until
harvested.
2.2.3 Preparation of virus stocks
Stocks of PIV5 isolates, other paramyxoviruses and EMC virus were kindly
maintained and provided as required by D. Young (University of St. Andrews).
To prepare stocks of IAV, 90% confluent MDCK of MDCK/V monolayers were
washed twice in serum-free DMEM in order to remove traces of serum. Cells were
inoculated in serum-free DMEM at an MOI of ~ 0.001 plaque-forming units
(PFU)/cell. After a 1-2h adsorption period (rocking, 37C), virus inoculum was
removed and monolayers washed with serum-free DMEM. 12mls (per 75cm2 flask) of
serum-free DMEM supplemented with 2.5g/ml N-acetyl trypsin (NAT) were added to
the monolayers and cells were incubated at 37C/5% CO2. Supernatants were
harvested when 50-70% CPE (cytopathic effect) was observed (~36h). Cellular
debris was removed by centrifugation (~3000xg for 10mins) and aliquots were frozen
at -70C. Virus titres were determined by plaque assay as described below.
2.2.3 Virus titration
To titrate PIV5 virus, monolayers of Vero cells were grown in 6-well plates until 80-
90% confluent. Preparations of virus were serially diluted 10-fold in DMEM/2% FCS
and monolayers were inoculated with 1ml of each virus dilution per well. After
adsorption for 1h, rocking at 37°C/5% CO2, virus inoculum was removed, and 6mls of
overlay medium (DMEM supplemented with 2% FCS and 0.5% carboxy methyl
cellulose [Methocel; Sigma-Aldrich]) was added to each well. Cells were incubated at
37°C/5% CO2 for 8-10 days until plaques had formed. Overlay medium was then
aspirated from the well and monolayers fixed with PBS/5% formaldehyde/2%
sucrose. Plaques were visualised by staining the monolayers with crystal violet (0.1%
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crystal violet, 3.6% formaldehyde, 1% methanol, 20% ethanol in H2O) for 20mins,
followed by rinsing in water. Plaques were counted, and titres estimated as PFU/ml
virus preparation, taking into account the original dilutions made.
Titration of IAV was carried out on confluent MDCK monolayers in 6-well plates.
Cells were washed twice in serum-free DMEM in order to remove all traces of serum.
Virus preparations were serially diluted 10-fold in serum-free DMEM, and cells were
inoculated with 400l of each virus dilution per well. Cells were incubated at 37°C/5%
CO2 and plates were agitated every 10 minutes to ensure even adsorption of the
virus. During this period, 2x overlay medium (13.4gDMEM/3.7g NaHCO3 per 485ml
water supplemented with 4g/ml NAT) was incubated at 37°C. 2% agarose in water
was melted and placed in a 55°C water bath until required. After an adsorption period
of 1h, virus inoculum was removed, the 2x overlay medium and the 2% agarose
(Biogene Ltd.) were mixed in a 1:1 ratio, and 2ml of this was added to each well.
After the overlay had set, plates were inverted and incubated at 37°C/5% CO2 until
distinct plaques had formed (~3 days). Cells were fixed by adding 2ml PBS/5%
formaldehyde/2%sucrose on top of the agarose plugs, and the monolayers were left
to fix overnight. Agarose plugs were then removed and plaques were stained with
crystal violet (0.1% crystal violet, 3.6% formaldehyde, 1% methanol, 20% ethanol in
H2O) or visualised by immunostaining as described below. Titres were estimated as
PFU/ml virus preparation, taking into account the original dilutions of virus that were
made.
2.2.4 Immunostaining of influenza virus plaques
Fixed MDCK monolayers were permeabilised (0.5% IGEPAL, 10% sucrose/ 0.1%
sodium azide in PBS) for 15 min, and then incubated in PBS supplemented with 1%
FCS for 1hr. Monolayers were incubated for 1h at room-temperature with 500l/well
of diluted (1/2000) primary antisera (rabbit antisera raised against whole X31 [H3N2];
diluted in PBS/1% FCS). Cells were washed with PBS/0.1%TWEEN, and
monolayers were subsequently incubated for 1h at room-temperature with 500l/well
of diluted (1/2000) secondary anti-rabbit IgG alkaline phosphatase (AP)-conjugated
antibody. Monolayers were subsequently washed with PBS/0.1%TWEEN, and
incubated with 500l/well of alkaline phosphatase substrate (as per manufacturer's
instructions; Sigma-Aldrich) until plaques were easily visualised. Monolayers were
rinsed with water in order to stop the reaction.
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2.2.5 Virus yield assay
To determine titres of infectious influenza virus over multiple replication cycles,
confluent cell monolayers were infected at a MOI of 0.001 PFU/cell in serum-free
DMEM as described above. After an adsorption period of 1-2hrs, virus inoculum was
removed and cells were washed in serum-free DMEM. Monolayers were
subsequently incubated at 37°C/5% CO2 in serum-free DMEM (supplemented with
NAT; 2g/ml for MDCK and A549, 1g/ml for MRC-5 cells). Samples of culture
supernatants were removed at desired times post-infection, centrifuged to remove
cell debris and frozen at -70°C until required. Virus titres were determined by plaque
assay on MDCK cells as described above.
2.3 Plasmid DNAs
2.3.1 Plasmids used in this study
Several plasmids were used in this study, either directly, or to produce lentivirus in
order to produce cell-lines stably expressing virus proteins.
pCMV5-HA-Akt: Plasmid expressing HA-tagged Akt1; a kind gift from B.
Vanhaesebroeck, Queen Mary University, London.
pCMVR8.91: Plasmid expressing the gag/pol, tat and rev genes of HIV-1
(used in lentivirus production, provided by Y.-H. Chen).
pdl'MCS(C'V5): Empty lentivirus vector for expressing proteins with a C-
terminal V5-tag, used as a control during transient
transfections. Expression is controlled by the constitutive SFFV
(spleen focus forming virus) promoter, which produces a single
bicistronic mRNA that encodes for the protein of interest with a
puromycin resistance product to enable cell selection (modified
from the self-inactivating lentivirus vector pHR-SIN-CSGW by
Y.-H. Chen, University of St Andrews).
pdl'BVDV/NPro Lentivirus vector expressing the N-terminally V5-tagged
(N'V5): BVDV/NPro; provided by M. Galliano, University of St
Andrews.
pdl'HCV/NS3/4A Lentivirus vector expressing the NS3/4A protease of HCV.
(C'V5): NS4A carries a C-terminal V5-tag; provided by Y.-H. Chen,
University of St Andrews.
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pdl'MuV/V(C'V5): Lentivirus vector expressing the C-terminally V5-tagged V
protein of MuV; provided by Y.-H. Chen, University of St
Andrews.
pdl'PIV5/V(CPI-): Lentivirus vector expressing the V protein of PIV5 (CPI- strain);
provided by Y.-H. Chen, University of St Andrews.
pdl'PIV5/V(w3): Lentivirus vector expressing the V protein of PIV5 (w3 strain);
provided by Y.-H. Chen, University of St Andrews.
pdl'PR8/NS1(C'V5): Lentivirus vector expressing C-terminally V5-tagged PR8/NS1;
provided by Y.-H. Chen, University of St Andrews (Hale et al.,
2006).
pdl'PR8/NS1-Y89F Lentivirus vector expressing C-terminally V5-tagged PR8/NS1
(C'V5): with the Y89F mutation; provided by B. G. Hale (Hale et al.,
2006).
pEF.PIV5/V: Plasmid expressing the V protein of PIV5 (w3 strain); provided
by J. Andrejeva, University of St Andrews.
pMD-G: Plasmid expressing the vesicular stomatitis virus glycoprotein
(VSV-G) gene (used in lentivirus production, provided by Y.-
H.Chen).
2.3.2 Propagation of plasmids
E. coli DH5 cells were grown in Luria-Bertani (LB) medium (10g/l bacto-tryptone,
5g/l yeast extract, 10mM NaCl, pH 7.5), or plated on solid LB medium supplemented
with 1.5% (w/v) agar and 10mM MgSO4. As appropriate, media were supplemented
with ampicillin (100 g/ml) for selection.
2.3.2 Transformation of competent cells
1µg plasmid was added directly to 100µl of thawed, competent cells (Invitrogen).
After incubation on ice for 1h, cells were transferred to a 42oC water bath for 2mins
before being immediately returned to ice for a further 2mins. Cells were resuspended
in 1ml LB broth and incubated at 37oC for 1h. The cell suspension was plated out
onto LB-agar plates supplemented with ampicillin (90 mm-diameter Petri dishes;
Scientific Laboratory Supplies Ltd., U.K.). Plates were inverted and incubated at 37oC
overnight. Mini-cultures were prepared from selected colonies.
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2.4.4 Preparation of plasmid DNA
For small-scale preparations, bacterial cell cultures of 10 ml (in LB broth containing
100μg/ml ampicillin) were grown overnight in a 37C shaking incubator. DNA was
extracted from cells and purified using the QIAGEN DNA mini-prep kit (QIAGEN Ltd.,
UK), according to the manufacturer’s instructions. To produce larger-scale DNA
preparations, 100ml of bacterial culture was grown overnight in a 37C shaking
incubator. DNA was extracted from cells using the QIAfilter Plasmid Maxi Kit
(according to the manufacturer’s instructions; QIAGEN).
2.3.5 UV spectrophotometry
The concentration of plasmid DNA was quantified by measurement of Abs260 using a
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). DNA purity was
estimated by calculating the Abs260/Abs280 ratio. Ratios greater then 1.8 were
considered acceptable.
2.4 Lentivirus-mediated generation of stable cell-lines
2.4.1 Lentivirus production
To generate recombinant lentivirus, a 75 cm2 tissue culture flask 293T cells (70%
confluent) was co-transfected with three plasmids: 3µg pCMVR8.91, 3µg pMD-G,
and 5µg of the pdl vector containing the construct of interest. Supernatants were
harvested at 48h and 72h post-transfection and pooled. Cellular debris was removed
by centrifugation at 3,000xg for 10mins and filtering through 0.45µm Tuffryn
membrane filters (Invitrogen). Virus aliquots were stored at -70C until required.
2.4.2 Transduction of target cells
30% confluent target cell monolayers (25cm2 flask) were infected with the harvested
lentivirus supernatant (estimated MOI of 1PFU/cell) in the presence of polybrene
(8g/ml; Sigma-Aldrich). 48h post-infection, transformed cells were selected by
resistance to puromycin (Invivogen); MRC5 cells, 1g/ml; A549/ 1321N1 cells
2g/ml. Puromycin-containing medium was replaced every four days until control
naïve cells were dead. Cells were kept under continuous selection with puromycin
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and stocks were stored in liquid nitrogen. Expression of the required protein was
confirmed by immunoblot or immunofluorescence analysis.
2.5 Protein analysis
2.5.1 SDS polyacrylamide gel electrophoresis
Cell lysates were prepared by adding disruption buffer (6M Urea, 2M -
mercaptoethanol, 4% (w/v) SDS, with bromophenol blue colouring) to cells in a 1:1
ratio. Viscosity of samples was reduced by sonication (2 x 20s) or digestion with
benzonase (Novagen). Polypeptides were separated through 4-12% NuPAGE
polyacrylamide gradient gels (Invitrogen) by electrophoresis (200V for 50 min) in
MOPS [3-(N-morpholino)propanesulphonic acid] buffer (Invitrogen).
2.5.2 Immunoblotting
Protein lysates were subjected to SDS-PAGE as described above, and transferred to
polyvinylidene difluoride (PVDF) membrane using the XCell II Blot Module according
to the manufacturer’s instructions (Invitrogen, U.K.). After transfer, membranes were
blocked for 30 mins in 5% (w/v) skimmed milk powder, 0.1% (v/v) Tween 20 in PBS
(blocking buffer), and incubated for either 1h or overnight with primary antibody
diluted (in blocking buffer) according to the manufacturer’s instructions. After multiple
washes with PBS/ 0.1% Tween 20, interactions between protein and antibody were
detected by incubating the membrane for 1h with horseradish peroxidase (HRP)-
conjugated antibody raised against the appropriate species, diluted appropriately in
blocking buffer. Unbound antibody was washed away with PBS/ 0.1% Tween 20, and
specific polypeptide bands were visualised using western blotting
chemiluminescence luminal reagent (Santa Cruz) according to the manufacturer's
instructions. N.B. For probing for phospho-proteins, 5%BSA/0.1%Tween/PBS was
used instead of milk as blocking buffer.
2.5.3 Immunofluorescence
On coverslips
Cells grown on 10mm coverslips were fixed for 10mins in 5% formaldehyde/2%
sucrose/PBS then permeabilised with 0.5% NP-40/10% sucrose/PBS. Non-specific-
binding sites were blocked for at least 30 min with PBS/ 1% FCS/ 0.1% sodium
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azide, then monolayers were incubated with appropriately diluted primary antibody
for 1h. Unbound antibody was washed away with PBS, and cells were incubated for
1h with Texas Red or fluoroscein isothiocyanate (FITC) conjugated secondary
antibody (Oxford Biotechnology Ltd., U.K.). If staining of the nucleus was required,
the DNA-binding fluorochrome 4', 6-diamidino-2-phenylindole (DAPI; 0.5 μg/ml;
Sigma Aldrich) or acridine orange was also added to this solution. Coverslips were
washed in PBS, fixed again in 5% formaldehyde/2% sucrose/PBS and mounted on
slides using Citifluor AF-1 mounting solution (Citifluor). All reactions were performed
at room temperature in a humidified chamber. Immunofluorescence was visualised
using a Nikon Microphot-FXA microscope.
In 96-well plates
For checking for 100% infection of cells in 96-well plates, duplicate wells in the 96-
well plate were set-up and infected in the same manner. At desired times post-
infection, monolayers were fixed with PBS/ 5% formaldehyde/ 2% sucrose for at least
an hour, then permeabilised and stained as above. In between antibody incubations,
monolayers were washed multiple times in PBS/ 0.1% Tween 20. Following staining,
plates were re-fixed in 5% formaldehyde/2% sucrose/PBS and immunofluorescence
was visualized using an Olympus CKX41 fluorescence microscope.
2.5.4 Immunoprecipitations
Cells were washed twice in ice-cold PBS and lysed for at least 10mins on ice in
immunoprecipitation buffer (20 mM Tris-HCl (pH 7.8)/5 mM EDTA/ 0.5% NP-
40/150mM NaCl freshly supplemented with a protease inhibitor cocktail tablet; Roche
Diagnostics); 300l/2x106 cells. Viscosity of lysates was reduced by sonication.
Soluble antigen extract was prepared by centrifuging the cell lysate at 12,000xg for
50mins to pellet cell debris. 1ml soluble antigen extract was incubated with 15µl
cross-linked Ab beads (see below) overnight (with agitation) at 4°C. Siliconised tubes
(Sigma-Aldrich) were used to minimize any non-specific protein binding to the tube.
After extensive washing in immunoprecipitation buffer, proteins in complex with
antibody were dissociated by heating in SDS-PAGE loading buffer at 100°C for 5min.
Proteins were analysed by SDS-PAGE.
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2.5.5 Production of cross-linked Ab beads
Protein G-Sepharose beads (binding capacity for IgG >20mg/mL; Sigma-Aldrich)
were pre-washed several times with ice-cold PBS. An appropriate amount of isolated
beads was mixed with anti-V5 mAb or anti-Akt polyclonal Ab (approx. 4mg of mAb
per mL of beads), resuspended in binding buffer A (20mM Tris-HCl (pH 7.8); 650mM
NaCl), and incubated overnight at 4C with agitation. Ab-bead complexes were
rescued and isolated after four repeated wash cycles of low-speed centrifugation to
pellet beads, aspiration of supernatant and resuspension of beads in binding buffer
Complexes were then washed twice in buffer B (3M NaCl/1.5M glycine [buffered to
pH 8.9 with 3M NaOH]), and twice with buffer C (3M NaCl/50mM Borate [buffered to
pH 8.9 with 3M NaOH]). Complexes were incubated with freshly prepared buffer D
(40mM di-methyl-pimelimidate/3M NaCl/200mM Borate [buffered to pH 8.9 with 3M
NaOH]) for 1h at 4C with agitation. Beads were pelleted by low-speed centrifugation
and incubated on ice for 10 min with buffer E (200mM ethanolamine [buffered to pH
8.0 with HCl]). Complexes were washed twice more with buffer E and then re-
incubated for a further 2h at room temperature with buffer E with agitation. Finally,
the cross-linked Ab beads were washed four times with buffer A. Efficiency of cross-
linking was determined by analysing bead samples by SDS-PAGE at various stages
throughout the procedure. Cross-linked beads were produced as required and stored
as a 50% (v/v) slurry in buffer A at 4C.
2.5.6 Antibodies
Antibodies were used in immunoprecipitations, immunoblotting, immunostaining,
immunofluorescence and apoptosis induction.
Primary antibodies used are shown in Table 2.1.
Secondary antibodies: Anti-mouse, rabbit and sheep IgG Texas Red and FITC
conjugated antibodies were from Oxford Biotechnology. HRP-conjugated anti-mouse
IgG was from Sigma, anti-rabbit IgG HRP conjugated antibody was from Santa Cruz
and anti-sheep IgG HRP conjugates were from Abcam.
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Target Protein/ Tag Manufacturer
β-actin (monoclonal) Sigma-Aldrich
Akt (polyclonal) Cell Signaling Technology
Phospho-Akt
(Ser 473; monoclonal)
Cell Signaling Technology
Cleaved caspase-3
(Asp 175; polyclonal)
Cell Signaling Technology
FasL (polyclonal) Abcam
FLAG (M2; monoclonal) Sigma-Aldrich
IRF3 (polyclonal) Santa Cruz Biotechnology
ISG15 (polyclonal)
A kind gift from A. L. Haas, Medical
College of Wisconsin, USA.
MAVS (polyclonal)
A kind gift from I. Julkunen, National
Public Health Institute, Helsinki, Finland.
p53 (DO1; monoclonal)
A kind gift from R. T. Hay, Dundee
University
Phospho-p53 (Ser 15; polyclonal) Cell Signaling Technology
PARP (full-length; monoclonal) Abcam
PARP (full-length & cleaved;
polyclonal)
Roche
PIV5 V (polyclonal)
Serum produced by Diagnostics Scotland.
Affinity-purified by B. Precious.
PIV5 V (C-terminus; monoclonal)
A kind gift from R. Lamb, Northwestern
University, US.
STAT1α p91 (monoclonal) Santa Cruz Biotechnology
V5 (also reacts with PIV5 V protein;
monoclonal)
Serotec
V5 (HRP-conjugated; monoclonal) Serotec
X31 (H3N2; polyclonal)
A kind gift from A. Douglas, National
Institute for Medical Research, London
NS1 (polyclonal)
Serum produced by Diagnostics Scotland.
Affinity-purified by H. Xiao.
Table 2.1: Primary antibodies used in this study.
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2.6 Miscellaneous assays
2.6.1 Cell-based IFN production assay
The relative amount of IFN present in cell culture supernatants was estimated using
a cell-based EMCV-inhibition assay. Supernatant samples were centrifuged to
remove any cell debris and exposed to UV light for 3 min (to inactivate any virus
present). Samples were titrated by serial 2-fold dilution in DMEM/2% FCS and
transferred to confluent A549/BVDV/NPro cells in 96-well plates. Plates were
incubated for 24h at 37C/5% CO2 and then infected with EMCV at an MOI of 10.
When sufficient CPE was observed (~36-48h later), plates were fixed in
PBS/5%formaldehyde/2% sucrose and stained with crystal violet. The “end point” for
each sample was taken to be the dilution at which cells showed ~50% CPE.
2.6.2 Luciferase assays
For NF-kB and ISRE activation
Following virus infection and/or desired treatment, cell monolayers (in 6-well plates)
were washed once in PBS and lysed for 2mins in 300μl (per well) luciferase buffer A
(25mM Tris-phosphate (pH 7.8), 8mM MgCl2, 1mM DTT, 1mM EDTA, 1% TritonX-
100). Plates were frozen at -70°C until required. Upon thawing, 300μl of luciferase
buffer B (30% glycerol, 0.8mM ATP, 2% BSA in luciferase buffer A) was added to
each well. Cell extracts were transferred to a microfuge tube and briefly centrifuged ()
to remove debris. 200 μl of soluble cell extract was transferred to a cuvette and
mixed with 100μl of luciferase substrate (1.5mM luciferin in Tris/EDTA buffer). Light
emitted over the first 10s following substrate addition (in relative light units; RLU),
was measured using a Lumat LB9501 luminometer (Bertold, Germany).
For caspase activity
Cells were seeded in sterile white-walled 96-well plates suitable for luminometry and
infected as required. To measure activation of caspases-3 and -7, Caspase-Glo 3/7
Reagent (Promega) was added to directly to wells according to the manufacturer’s
instructions. This reagent lyses cells and contains a caspase-3/7 substrate. Caspase
cleavage generates a substrate for luciferase; a “glow-type” luminescent signal
results that is proportional to caspase activity in the sample. Plates were briefly
shaken and incubated for 1h at room temperature. Luminescence was read on a 96-
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well microplate reader. Blank (medium only) wells were included on each plate and
blank readings were subtracted from experimental values.
2.6.3 Cell viability assay
Cells were seeded in 96-well plates and infected and/or treated and incubated at
37C/5% CO2. At desired times post-infection/treatment, wst-1 cell-viability reagent
(Roche) was added to each well according to the manufacturer’s instructions and
plates were briefly shaken to mix culture medium and reagent. Plates were incubated
at 37C until significant colour had developed in the wells containing
untreated/uninfected cells. Plates were then read at 450nm on an ELISA microplate
reader using 690nm as a reference wavelength. Assays were carried out in triplicate
and averaged. Percentage cell viability for each condition was calculated relative to
uninfected and/or untreated cells.
2.6.4 Flow cytometry
Following desired treatment, cells were labeled with annexin V and propidium iodide
(PI). 2µl FITC-conjugated annexin V (final concentration 5µM) was added to 1ml
annexin V binding buffer (HBBS, 5mM CaCl2). 280µl annexin V and buffer was then
added to a tube containing 20µl of neutrophils at 4x106 cells /ml and incubated on ice
for 10 min. Adherent A549 cells were trypsinised and regularly agitated to keep them
in suspension, and were used at a similar cell number/ml as neutrophils. Immediately
prior to analysing the sample, 1µl of 1mg/ml PI was added to the cells. Annexin V
and PI were measured using FL1 and FL2 detectors respectively on a FACSCalibur
flow cytometer (BD Biosciences). Apoptotic cells were those that stained positive for
annexin V but negative for PI, and were calculated as a percentage of the total cell
population. Data were analysed using CellQuest software.
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3 RESULTS
The first part of this section concerns the setting up of a system for the study of
apoptosis in subsequent sections. Secondly, modulation of apoptosis by the PIV5 V
protein is explored, while the third section concerns activation of PI3K signalling by
IAV NS1 and its implications for host IFN and apoptotic responses. In addition, the
contributions of other cellular-protein-binding functions of NS1 to apoptosis inhibition
and IFN antagonism are examined.
3.1 Sensitivity of cell-lines to apoptosis inducers
Human cell-lines differ wildly in their sensitivity to apoptosis (Shima et al., 1995,
Smets et al., 1994, Shafer and Williams, 2003). For the study of virus-induced
apoptosis in vitro then, it is desirable to use cells similar to the genuine in vivo target
tissue of the virus. By their very definition, immortalised (or continuous) cell-lines are
transformed in order to allow indefinite passage. Although immortalised cells are not
necessarily neoplastically or malignantly transformed, many are derived from
tumours, and as such, possess mutations in genes encoding apoptosis and cell
proliferation regulators (Williams et al., 1993); this adds a degree of complexity to in
vitro apoptosis studies carried out in these cell-lines. Untransformed cells are
considered to be more suitable for the study of apoptosis since they cannot be
propagated indefinitely and undergo senescence after a finite number of passages.
However, untransformed cells are not without their caveats. Their expression profiles
alter with increased population doublings (McSharry et al., 2001), so differences in
cell passage number between experiments may lead to inconsistency in results.
Additionally, untransformed cell-lines (particularly those that have undergone a
number of passages) may comprise a mixed population of replicating and senescent
cells: senescent cells differ from replicating cells in their morphology, gene-
expression profiles and, potentially, in their sensitivity to virus infection (McSharry et
al., 2001, Faragher and Kipling, 1998). When carrying out apoptosis studies in vitro
therefore, it is very important to consider the limitations of the particular cell-lines
used. This section will examine apoptosis induction in a number of different cell-lines,
including tumour-derived and untransformed cells, in order to select suitable cells for
subsequent experiments.
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3.1.1 Response of A549 cells to apoptosis inducers
The main criteria for choosing suitable cell-lines for this study are that cells should be
representative of IAV and PIV5 target tissue and that both viruses should be able to
replicate efficiently in the chosen cells. Although A549 cells are derived from a
human lung carcinoma, they display properties similar to type II alveolar epithelial
cells (Standiford et al., 1990, Smith, 1977, Lieber et al., 1976, Garofalo et al., 1996);
studies using ex vivo lung tissue revealed these cells are the primary site of IAV
infection (Nicholls et al., 2007, van Riel et al., 2006). They are therefore considered
to be biologically relevant to IAV infection and are used widely used in influenza
research. A549 cells are also routinely used to study paramyxovirus infection of the
respiratory tract (Zhang et al., 2001, Young et al., 2003, Garofalo et al., 1996,
Watanabe et al., 2005a), making them an ideal choice of cell-line for this study.
A549 cell sensitivity to the apoptosis inducers FasL, TNF-α and staurosporine (STS)
was investigated: FasL and TNF-α are DR ligands, while STS causes apoptosis in a
wide range of cell-lines through inhibition of protein kinase C (Jarvis et al., 1994,
Bertrand et al., 1994, Tamaoki et al., 1986). Cell viability assays following treatment
with these apoptosis inducers revealed that A549 cells were sensitive to STS but
resistant TNF-α- or FasL-induced cell death, even after extended periods of
treatment (Figure 3.1).
3.1.2 Cycloheximide sensitises A549 cells to DR-mediated apoptosis
Binding of DR ligands to their receptors activates anti-apoptotic NF-kB signalling in
addition to apoptosis (Qin et al., 2002, Mitsiades et al., 2006, Imamura et al., 2004,
Laegreid et al., 1994, Meichle et al., 1990). Protein synthesis inhibitors such as
cycloheximide (CHX) are reported to sensitise cells to TNF-α- and FasL-induced
apoptosis by preventing synthesis of anti-apoptotic proteins (Kreuz et al., 2001,
Ogura et al., 2008, Micheau et al., 2001, Fulda et al., 2000, Mitsiades et al., 2000,
Arscott et al., 1997). In agreement with these studies, treatment of A549 cells with
TNF-α or FasL in combination with CHX caused markedly more cell death than TNF-
α, FasL or CHX treatment alone; TNF-α/CHX or FasL/CHX treatment killed ~80% of
cells within 24h (Figure 3.2).
To determine whether the sensitising effect of CHX on TNF-α- and FasL-treatment
was due to inhibition of NF-kB signalling, NF-kB activity in A549 cells expressing an
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NF-kB-responsive luciferase gene was measured following treatment with apoptosis
inducers. Untreated cells exhibited a basal level of NF-kB activity that was CHX-
sensitive (Figure 3.3). Inhibition of this basal activity had no effect on cell death,
since CHX treatment alone caused no reduction in cell viability (Figure 3.2). As
expected, TNF-α treatment resulted in a large increase in NF-kB activity which is
completely blocked by CHX treatment (Figure 3.3). However, FasL treatment did not
activate NF-kB: NF-kB was activated to a similar extent to mock- and FasL-treated
cells both in the presence and absence of CHX. STS treatment alone inhibited NF-kB
activity and STS/CHX was unable to reduce NF-kB activity any further.
3.1.3 Cytokines can act synergistically to induce apoptosis
Many factors affect the biological effects of a particular cytokine on a target cell,
including the target cell type, the cytokine concentration and the abundance of
complementary receptors on the target cell surface. In addition, cytokines can
modulate sensitivity of target cells to the activity of other cytokines. For instance,
cytokines, including IFNs, induced during virus infection can render infected cells
more prone to FasL and TNF-α-mediated NK cell and CTL cytotoxicity. Pretreatment
of a number of cell-lines, including A549, with IFN sensitises them to Fas-mediated
apoptosis induced by agonist anti-Fas antibody (Tamura et al., 1996, Kim et al.,
2002, Wen et al., 1997, Kurdi and Booz, 2007). To determine whether IFN/FasL
treatment was also able to induce apoptosis, A549 cells were pretreated with IFN (-α
or -γ) overnight, then treated with FasL. No significant cell death was apparent 
following FasL or IFN-α treatment alone (Figure 3.4A). While IFN-γ treatment 
induced a significant amount of cell death (~25%), treatment with IFN-γ and FasL in 
concert caused considerably more; IFN-γ/FasL caused ~75% reduction in cell
viability. Immunoblot analyses revealed that this cell death was apoptotic, as cleaved
PARP (a marker for apoptosis) was detected in IFN-γ/FasL-treated cells, but not cells
treated with IFN-γ or FasL alone (Figure 3.4C). IFN-α also seemed to potentiate
FasL-induced apoptosis (albeit less efficiently than IFN-γ), since IFN-α/FasL (~20%)
caused 20% more cell death than either IFN-α or FasL (Figure 3.4A).
IFN-γ is reported to sensitise vascular smooth muscle cells to Fas-mediated
apoptosis by stimulating trafficking of the Fas receptor to the cell surface in a
PI3K/Akt-dependent manner (Rosner et al., 2006). To determine whether a similar
PI3K-dependent mechanism of IFN-γ/FasL synergy exists in A549 cells, it was first
determined whether IFN-γ could activate PI3K/Akt signalling. A549 monolayers were
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treated with IFN-α or IFN-γ and cell lysates were probed for phospho-Akt (the
activated form of Akt). Foetal calf serum (FCS) used in cell culture contains growth
factors that activate PI3K/Akt (Hale et al., 2006); as a result, cells were IFN-treated in
both serum-free medium and medium supplemented with 10% FCS. In the absence
of serum, Akt was not activated in untreated cells, while IFN-α or IFN-γ treatment
slightly increased Akt activation (Figure 3.5A). In the presence of serum, Akt was
activated while IFN-γ treatment, but not IFN-α, significantly activated Akt in the
presence of serum (Figure 3.5A). Since IFN-γ could activate PI3K/Akt signalling, the
effects of the PI3K inhibitor LY294002 (LY) on IFN-γ/FasL synergy were investigated. 
Cells were treated with LY or mock-treated with DMSO, then treated with IFN-γ/FasL. 
IFN-γ/FasL treatment activated Akt and induced apoptosis in DMSO-treated cells (as
demonstrated by the presence of phospho-Akt and cleaved PARP; Figure 3.5B). It is
worth noting that the phospho-Akt band in IFN-γ/FasL-treated cells appeared to have
a slightly higher mobility than Akt in untreated cells. This smaller Akt fragment is
likely to be a caspase-cleavage product, as cleavage and inactivation of Akt by
caspases during apoptosis has been reported (Rokudai et al., 2000, Asselin et al.,
2001, Jahani-Asl et al., 2007). LY treatment alone did not cause any apoptotic cell
death and reduced the basal level of phospho-Akt, consistent with PI3K inhibition
(Figures 3.5B,C). However, LY did not prevent IFN-γ/FasL-induced apoptosis;
LY/IFN-γ/FasL-treated cells displayed similar apoptotic morphologies (Figure 3.5C)
and levels of PARP cleavage (Figure 3.5B) to those treated with DMSO/IFN-γ/FasL. 
Interestingly though, LY did not prevent Akt activation by IFN-γ/FasL treatment,
perhaps indicating that Akt becomes activated during apoptosis in a PI3K-
independent manner. These data demonstrate that IFN-γ/FasL synergy does not 
require PI3K activity. Furthermore, studies into the effects of PIV5/V on IFN-γ/FasL-
induced apoptosis revealed that IFN-γ acts via a STAT1-dependent pathway to
promote FasL-induced cell death (see Section 3.2.3).
In some cells types, IFN-α or IFN-γ can also sensitise cells to TNF-α-induced
apoptosis (Kulkarni et al., 2006, Frankel et al., 2006, Kimura et al., 2003, Manna et
al., 2000, Suk et al., 2001, Sasagawa et al., 2000). This does not appear to be the
case in A549 cells however, since these cells were resistant to TNF-α-induced
apoptosis irrespective of IFN-α or IFN-γ pre-treatment (Figure 3.4B).
It has been reported that agonist anti-Fas antibody and TNF-α can act synergistically
to induce apoptosis (Kimura and Gelmann, 2000, Frankel et al., 2006), so it was
investigated whether A549 cells could be sensitised to FasL- or TNF-α-induced
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apoptosis through treatment with FasL and TNF-α simultaneously. This was found
not to be the case: FasL/TNF-α treatment did not cause any more cell death than
FasL or TNF-α treatment alone (Figure 3.2), indicating that concurrent activation of
more than one type of death receptor is insufficient to cause death in A549 cells.
3.1.4 Comparison of rates of apoptosis induction in different cell-lines
A549 cells are derived from a malignant tumour; they consequently exhibit defects in
tumour-suppressor expression and may express higher levels of anti-apoptotic
proteins than untransformed cells (Uno et al., 2004, Ji et al., 1999, Roz et al., 2002,
Leech et al., 2000, Reeve et al., 1996). To investigate whether A549 cells were more
resistant to apoptosis than untransformed cells, cell death responses of A549 and
MRC-5 cell-lines were compared. MRC-5 cells are diploid lung fibroblasts that are
untransformed and subsequently undergo senescence following continued passage
(Jacobs et al., 1970). As an additional comparison, apoptosis induction in cervix
carcinoma-derived Hep2 cells, which are routinely used in virus research, was
investigated. Like A549 cells, Hep2 cells were FasL-resistant (Figure 3.6A) but were
sensitive to TNF-α/CHX and STS (Figures 3.6B,C). A549 cells were more resistant
to STS than Hep2 cells while Hep2 cells displayed greater resistance to TNF-α/CHX,
probably due to cell-type-specific or tumour-type-specific differences in expression of
apoptosis regulators. In contrast to A549 and Hep2 cells, MRC-5 cells were
sensitive to FasL alone (in the absence of CHX or IFN; Figure 3.6A) and exhibited
considerable cell death within 6 hours of FasL treatment (Figures 3.6A,D ). MRC-5
cells also died rapidly following treatment with TNF-α/CHX and STS: while prolonged
treatment (up to 24 hours) was required to induce 50% cell death in A549 and Hep2
cells, the majority of MRC-5 cells died within 10 hours. Like A549 cells however,
MRC-5 cells still require protein synthesis inhibition by CHX to undergo TNF-α-
induced apoptosis, as they were resistant to TNF-α treatment alone (data not
shown). MRC-5 cell death induced by FasL, TNF-α/CHX and STS was apoptotic, as
cleaved PARP was detectable by immunoblotting from as early as 4hrs post-
treatment (Figure 3.6E). It should also be noted that even untransformed cells show
considerable variation in their response to apoptosis inducers. Like MRC-5, HFFF
cells are untransformed and undergo rapid apoptosis following FasL or STS
treatment. Unlike MRC-5 however, these cells are resistant to TNF-α/CHX-induced
apoptosis (data not shown).
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As stated previously, the criteria for choosing suitable cell-lines for this study were
that cells should be representative of IAV and PIV5 target tissue and should be able
to support replication of these viruses. Hep2 cells do not fulfil this criteria as, in
addition to being persistently infected with oncogenic papillomavirus (Abdulkarim et
al., 2002, Pater and Pater, 1985), IAV cannot replicate efficiently in these cells
(Ludwig, 2006). A549 cells however are ideal for the study of human respiratory
viruses as they represent the in vivo target tissue of IAV and PIV5 and have
previously been used to study these viruses (Standiford et al., 1990, Smith, 1977,
Lieber et al., 1976, Garofalo et al., 1996, Nicholls et al., 2007, van Riel et al., 2006,
Zhang et al., 2001, Young et al., 2003, Watanabe et al., 2005a). The sensitivity of
MRC-5 cells to apoptosis also makes them an excellent choice for the study of virus-
induced cell death. These cells have also been used previously to study
paramyxoviruses, including PIV5 (Young et al., 2003), and while they are not
routinely used in IAV research, MRC-5 cells support productive IAV infection
(Herrero-Uribe et al., 1983, de Ona et al., 1995). Since both tumour-derived and
untransformed cells have their disadvantages (discussed above), and MRC-5 cells
are difficult to handle in the laboratory and have slow doubling rates, it was decided
that A549 and MRC-5 cells should both be used in this study.
Conclusions
A549 cells were sensitive to STS, but required treatment with the protein synthesis
inhibitor CHX to undergo TNF-α- or FasL-induced cell death. NF-kB activity
contributed to TNF-α but not FasL resistance. IFN-γ pre-treatment sensitised cells to
FasL-induced apoptosis in a manner that was independent of PI3K/Akt signalling, but
was unable to promote TNF-α-induced cell death. MRC-5 cells underwent rapid
apoptosis in response to TNF-α/CHX and STS; they were also sensitive to FasL
without the need for CHX or IFN-γ treatment.
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3.2 The PIV5 V protein, IFN and apoptosis
The V protein is essential for PIV5 evasion of host antiviral responses. In addition to
its effects on IFN production and signalling (Poole et al., 2002, Didcock et al.,
1999b), V has been implicated in inhibition of host cell apoptosis (Wansley and
Parks, 2002, Wansley et al., 2003, Sun et al., 2004, Dillon et al., 2006): this section
examines the role of PIV5/V in apoptosis regulation.
3.2.1 Characterisation of cell-lines expressing viral IFN antagonists
To determine the effects of PIV5/V ectopic expression on apoptosis, A549 and MRC-
5 cell-lines stably expressing V (from the w3 strain of PIV5) were created using
lentivirus vectors. In parallel, cells expressing the Npro protease of BVDV and the
NS3/4A serine protease of hepatitis C virus (HCV) were produced. Both proteins
block IFN production much more efficiently than PIV5 V (Foy et al., 2005, Li et al.,
2005a, Li et al., 2005b, Seago et al., 2007, Gil et al., 2006): BVDV/NPro targets IRF3
for degradation (Hilton et al., 2006, Chen et al., 2007), while HCV/NS3/4A cleaves
MAVS to inhibit RIG-I/mda-5 signalling (Li et al., 2005a, Li et al., 2005b). IRF3 and
MAVS have been implicated in apoptosis induction as well as IFN production (see
Section 1.2.7); BVDV/NPro and HCV/NS3/4A were therefore included to determine
whether IRF3- and MAVS-deficient cells are more resistant to apoptosis.
BVDV/NPro and HCV/NS3/4A carry the V5 epitope tag which is derived from a small
14-amino acid region of PIV5/V (Hanke et al., 1992). Immunoblot analyses showed
that expression of all three viral proteins could be detected in the A549 and MRC-5
cell-lines using antibody to the V5 tag (Figures 3.7A,B). To confirm proper
functioning of these proteins, cell lysates were also probed for their cellular targets.
As described above, PIV5/V targets STAT1 for degradation. STAT1 is normally
present in cells at low levels, but its expression is increased by IFN (Der et al.,
1998a). As expected, in naïve A549 and MRC-5 cells, STAT1 was upregulated by
IFN-α treatment, while STAT1 was not detectable in A549/PIV5/V or MRC-5/PIV5/V
cells even following IFN-α treatment (Figures 3.7A,B). STAT1 expression was not
affected by expression of BVDV/NPro (Figures 3.7A,B) or HCV/NS3/4A (data not
shown). IRF3 was undetectable in A549 and MRC-5 cells expressing BVDV/NPro,
irrespective of IFN-α treatment. Interestingly though, an IRF3 fragment (of ~35kDa;
the band is indicated by an asterisk in Figure 3.7B) was present in considerable
amounts in MRC-5/BVDV/NPro cells. This fragment disappeared following IFN-α
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treatment and was absent from A549/BVDV/NPro cells, indicating that its generation
was cell-type specific. HCV/NS3/4A clips MAVS away from the mitochondrion and in
accordance with this, no full-length MAVS could be detected in HCV/NS3/4A-
expressing cells; MAVS appeared as a slightly smaller fragment corresponding to its
cleavage by HCV/NS3/4A at its C-terminus (Figure 3.7A,B, Li et al., 2005b).
To confirm that these viral proteins could inhibit IFN production, levels of IFN
secretion from A549/PIV5/V, A549/BVDV/NPro and A549/HCV/NS3/4A cells in
response to an IFN-inducing virus (rPIV5-VΔC) were quantified using a cell-based
IFN assay. A549/PIV5/V produced a similar level of IFN to naïve cells while
A549/BVDV/NPro and A549/HCV/NS3/4A did not produce detectable amounts of
IFN (Figure 3.7C), indicating that BVDV/NPro and HCV/NS3/4A were blocking IFN
induction efficiently. PIV5/V expression does not significantly limit IFN induction in
response to rPIV5-VΔC; reasons for this will be described in the Discussion.
In addition, effects of PIV5/V, BVDV/NPro and HCV/NS3/4A on activation of the
ISRE were investigated. The same lentivirus vectors used to infect cells in Figure
3.10A were used to express these viral proteins in an A549 ISRE-reporter cell-line.
Luciferase activity in these cells was measured following mock-treatment or
treatment with IFN-α. As expected, IFN-α induced significant ISRE activation in naïve
cells due to activation of JAK/STAT signalling (Figure 3.7D). This induction was
completely abrogated by expression of PIV5/V. In comparison, expression of the V
protein of PIV5-CPI- was unable to block ISRE activation by IFN-α due to its inability
to target STAT1 for degradation. Similarly, BVDV/NPro and HCV/NS3/4A, which are
not reported to block IFN signalling, did not abrogate ISRE activation by IFN-α. The
viral IFN antagonists expressed in A549 and MRC-5 cells are therefore functioning
correctly.
3.2.2 Effect of viral IFN antagonists on apoptosis
Given that IFN is an important regulator of apoptosis, viral IFN antagonists may
affect the sensitivity of cells to apoptosis inducers. Additionally, PIV5/V, BVDV/NPro
and HCV/NS3/4A are multifunctional proteins and may play a role in apoptosis
regulation that is independent of their ability to antagonise the IFN response. It was
therefore of interest to determine whether ectopic expression of these proteins
rendered cells more or less resistant to apoptosis. A549 and MRC-5 cells expressing
PIV5/V, BVDV/NPro or HCV/NS3/4A were treated with FasL alone (MRC-5 only),
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FasL/CHX (A549 only), TNF-α/CHX or STS, and cell viability was measured at
several times post-treatment. FasL/CHX induced a similar cell death curve in A549
naïve, A549/BVDV/NPro and A549/HCV/NS3/4A cells (Figure 3.8A; left panel). In
A549/PIV5/V cells however, induction of cell death was delayed, and these cells
exhibited a higher basal survival level (the proportion of cells still viable following
prolonged treatment) than naïve cells. Similarly, expression of PIV5/V limited
apoptosis induction by TNF-α/CHX or STS in A549 cells (Figures 3.8B,C; left
panel). Interestingly, following TNF-α/CHX treatment, apoptosis was also reduced in
A549/HCV/NS3/4A cells. These data indicate that, in A549 cells, PIV5/V delays
apoptosis induced by FasL, TNF-α/CHX and STS. In addition, HCV/NS3/4A may
inhibit TNF-α/CHX in A549 cells, while BVDV/NPro expression has no effect on cell
death.
The same experiment in MRC-5 cells was much less conclusive. MRC-5/PIV5/V cells
exhibited higher cell viability levels at 4h post-treatment with FasL and STS, but there
was no elevation of the basal survival level (Figures 3.8A,C; right panel).
Additionally, neither PIV5/V nor HCV/NS3/4A seemed to offer protection from TNF-
α/CHX in MRC-5 cells (Figure 3.8B; right panel).
STAT1 promotes apoptosis by stimulating transcription of pro-apoptotic genes and
through direct interactions with apoptotic regulators (see Section 1.2.5). It was
therefore determined whether the delay of apoptosis exhibited in PIV5/V-expressing
cells was due to knockdown of STAT1 levels. Cell viability following treatment with
apoptosis inducers was compared in A549 and MRC-5 cells expressing PIV5/V(w3),
which are STAT1-deficient, and PIV5/V(CPI-), which express STAT1. PIV5/V(w3)
expression protected A549 cells from treatment with FasL/CHX- and TNF-α/CHX-
induced apoptosis while V(CPI-) expression did not (Figures 3.9A,B; left panel).
PIV5/V(w3) appears then to limit apoptosis induced by DR ligands in A549 cells by
promoting STAT1 degradation. Results obtained in MRC-5 cells were more difficult to
interpret. V(w3), but not V(CPI-), limited FasL-induced apoptosis, but neither V(w3)
nor V(CPI-) delayed apoptosis induced by TNF-α/CHX (Figures 3.9A,B; right
panel). V(w3) and V(CPI-) both protected A549 cells from STS treatment (although
V(w3) was more efficient in this respect; Figure 3.9C; left panel). In MRC-5 cells
however, V(CPI-) is unable to limit STS-induced apoptosis (Figure 3.9C; right
panel), perhaps indicating that the involvement of STAT1 in apoptosis is cell-type-
specific.
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3.2.3 IFN-γ/FasL synergy is inhibited by PIV5/V
Since PIV5/V antagonises IFN signalling by targeting STAT1 for degradation, it was
investigated whether IFN-γ/FasL synergism was inhibited in A549/PIV5/V cells. As
demonstrated above, A549/PIV5/V(w3) cells express no STAT1, even following IFN
treatment (Figure 3.7A). Significantly, A549/PIV5/V(w3) cells did not die following
24hrs treatment with IFN-γ/FasL, compared to the extensive (~70%) cell death
observed in naïve cells (Figure 3.10A). Since PIV5/V is multifunctional and was
found to delay apoptosis in the previous section, it was necessary to confirm that
PIV5/V inhibition of IFN-γ/FasL-induced apoptosis was dependent on its ability to
promote STAT1 degradation. A549/PIV5/V(CPI-) cells, in which IFN signalling
pathways are intact, were sensitive to IFN-γ/FasL, exhibiting over 50% cell death
within 24hrs (Figure 3.10A). Interestingly though, the level of cell death in
A549/PIV5/V(CPI-) was lower than in naïve cells, perhaps suggesting that PIV5/V
also inhibits apoptosis independently of its effects on STAT1. Additional evidence for
PIV5/V(w3)-mediated inhibition of IFN-γ/FasL synergy was obtained by serial titration 
of FasL on IFN-γ-pre-treated A549 cells. Even at the highest concentration of FasL
(200ng/ml), V(w3)-expressing cell monolayers remained intact, while naïve and
PIV5/V(CPI)-expressing cells exhibited cell death down to 25ng/ml FasL (Figure
3.10B). In support of these data, immunoblot analyses showed that both naïve and
PIV5/V(CPI-) expressing cells, but not A549/PIV5/V(w3), exhibited significant PARP
cleavage in response to IFN-γ/FasL (Figure 3.10C). An additional observation was
that in A549 naïve and A549/PIV5/V (CPI-) cells, STAT1 expression decreased
following treatment with IFN-γ/FasL. This was probably due to caspase-dependent
cleavage and inactivation of STAT1 during apoptosis (King and Goodbourn, 1998).
To determine whether expression of other viral IFN antagonists could block IFN-
γ/FasL-induced apoptosis, A549 cells stably expressing PIV5/V(w3), HCV/NS3/4A,
BVDV/NPro, the V protein of mumps virus (MuV/V) or IAV/NS1 were treated with
IFN-γ/FasL. HCV/NS3/4A, BVDV/NPro and IAV/NS1-expressing monolayers
exhibited considerable cell death (Figure 3.10D). These viral proteins did not block
IFN-γ/FasL-induced apoptosis because, while they block activation of the IFN
promoter, they do not affect transduction of the IFN signal so are unable to block the
pro-apoptotic effects of IFN-γ. In contrast, there was no evidence of cell death in
MuV/V-expressing cells; expression of MuV/V therefore conferred resistance to IFN-
γ/FasL-induced apoptosis. This is because, like PIV5/V, MuV/V targets STAT1 for
degradation (Kubota et al., 2001, Yokosawa et al., 2002). In conclusion, IFN-γ/FasL 
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synergy was dependent on STAT1 expression, and as such could be inhibited by
PIV5 and MuV V proteins.
3.2.4 IFN and apoptosis induction by different PIV5 strains
The previous section reported that the STAT1-degradative function of V was
responsible for inhibiting apoptosis caused by non-viral inducers. It was next
determined whether V contributed to apoptosis regulation during PIV5 infection. The
PIV5-w3, PIV5-CPI+, PIV5-CPI- and rPIV5-VΔC strains of PIV5 all express V 
proteins with different biological properties, including their ability to target STAT1 for
degradation. The amino acid differences in V between these strains and the
consequences for STAT1 and mda-5 inhibition are depicted in Figure 3.11. The w3
strain of PIV5 is generally considered to be a PIV5 prototype virus. As described
above, its V protein is an IFN antagonist; it targets STAT1 for proteasomal
degradation and limits IFN induction by inhibiting mda-5 activity (Didcock et al.,
1999b, Andrejeva et al., 2004). The V protein of PIV5-CPI+ behaves much like
V(w3), even though these proteins differ by three amino acids in their N-termini
(Chatziandreou et al., 2002); its V protein is also able to bind mda-5 and target
STAT1 for degradation. The PIV5-CPI- virus was isolated from a dog experimentally
infected with PIV5-CPI+ (Baumgartner et al., 1987). V(CPI-) is unable to target
STAT1 for degradation due to a further three amino acid substitutions in its N-
terminus, but is still able to bind mda-5 to limit IFN induction (Poole et al., 2002,
Chatziandreou et al., 2002, Southern et al., 1991). The recombinant rPIV5-VΔC virus 
lacks the conserved C-terminus of V; as a result, this virus is unable to block either
IFN production or JAK/STAT signalling (He et al., 2002a, Poole et al., 2002). PIV5-
w3, PIV5-CPI+, PIV5-CPI- and rPIV5-VΔC are reported to vary in their ability to
induce IFN (Poole et al., 2002). Since an important function of the IFN response is to
establish a pro-apoptotic state in cells (Barber, 2000), induction of large amounts of
IFN by a virus may increase cell death. Indeed, rPIV5-VΔC is reported to induce 
significant amounts apoptosis as well as IFN (Sun et al., 2004). It was therefore
investigated whether differences in V altered IFN and apoptosis induction by these
viruses.
IFN production by A549 cells infected with PIV5-w3, PIV5-CPI+, PIV5-CPI- and
rPIV5-VΔC was estimated in a cell-based IFN assay. As expected, these viruses
induced different levels of IFN. rPIV5-VΔC was the best inducer; infected cells
produced at least 5-fold more IFN than any of the other strains at 48 hours post-
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infection (hpi) (Figure 3.12). In contrast, cells infected with PIV5-w3 produced no IFN
until very late in infection and even at 48hpi, only small amounts of IFN were
detectable. PIV5-CPI+ and PIV5-CPI- induced similar levels of IFN, with both strains
inducing significantly more IFN than PIV5-w3. Naturally-occurring and
experimentally-introduced mutations in the V protein therefore affect the ability of
PIV5 to induce IFN.
To determine whether these PIV5 strains also varied in their ability to induce
apoptosis, A549 cell viability following PIV5 infection was measured by wst-1 assay.
While PIV5-w3 did not cause significant cell death, even as late as 7 days post-
infection (dpi), infection with PIV5-CPI- virus did (~60% reduction in viability at 7 dpi;
Figure 3.13A). Infection with PIV5-CPI+ caused less cell death than PIV5-CPI-,
despite both viruses being similar inducers of IFN. Surprisingly, rPIV5-VΔC, which is 
reported to be apoptogenic, did not cause any cell death.
To investigate whether induction of cell death by PIV5-CPI- was due to its inability to
target STAT1 for degradation, A549 cells defective in the IFN response (IRF3-
deficient A549/BVDV/NPro and STAT1-deficient A549/PIV5/V) were infected with all
four strains of PIV5. Despite induction of considerable cell death in naïve A549 cells,
PIV5-CPI- caused no cell death in A549/BVDV/NPro cells (Figure 3.13B). PIV5-CPI-
induced cell death was also reduced in A549/PIV5/V cells, to levels similar to PIV5-
CPI+ (Figure 3.13C). Notably, rPIV5-VΔC, which did not induce cell death in naïve
A549 cells, caused large amounts of apoptosis in A549/BVDV/NPro and
A549/PIV5/V (~80% at 4 days post-infection; Figures 3.13B,C). These results
suggest that rPIV5-VΔC was unable to replicate in naïve cells due to the
establishment of an IFN-induced antiviral state. In A549/BVDV/NPro and
A549/PIV5/V cells however, IFN is either not produced or cannot signal effectively,
so is virus replication is not inhibited and virus induces significant cell death.
3.2.5 PIV5 infection and apoptosis induction by non-viral inducers
It was next determined whether V expression in the context of PIV5 infection was
able to inhibit apoptosis in response to non-viral inducers. A549 cells were infected
with PIV5-w3, rPIV5-VΔC, PIV5-CPI+ and PIV5-CPI- at high MOI, then treated with
the DR ligands TNF-α or FasL (in the presence of CHX), or STS. Surprisingly, given
the inhibitory effects of PIV5/V ectopic expression on apoptosis, the response of cells
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to TNF-α/CHX, FasL/CHX or STS treatment was not significantly affected by
infection with any of the PIV5 strains (Figures 3.14).
Conclusions
Depletion of IRF3 by BVDV/NPro expression had no effect on cell death, while
NS3/4A expression was able to limit TNF-α/CHX-induced apoptosis. PIV5/V(w3)
ectopic expression limited apoptosis induction by FasL/CHX, TNF-α/CHX and STS in
A549 cells. In addition, PIV5/V(w3) could block the facilitatory effect of IFN-γ on 
FasL-induced apoptosis. In MRC-5 cells, PIV5/V(w3) expression inhibited FasL and
STS, but not TNF-α/CHX-induced apoptosis. These effects were dependent on the
ability of V to promote STAT1-degradation. Expression of V in the context of PIV5
infection was unable to block apoptosis in response to the same inducers however.
Naturally occurring and experimentally introduced substitutions in V affected the
ability of PIV5 to induce IFN and apoptosis. Compromising the IFN response by
knocking out STAT1 or IRF3 altered the apoptosis induction profiles of viruses
expressing these V proteins.
3.2.6 Modulation of PI3K/Akt signalling by PIV5/V
The ability of PIV5/V (CPI-) to partially block STS-induced apoptosis in A549 cells
suggests PIV5/V may regulate host-cell apoptosis independently of STAT1; V may
be therefore be modulating additional signalling pathways in the cell. A role of Akt in
PIV5 infection has been proposed: V is reported to interact with Akt to enhance virus
replication (Sun et al., 2008a). Many viruses activate PI3K/Akt to prevent or delay
virus-induced apoptosis (Peters et al., 2008, Lee et al., 2001, Dawson et al., 2003,
Zhang et al., 2002, Bitko et al., 2007), so the interaction between V and Akt may also
play a role in limiting apoptosis inhibition. However, modulation of Akt signalling by V
has not yet been reported. This section seeks to elucidate the effects of V expression
on Akt activation.
3.2.6.1 Akt activation is inhibited by PIV5/V
To determine whether ectopic PIV5/V expression could affect Akt activation, naïve
A549 and A549/PIV5/V(w3) cells were probed for levels of phospho-Akt in the
presence of serum. While PIV5/V(w3) expression did not activate Akt, it was
surprising to note that phospho-Akt levels were lower in A549/PIV5/V(w3) than naïve
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cells (Figure 3.15). Since IFN activates Akt (Figure 3.5A) and PIV5/V blocks IFN
signalling by promoting STAT1 degradation, it follows that V may be able to block
IFN-stimulated Akt activation. Indeed, Akt activation by IFN-α or IFN-γ was inhibited
in A549 cells expressing PIV5/V(w3) (Figure 3.15). PIV5/V(w3) can therefore block
Akt activation by both serum and IFN.
The V protein is reported to directly interact with Akt (Sun et al., 2008a); this
interaction may be important for PIV5/V inhibition of Akt. To determine whether a
V:Akt interaction could be detected, 293T cells were transfected with plasmids
expressing PIV5/V(w3), Akt or V and Akt and lysed 24hrs later. V and Akt were
immunoprecipitated using anti-V5 and anti-Akt antibodies under low-salt conditions
then immunoprecipitated V and Akt were detected by immunoblotting. The data
shown in Figure 3.16 is representative of three independent experiments. No Akt
was detected in lysates immunoprecipitated with antibody to V and conversely, V
could not be detected in lysates immunoprecipitated with anti-Akt antibody. No
evidence of V:Akt interaction was therefore obtained in this experiment.
To determine whether the ability of PIV5/V(w3) to inhibit Akt activation was
dependent on its ability to target STAT1 for degradation, A549 cells expressing
PIV5/V(CPI-) were treated with IFN and probed for active Akt. Following IFN-α and
IFN-γ treatment or in the presence of serum only, A549/PIV5/V(CPI-) cells showed a
similar level of Akt activation to naïve cells (Figure 3.15). This suggests that the
ability of serum and IFN to activate Akt is dependent on an intact STAT signalling
pathway and that PIV5/V inhibits Akt activation through its effects on STAT1
expression.
3.2.6.2 Akt activation during PIV5 infection
It has been suggested previously that the V protein may inhibit PIV5-induced Akt
activation (Luthra et al., 2008). To investigate Akt activation during PIV5 infection,
A549 cells were infected with PIV5-w3, SeV and IAV. SeV and IAV were included as
positive controls as both viruses are reported to activate PI3K/Akt (Peters et al.,
2008, Hale et al., 2006). As expected, IAV infection strongly activated Akt: large
amounts of phospho-Akt could be detected from 4 to 24 hpi (Figure 3.17A).
Transient Akt activation was also induced by SeV but this was much weaker than
during IAV infection; phospho-Akt was detectable between 8 and 12 hpi, but had
completely disappeared by 24 hpi. PIV5-w3 infection, on the other hand, did not
92
activate Akt significantly, as even at 24 hpi, phospho-Akt levels were only slightly
higher than background.
As demonstrated in the previous section, IFN treatment activates Akt and this can be
inhibited by PIV5/V. PIV5-w3-infected cells may be unable to activate Akt either
because PIV5-w3 induces only minimal amounts of IFN or because its V protein
blocks IFN signalling and Akt activation. Strains of PIV5 that are better IFN inducers
than w3 or that are unable to block IFN signalling may therefore activate Akt more
efficiently. To investigate whether this was the case, A549 cells were infected with
PIV5-w3, PIV5-CPI+, PIV5-CPI- and rPIV5-VΔC at equal MOI and cell lysates
probed for Akt activation and viral protein expression. The polyclonal anti-V antibody
used to detect V also reacts with the PIV5 P protein due to their shared N-termini
(Figure 3.17B). Although rPIV5-VΔC does not express a full-length V protein, a
protein with a similar mobility to full-length V was detected in rPIV5-VΔC-infected
cells. This band corresponds to a degradation product of the P protein (Thomas et
al., 1988, He et al., 2002a), and is labelled P* in Figure 3.17B. Lysates were
therefore also probed with antibody specific to the C-terminus of V: no V expression
was detectable in rPIV5-VΔC-infected cells. In PIV5-w3 and PIV5-CPI+ infected
cells, phospho-Akt could only be detected late in infection (36 hpi; Figure 3.17B). In
contrast, PIV5-CPI- infection activated Akt from 24hrs with even more potent
activation at 36hpi, while rPIV5-VΔC activated Akt strongly from 12 hpi onwards.
Activation of Akt by PIV5 therefore appears to be related to both the levels of IFN
induction and the functionality of STAT signalling in infected cells.
Conclusions
PIV5/V inhibits Akt activation by serum and IFN in A549 cells in a manner that
requires its ability to degrade STAT1. In support of this, PIV5 strains that are unable
to degrade STAT1 (PIV5-CPI- and rPIV5-VΔC) activate Akt much more strongly than 
those that do (PIV5-w3 and PIV5-CPI+).
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3.3 IAV NS1, PI3K activation and innate antiviral responses
The NS1 protein of IAV is reported to interact with a number of host cell proteins to
interfere with the IFN system and apoptosis. One of these interactors is PI3K: a
direct interaction between the IAV NS1 protein and the p85 regulatory subunit of
PI3K results in activation PI3K/Akt signalling (Hale et al., 2006, Shin et al., 2007c).
As discussed in the Introduction, PI3K and its downstream target Akt play a pivotal
role in the regulation of apoptosis and the IFN response. This section explores the
implications of this p85:NS1 interaction for host cell apoptosis and the IFN system. In
addition, the biological consequences of NS1 mutations that prevent its interaction
with other host cell proteins are investigated.
3.3.1 IAV NS1 activates PI3K
3.3.1.1 The kinetics of PI3K activation by IAV are cell-type specific
The ability of IAV to activate PI3K in a wide range of cell-lines was investigated.
Lysates of cells infected with the Udorn strain of IAV were prepared at various times
post-infection, then probed for PI3K activation using Akt phosphorylation at Ser473
as a marker. In MDCK (canine kidney epithelial) cells, PI3K activation was extremely
transient (Figure 3.18); phospho-Akt was present in large amounts at 8h, but
reduced to just above background level from 12h onwards, despite significant
expression of NS1. In contrast, A549 cells displayed considerable Akt activation until
24hrs, after which phospho-Akt levels decreased to background levels at 48 hrs. In
the fibroblast cell-lines MRC-5 and HFFF, Akt activation was much more prolonged,
with significant phospho-Akt still detectable at 48 hrs post-infection. Similarly,
1321N1 (human brain astrocytoma) cells displayed considerable amounts of
phospho-Akt as late as 60 hrs post-infection. Akt was also activated by IAV infection
(albeit transiently) in Vero (monkey kidney) cells, which are unable to produce IFN
due to deletion of IFN-α/β genes (Desmyter et al., 1968), and in Hep2 cells in which
IAV cannot replicate productively (Ludwig, 2006). These data demonstrate that the
kinetics of Akt activation by IAV differ significantly with cell-type.
3.3.1.2 rUd-Y89F is unable to activate PI3K
The introduction of a Y89F substitution into NS1 abrogates the NS1:PI3K interaction;
consequently, a recombinant virus expressing this mutant NS1 is unable to activate
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PI3K in MDCK cells (Hale et al., 2006). For reasons described in Section 3.1.4,
A549 and MRC-5 were considered the most suitable cell-lines for this study. To
investigate the biological implications for PI3K activation by NS1 then, it was
important to ensure that rUd-Y89F was also unable to activate PI3K/Akt in these cell
types. A significant amount of previous work on the PI3K:NS1 interaction has been
carried out in MDCK cells, so these cells were also included to enable direct
comparison of results with these studies. In accordance with previous work (Hale et
al., 2006), rUd wt infection of MDCK cells transiently activated Akt while no phospho-
Akt was detectable in cells infected with the rUd-Y89F virus (Figure 3.19). Similarly,
A549 and MRC-5 cells exhibited significant Akt activation following infection with rUd
wt but not rUd-Y89F.
3.3.1.3 rUd-Y89F is attenuated in A549 and MRC-5 cells
In MDCK cells, rUd-Y89F displays a small-plaque phenotype and grows to a titre
~10-fold lower than rUd wt in a single-step growth curve (Hale et al., 2006). To
establish whether rUd-Y89F was also attenuated in A549 and MRC-5 cells, the
growth rates of rUd wt and rUd-Y89F were determined in a multi-step growth curve.
In A549 cells, rUd-Y89F virus yield was ~2 orders of magnitude lower than for rUd wt
(Figure 3.20A). rUd-Y89F was also attenuated in MRC-5 cells, but the difference
was less pronounced than in A549: rUd-Y89F grew to a titre ~10-fold lower than rUd
wt (Figure 3.20B).
Conclusions
rUd wt activates PI3K/Akt in a wide range of cells, but the kinetics of Akt activation
differ according to the cell-type. The rUd-Y89F virus is unable to activate PI3K/Akt
signalling and is attenuated in A549 and MRC-5 cells.
3.3.2 Effect of PI3K activation by NS1 on apoptosis
3.3.2.1 IAV induces apoptosis at high multiplicity
IAV infection causes apoptosis in vitro and in vivo (Mori et al., 1995, Hinshaw et al.,
1994, Fesq et al., 1994, Takizawa et al., 1993, Price et al., 1997). Phase-contrast
time-lapse microscopy of IAV-infected A549 cells (Figure 3.21; supplied disc)
revealed that a proportion of infected cells went into apoptosis within a 24hr period;
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these cells exhibited membrane blebbing and detached from the cell monolayer.
However, apoptosis was only seen at very high MOI (~50 PFU/cell) and most cells
did not go into apoptosis, suggesting that IAV may be able to inhibit cellular
apoptosis.
3.3.2.2 NS1 expression does not protect cells from apoptosis
Numerous studies have attributed NS1-mediated PI3K activation an anti-apoptotic
role in the host cell (Zhirnov and Klenk, 2007, Ehrhardt et al., 2007, Shin et al.,
2007c). It was therefore determined whether NS1-mediated PI3K activation could
protect cells from DR ligand and STS-induced apoptosis. A549 cell lines stably
expressing the NS1 or NS1-Y89F proteins from the PR8 strain of IAV were produced
using lentivirus vectors. Both NS1 proteins were expressed at similar levels, and
expression of NS1, but not NS1-Y98F, in A549 cells activated Akt in the absence of
serum (Figure 3.22F). Cell viability was measured in these cells following treatment
with TNF-α (+/- CHX), FasL (+/- CHX) and STS. Surprisingly, there was no significant
difference in apoptosis induction in NS1 wt and NS1-Y89F-expressing cells following
treatment with any of these inducers (Figures 3.22).
3.3.2.3 rUd-Y89F does not cause more apoptosis than rUd wt in epithelial cells and
fibroblasts
The results obtained in the previous section contradicted a previous report that NS1-
mediated PI3K activation could prevent STS-induced apoptosis (Ehrhardt et al.,
2007). The role of PI3K activation in IAV-induced apoptosis was therefore
investigated further: it was determined whether viruses expressing NS1-Y89F
induced apoptosis more readily than wt virus. MDCK, A549 and MRC-5 cells were
infected with wt or -Y89F rUd or rWSN viruses and cell viability was measured at
various times post-infection. Neither rUd-Y89F nor rWSN-Y89F, also unable to bind
and activate PI3K (Hale, 2007), caused any more cell death than wt virus in A549
and MDCK cells (Figures 3.23A,B). In MRC-5 cells, rUd-Y89F and rWSN-Y89F
seemed to cause slightly (~15%) more cell death than wt virus (Figure 3.23C) at very
late times in infection (at least 30 hpi). However, as PI3K/Akt is activated from 8hpi in
MRC-5 cells (Figure 3.19), this difference in cell death late in infection is unlikely to
be a direct effect of PI3K activation on apoptosis. In addition, given the sensitivity of
MRC-5 cells to apoptosis (Figure 3.6), it was surprising to note that MRC-5 cells did
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not readily die following infection with either wt or -Y89F virus; ~60% of cells are still
alive up to 50 hpi.
To further compare onset of apoptosis following rUd wt and rUd-Y89F infection,
lysates from infected cells were probed for caspase activation. The activation of
caspase-3 or cleavage of PARP, both hallmarks of apoptosis, in rUd-Y89F-infected
MDCK, A549 and MRC-5 cells was not any higher than in rUd wt-infected cells
(Figure 3.24).
3.3.2.4 rUd wt infection does not protect cells from non-viral apoptosis inducers
A similar experiment to the one in Figure 2.22 was carried out to determine whether
PI3K activation during rUd infection could protect cells from non-viral apoptosis
inducers. A549 and MRC-5 cells were infected with rUd wt and rUd-Y89F for a period
of 12-14hrs, then treated with FasL, FasL/CHX (A549 only), TNF-α, TNF-α/CHX and
STS. Notably, there was no difference between the cell death responses of rUd wt
and rUd-Y89F-infected cells in response to any of these treatments (Figure 3.25).
However, IAV infection (either rUd wt or rUd-Y89F) did appear to sensitise cells to
apoptosis. FasL-resistant A549 cells (Figure 3.1) were sensitised to FasL-mediated
apoptosis (Figure 3.25A; left panel) following IAV infection, and infected MRC-5
cells, which are already FasL sensitive (Figure 3.6), went into FasL-induced
apoptosis more rapidly than uninfected cells (Figure 3.25A; right panel). In addition,
prior infection of A549 cells with rUd accelerated FasL/CHX-induced cell death
compare to either infection or treatment alone (Figure 3.25B). MRC-5 cells are
normally resistant to TNF-α treatment, but were sensitised to TNF-α following IAV
infection, but infection did not have the same facilitatory effect on TNF-α treatment in
A549 cells for unknown reasons (Figure 3.25C). Virus infection offered slight
protection from TNF-α/CHX-induced apoptosis, particularly in MRC-5 cells (Figure
3.25D), while there was no significant difference in the rate of STS-induced apoptosis
between infected and mock-infected A549 and MRC-5 cells (Figure 3.25E).
3.3.2.5 The PI3K inhibitor LY294002 can give misleading results
Previous studies into the effect of PI3K activation by NS1 on apoptosis relied on the
pharmacological PI3K inhibitor LY294002 (LY) to inhibit PI3K activation (Ehrhardt et
al., 2007, Zhirnov and Klenk, 2007). However, LY is also a potent inhibitor of several
other kinases and may inhibit virus entry to cells (Ehrhardt et al., 2006, Bain et al.,
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2007, Davies et al., 2000, Gharbi et al., 2007). To investigate whether use of LY in
previous studies was the reason for contradictions with data obtained in this study,
cell viability was measured during infection with rUd wt or rUd-Y89F in the presence
of DMSO or LY. LY treatment alone caused significant cell death in both A549 and
MRC-5 cells (Figure 3.26). rUd infection in the presence of LY caused more cell
death than either LY or rUd alone: this result could be interpreted to mean that
inhibition of PI3K activation by NS1 causes significant cell death. An alternative
explanation is that the dual assault of drug treatment and virus infection sensitises
cells to apoptosis independently of PI3K inhibition. Indeed, combining LY treatment
and rUd-Y89F infection also caused more cell death than either LY or rUd-Y89F
alone in A549 cells (Figure 3.26A). In MRC-5 cells, which are very sensitive to
apoptosis, the difference between rUd-Y89F-induced cell death with/without LY was
particularly marked (~25%; Figure 3.26B). The effect of LY on IAV-induced
apoptosis is therefore independent of its ability to inhibit PI3K activation by NS1, and
results obtained using LY should be interpreted with caution.
3.3.2.6 PI3K activation by NS1 reduces p53 expression and activation
p53 is activated during IAV infection but is not a major factor in promoting IAV-
induced apoptosis (Technau-Ihling et al., 2001, Turpin et al., 2005, Zhirnov and
Klenk, 2007). Since PI3K activation reduces p53 expression and activation (Mayo
and Donner, 2001, Chun-gen Xing, 2008, Filiz et al., 2008), the effects of PI3K
activation by NS1 on p53 were investigated. In both rUd wt and rUd-Y89F-infected
cells, p53 was phosphorylated at Ser-15 from 10hrs post-infection onwards (Figure
3.27A). However, the level of active p53 was greater in cells infected with rUd-Y89F.
Total p53 also seemed to increase during rUd-Y89F, but not rUd wt, infection despite
similar levels of NS1. In support of these observations, 1321N1 cell-lines expressing
PR8/NS1-Y89F exhibited higher phospho-p53 levels than 1321N1 naïve and
1321N1/NS1 wt (Figure 3.27B). In addition, cells expressing NS1 wt had decreased
total p53 levels compared to NS1-Y89F.
3.3.2.7 PI3K activation by NS1 does not affect FasL expression
Akt negatively regulates FasL expression through inhibition of FOXO transcription
factors (Suhara et al., 2002, Uriarte et al., 2005, Tang et al., 1999, Ciechomska et al.,
2003). In addition, p53 activation can promote FasL expression (Hsu et al., 2004b).
While data obtained thus far indicates that PI3K does not mediate-anti-apoptotic
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signalling during IAV infection, it may still be able to modulate FasL expression.
Although FasL is predominantly expressed on the surfaces of NK cells, it is also
expressed on the surface of various tumour cell-lines (Kawasaki et al., 2000, Strand
et al., 1996, Hahne et al., 1996, Shurin et al., 1998, Muschen et al., 2000, O'Connell
et al., 1996, Niehans et al., 1997). To investigate whether PI3K/Akt activation by NS1
could affect FasL expression, A549 cells which express FasL (Hsu et al., 2004b, Du
et al., 2006, Kawasaki et al., 2000), were infected with rUd wt or rUd-Y89F and
probed for FasL expression. The levels of FasL were similar in rUd wt and rUd-Y89F-
infected cells however, despite differences in PI3K/Akt activation (Figure 3.28).
3.3.2.8 PI3K activation by NS1 prevents apoptosis in neutrophils
Neutrophils, mobile phagocytes that are rapidly recruited to the sites of virus
infections to promote virus clearance (Grundy et al., 1998, Tate et al., 2008), are
reported to function as a vehicle for IAV systemic spread (Zhao et al., 2008, Ratcliffe
et al., 1992). These cells have a short-half life of about 24hrs and undergo apoptotic
cell death after this period (Savill et al., 1989). PI3K/Akt promotes neutrophil survival
(Webb et al., 2000, Francois et al., 2005, Yasui et al., 2002), so a preliminary
experiment was carried out to determine whether PI3K activation by NS1 could
inhibit neutrophil apoptosis. Freshly isolated neutrophils or A549 cells (as a negative
control) were infected with rUd wt and rUd-Y89F and the proportion of apoptotic cells
quantified at 24hpi by annexin V/propidium iodide (PI) staining and flow cytometry. In
support of previously obtained data, rUd-Y89F did not cause any more apoptosis
than rUd wt in A549 cells (Figure 3.29A). In neutrophils however, infection with rUd-
Y89F caused over 15% more apoptosis than wt (Figure 3.29B).
Conclusions
PI3K activation by NS1 down-regulates p53 expression and activity, but this does not
correlate with apoptosis induction: IAVs expressing NS1-Y89F did not cause any
more apoptosis than wt virus in MDCK, A549 and MRC-5 cells. In addition, PI3K
activation by IAV infection or ectopic NS1 expression was unable to protect cells
from non-viral apoptosis inducers. However, PI3K activation by IAV may play a role
in prolonging neutrophil survival.
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3.3.3 Effect of PI3K activation by NS1 on the IFN response
3.3.3.1 PI3K activation by NS1 has no effect on IFN production
As described in the Introduction, PI3K activation limits induction of the IFN promoter
by inhibiting NF-kB (Aksoy et al., 2005). Additionally, p53 contributes to IFN release
from virus-infected cells (Munoz-Fontela et al., 2008). It follows then that PI3K/Akt
activation and/or the decrease in p53 expression and activation seen during rUd wt
infection (Figure 3.27) may affect IFN induction in infected cells. The amount of IFN
secreted from A549 cells infected with rUd wt or rUd-Y89F viruses was quantified at
several points post-infection by cell-based IFN assay. However, there was no
difference in IFN induction by rUd wt or rUd-Y89F viruses (Figure 3.30).
3.3.3.2 PI3K activation by NS1 has no effect on NF-kB activation
While PI3K activation can interfere with IFN production by inhibiting NF-kB activation
in response to dsRNA (Aksoy et al., 2005), PI3K/Akt can also activate NF-kB
signalling in response to IFN treatment (Du et al., 2007). It was therefore of interest
to determine whether PI3K activation by NS1 had any effect on NF-kB transcriptional
activity. A549 cells stably expressing luciferase under the control of an NF-kB-
responsive promoter were infected with rUd wt or rUd-Y89F. TNF-α treatment served
as a positive control and increased NF-kB activity over two-fold in these cells (Figure
3.31A). Basal levels of NF-kB activity in uninfected cells were relatively high and
were significantly reduced by rUd infection (from 2hpi), indicating that rUd can shut-
off host protein expression from a very early point in infection. However, there was
no difference in NF-kB activation between cells infected with rUd wt and rUd-Y89F,
despite differences in Akt activation (Figure 3.31).
3.3.3.3 PI3K activation by NS1 has no effect on ISRE activation and ISG expression
IFN treatment induces Ser727 phosphorylation of STAT1 and enhances its
transcriptional activity through a kinase downstream of PI3K/Akt (Nguyen et al.,
2001, Wen et al., 1995). PI3K can also increase mRNA translation of ISGs through
an mTOR-mediated pathway (Kaur et al., 2008a, Lekmine et al., 2003). Additionally,
p53 has been reported to enhance IFN signalling (Munoz-Fontela et al., 2008).
Activation of PI3K and/or the subsequent reduction of p53 activity may therefore
affect transcription from the ISRE. ISRE activation during rUd wt and rUd-Y89F
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infection was examined using A549 cells expressing luciferase under the control of
an ISRE. Treatment of these cells with IFN-α (the positive control) increased
luciferase activity ~10-fold (Figure 3.32A). The ISRE was also activated (to a much
smaller extent) following rUd infection, although ISRE activation declined as the
infection proceeded. However, there was not a significant difference between ISRE
induction with rUd wt and rUd-Y89F viruses. Similarly, PI3K activation by NS1 did not
affect IFN-α signalling to the ISRE activation either, as determined by IFN-α
treatment of rUd-infected cells (Figure 3.32B). The ability of rUd wt and rUd-Y89F
infection to affect ISG15 expression was also investigated. In accordance with its role
as an ISG, ISG15 levels in A549 cells were upregulated by IFN-α treatment (Figure
3.33), and rUd infection significantly reduced ISG15 expression levels due to shut-off
of cellular protein synthesis. However, there was not a significant difference in ISG15
expression between rUd wt and rUd-Y89F-infected cells, either with or without IFN-α
treatment.
Conclusions
rUd wt and rUd-Y89F did not differ in their induction of IFN or activation of NF-kB.
Similarly, no difference in ISRE activation and ISG15 expression was observed in
infected cells. However, IAV infection (either rUd wt or rUd-Y89F) inhibited ISG15
expression in response to IFN-α, and prevented expression of luciferase in NF-kB
and ISRE reporter systems due to shut-off of host protein synthesis.
3.3.4 Mutations in NS1 affect apoptosis and IFN induction
NS1 is reported to interact with a significant number of cellular and viral factors,
including dsRNA, PKR and CPSF30, to modulate host antiviral responses. The
residues of NS1 responsible for these interactions have been mapped and
introduced into recombinant viruses to investigate the biological consequences of
each interaction. The relative contribution of the dsRNA, PKR, CPSF30 and PI3K
interactions to evasion of antiviral responses has not yet been established, as direct
comparison between these studies is difficult due to the different virus backgrounds
used for the production of mutant viruses. As part of ongoing influenza research at
the University of St Andrews, a series of recombinant Udorn viruses have been
produced (by D. Jackson and C. Galloway). Since these NS1 mutations are
expressed in the same virus background, comparative study of the contribution of
each mutation to virus replication and pathogenesis is enabled. The generated
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mutants are shown in Table 3.1. They comprise those reported to interfere with PI3K
binding and activation (rUd-Y89F, rUd-P164/7A and rUd-P162/4/7A), dsRNA binding
(rUd-R38A), PKR binding (rUd-123/4), and interaction with CPSF30 (rUd-184-8(L)
and rUd-103/106). During the rescue of these viruses, a virus expressing NS1 with a
C-terminal truncation (rUd-Δ99) and a virus related to rUd-184-8(L), rUd-184-8(P),
were also isolated. The positions of these mutations in the NS1 protein are displayed
in Figure 3.34.
3.3.4.1 Effects of NS1 mutations on PI3K activation
As part of the characterisation of these mutant viruses, NS1 expression and PI3K
activation in response to virus infection was investigated. By 24 hpi, NS1 expression
was detected following infection with all viruses except rUd-Δ99 in both A549 and
MRC-5 cells (Figure 3.35). However, the level of NS1 in rUd-184-8(P)-infected cells
was significantly lower than for rUd wt. As expected, Akt was strongly activated in
rUd wt-infected A549 and MRC-5 cells and similar levels of phospho-Akt were
detected in cells infected with rUd-R38A, rUd-123/4 and rUd-103/106 (Figures 3.35).
In comparison, cells infected with rUd-Y89F, rUd-164/7A, rUd-162/4/7A, rUd-Δ99 and 
rUd-184-8(P) did not express more phospho-Akt than background.
3.3.4.2 Mutations in NS1 affect IAV-induced apoptosis
The panel of recombinant viruses was used to determine whether any of these NS1
mutations rendered IAV more apoptogenic. Cell viability was measured in MDCK and
A549 cells following infection with these viruses. rUd-Y89F, rUd-P164/7A, rUd-123/4
and rUd-103/106 caused no more cell death than infection with wt in both cell-types
(Figures 3.36A,B). In contrast, rUd-162/4/7A, rUd-Δ99 and rUd-184-8(P) caused
significantly more cell death than wt virus. Cell death caused by the remaining
mutants appears to be cell-type specific: rUd-R38A induced cell death in MDCK but
not A549 cells, while rUd-184-8(L) induced apoptosis in A549 but not MDCK cells
(Figures 3.36A,B).
MRC-5 cells, which are extremely sensitive to apoptosis (Figure 3.6), were infected
with a selection of mutant viruses: rUd-Y89F, rUd-P164/7A, rUd-P162/4/7A and rUd-
184-8(P). While rUd-Y89F and rUd-P164/7A did not induce any more cell death than
rUd wt, both rUd-P162/4/7A and rUd-184-8(P) did (~20% and ~55% respectively;
Figure 3.36C).
102
Caspase activity in infected cells was assessed qualitatively and quantitatively. At 24
hpi, cleaved PARP fragments could be detected by immunoblotting in rUd-184-8(P)-
infected A549 and MRC-5 cells (Figures 3.35A,B bottom panel). PARP cleavage
was also detectable in A549 cells infected with rUd-P162/4/7A. Caspase-3 and -7
activity was measured quantitatively by luciferase assay using a commercially
available kit. In both A549 and MRC-5 cells, caspase activity was higher in wt
infected than in mock cells (36- and 3-fold respectively; Figures 3.37) consistent with
IAV infection inducing a small amount of apoptosis. Significantly more caspase
activity was observed following infection with rUd-184-8(P) (3.2-fold increase in A549
cells; 6.8-fold increase in MRC-5 cells) and rUd-P162/4/7A (2.1-fold increase in A549
cells; 3.9-fold increase in MRC-5 cells). Interestingly, caspase activity in rUd-Δ99-
infected A549 cells was no higher than wt (Figure 3.37A); the reasons for this are
unknown.
Changes in nuclear morphology are characteristic of apoptosis: apoptotic cells
exhibit highly condensed and fragmented nuclear material (Toné et al., 2007). MDCK
cells infected with selected mutants were fixed and their nucleic acid stained with
acridine orange; cells were subsequently visualised by fluorescence microscopy. No
abnormal nuclear morphologies were detected in cells infected with rUd wt, rUd-
Y89F or rU-P164/7A (Figure 3.37C). In contrast, rUd-P162/4/7A and rUd-184-8(P)-
infected cells clearly displayed apoptotic nuclear condensation.
rUd-184-88(P) did not activate PI3K/Akt in infected cells (Figure 3.35). To
demonstrate that this inability to activate PI3K was not responsible for rUd-184-8(P)-
induced apoptosis, it was determined whether PI3K activation by serum could
prevent rUd-184-8(P)-induced cell death. A549 cells were infected with rUd-184-8(P)
then incubated in either serum-free medium or medium containing 10% FCS. Cell
lysates were prepared at 24 hpi, while cell viability was measured at 36 hpi. These
time-points were chosen as caspase activation can be detected in rUd-184-8(P)-
infected cells by immunoblotting at 24hpi, but there is no detectable reduction in cell
viability at this time; for this reason, cell viability was measured at 36hpi, when a
significant reduction in cell viability can be detected. rUd-184-8(P) induced the same
level of cell death and PARP cleavage in the absence or presence of serum (Figure
3.38). Consequently, NS1-independent PI3K activation does not prevent apoptosis
caused rUd-184-8(P)-induced apoptosis.
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3.3.4.3 IFN induction by NS1 mutant viruses correlates with apoptosis induction
Since NS1 is an IFN antagonist, NS1 mutant viruses that induce a large amount of
apoptosis may also be inducing significant levels of IFN. To investigate whether this
was the case, IFN induction by the panel of mutants was quantified by cell-based IFN
assay. In A549 cells, rUd-184-8(P) induced a large amount of IFN; ~250-fold higher
than wt at 24 hpi (Figures 3.39B). rUd-184-8(L) and rUd-Δ99 were also better IFN
inducers than wt virus. In fact, all mutants, with the exception of rUd-Y89F, induced
more IFN than wt in A549 cells. rUd-184-8(P), rUd-184-8(L) and rUd-Δ99 also 
induced more IFN than wt virus in MRC-5 cells (data not shown).
To determine whether apoptosis induction by the different mutant viruses correlated
with their ability to induce IFN, cell viability was measured following infection
A549/BVDV/NPro cells, which are unable to produce IFN due to IRF3 depletion
(characterised in Section 3.2.1). Viruses that caused extensive cell death in naïve
A549 cells (rUd-P162/4/7A, rUd-Δ99 and rUd-184-8(P)) were unable to cause
significant cell death in A549/BVDV/NPro (Figure 3.40A). Similar results were also
observed in STAT1-deficient A549/PIV5/V cells (data not shown).
Conclusions
Recombinant Ud viruses expressing NS1 mutations differed in their ability to activate
PI3K/Akt, induce apoptosis and induce IFN. A number of mutants (rUd-184-8(P),
rUd-Δ99 and rUd-P162/4/7A) caused more cell death than rUd wt virus. rUd-184-8(P)
caused significant caspase activation and nuclear fragmentation in infected cells.
While this virus was unable to activate PI3K/Akt, this was not responsible for its
ability to induce apoptosis. Significant induction of apoptosis by rUd-184-8(P) was
linked to its ability to induce large amounts of IFN; this virus was unable to cause cell
death in IFN-deficient cells.
Figure 3.1:  A549 cells are sensitive to staurosporine, but not 
  TNF-a- or FasL-induced apoptosis. 
A549 cell monoloayers were mock-treated or treated with TNF-a, FasL 
or staurosporine (STS). 24h and 48h later, cell viability was measured in 
triplicate by wst-1 assay. Mean viability is plotted as a percentage of mock-
treated cells. Error bars represent the standard deviation of each triplicate set.
Figure 3.2:  Cycloheximide sensitises A549 cells to TNF-a- and  
  FasL- induced apoptosis. 
A549 cell monolayers were mock-treated or treated with cycloheximide (CHX), 
TNF-a, FasL, or combinations of these treatments. After 24 hrs, cell viability was 
measured in triplicate by wst-1 assay. Mean viability is plotted as a percentage of 
mock-treated cells. Error bars represent the standard deviation of each triplicate set.
Figure 3.3:  TNF-a, but not FasL, activates NF-kB in a 
   CHX-sensitive manner.
A549 cells expressing a luciferase gene under the control of an 
NF-kB-responsive promoter were treated for 6h with 
TNF-a, FasL or STS in the presence or absence of CHX. 
Duplicate measurements of luciferase activity were made. Mean activity is 
plotted and error bars represent the standard deviation of each duplicate set.
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Figure 3.4: IFN-g sensitises A549 cells to FasL-induced, but   
  not TNF-a-induced apoptosis.
 
A549 cell monolayers were mock-treated or pre-treated with IFN-a or 
IFN-g. 16h later, cells were treated with FasL (A) or TNF-a (B) for 48h. 
Cell viability was measured in triplicate using wst-1.  Mean viability is 
plotted as a percentage of mock-treated cells and error bars represent 
the standard deviation of each triplicate set. (C) A549 cells were pre-
treated for 16h with IFN-a or IFN-g and treated with FasL for 24h. Cell 
lysates were prepared, subjected to SDS-PAGE and immunoblotted.
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Figure 3.5: IFN-g/FasL synergy is independent of PI3K    
  activation.
(A) A549 monolayers were mock-treated of treated with IFN-a or IFN-g in the 
presence or absence of 10% FCS. 16hrs later, cell lysates were prepared, 
subjected to SDS-PAGE and immunoblotted. (B) Cells were mock-treated 
with DMSO or treated with the PI3K inhibitor LY294002 for 1hr. IFN-g was 
added to culture medium overnight, then cells were treated with FasL for 
12hrs (all in the presence of 10% serum and DMSO or LY294002). Cells 
were harvested, subjected to SDS-PAGE and immunoblotted.  (C) Cells 
were treated as in (B) and photographed by phase contrast microscopy.
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Figure 3.6 :  MRC-5 cells are much more sensitive to apoptosis inducers  
  than other cell-types.
A549, MRC-5 and Hep2 cell monolayers were treated with FasL (A), TNF-a/CHX (B) 
or STS (C). At various times post-treatment, cell viability was measured in triplicate by 
wst-1 assay. Mean viability is plotted as a percentage of untreated cells and error bars 
represent the standard deviation of each triplicate set. (D) MRC-5 cells were treated with 
FasL, TNF-a/CHX or STS.  At various times post-treatment, cell viability was measured 
as above. (E) MRC-5 cells were treated with FasL, TNF-a/CHX or STS and harvested at 
various times post-treatment. Lysates were subjected to SDS-PAGE and immunoblotted. 
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Figure 3.7: PIV5/V, BVDV/NPro and HCV/NS3/4a antagonise the IFN response.
A549 (A) or MRC-5 (B) cells stably expressing PIV5/V(w3) or BVDV/NPro were mock-
treated or treated with IFN-a overnight. Cells were then harvested and immunoblotted. 
Naive cells or cells stably expressing HCV/NS3/4A were harvested and immunoblotted 
in the absence of IFN treatment. An IRF3 fragment seen in MRC-5/NPro cells is marked 
with an asterisk. (C) Monolayers of naive A549 cells or cells epressing PIV5 V, BVDV 
NPro or HCV NS3/4A were infected with PIV5 VDC at an MOI of 10. 24hrs later, culture 
supernatant was collected and the amount of secreted IFN was quantified in triplicate using 
a cell-based IFN assay. Briefly, supernatants were serially diluted 2-fold and incubated 
A549/BVDV/NPro cells. 24hrs later, cells were infected with EMC virus; IFN present in 
the supernatant protects cells from EMCV-induced cell death. Plates were fixed and cell 
monolayers were stained with coomassie blue. (D) A549 cells expressing a firefly luciferase 
gene under the control of an ISRE were made to stably express BVDV NPro, PIV5 V (w3 
and CPI- strains) or HCV NS3/4A. Triplicate monolayers were mock-treated or treated 
with 103 units/ml IFN-a overnight and luciferase activity was measured. Mean relative light 
units are plotted, and error bars show the standard deviation of each set of triplicates. 
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Figure 3.8:  The effect of viral IFN antagonists on apoptosis.
Naive A549 and MRC-5 cells or cells expressing PIV5, BVDV NPro or HCV 
NS3/4A were treated with FasL/CHX (A), TNF-a/CHX (B) or STS (C). At 
various times post-treatment, cell viability was measured in triplicate by wst-1 
assay. Mean viability is plotted as a percentage of untreated cells and error 
bars represent the standard deviation of each triplicate set.
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Figure 3.9:  Contribution of STAT1 degradation to the effects of  
  PIV5 V on apoptosis.
Naive A549 and MRC-5 cells or cells expressing PIV5 V (w3) or V (CPI-) 
were treated with FasL/CHX (A), TNF-a/CHX (B) or STS (C). At various times 
post-treatment, cell viability was measured in triplicate by wst-1 assay. Mean 
viability is plotted as a percentage of untreated cells and error bars represent 
the standard deviation of each triplicate set.
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Figure 3.10: IFN-g/FasL synergy is STAT1 dependent and is  
  inhibited by PIV5 V.
(A) A549 cells stable expressing the V protein of PIV5 w3 and CPI- strains 
were mock-treated or pre-treated with IFN-a or IFN-g for 16h, then mock-
treated or treated with FasL for 48hrs. Cell viability was then measured 
in triplicate by wst-1 assay. Mean viability is plotted as a percentage of 
mock-treated cells and error bars represent the standard deviation of each 
triplicate set. (B) Naive A549 cells or cells expressing V (w3) or V (CPI-) 
were seeded in a 96-well plate and were pre-treated with IFN-g for 16h. 
FasL was titrated by serial 2-fold dilution (starting at 200ng/ml). Dilutions 
were transferred to the plate of cells. 48h later, cells were fixed and 
stained with crystal violet. (C) Duplicate samples from (A) were subjected 
to SDS-PAGE and immunoblotted.   (D) A549 cells expressing PIV5/V, 
MuV/V, BVDV/NPro, HCV/NS3/4A or IAV/NS1 were treated with IFN-g/
FasL. 48h later, cells were photographed by phase-contrast microscopy.
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Figure 3.11:  Strain-specific differences in the PIV5 V protein.
The positions of naturally occuring or experimentally introduced amino acid substitutions in PIV5-w3, PIV5-
CPI+, PIV5-CPI-, PIV5-VDC are shown. The ability of each virus to target STAT1 for degradation and inhibit 
mda-5 is also indicated and their subsequent effects on STAT1 degradation and mda-5 inhibition are shown. 
Asterisks above the table denote the positions of the three amino acids required to target STAT1 for degradation.
Adapted from Wansley and Parks, 2002.
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Figure 3.12:  PIV5-w3, PIV5-CPI+, PIV5-CPI- and rPIV5-VDC vary in  
  their ability to induce IFN.
A549 cells infected with PIV5-w3, PIV5-CPI+. PIV5-CPI- and rPIV5-
VDC at an MOI of 10. At 12h,  24h and 48h post-infection, culture 
supernatants were collected  and the amount of IFN present was quantified 
in triplicate by cell-based IFN assay. Mean IFN production is plotted 
and error bars  represent the standard deviation of each triplicate set.
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Figure 3.13:  PIV5-w3, PIV5-CPI+, PIV5-CPI- and rPIV5-VDC induce  
  diferent amounts of cell death.
Naive A549 cells (A), A549/BVDV/NPro (B) or A549/PIV5/V (C) were infected 
with PIV5-w3, PIV5-CPI+. PIV5-CPI- and rPIV5-VDC at an MOI of 50. At 
various times post-infection, cell viability was measured in triplicate by 
wst-1 assay. Mean cell viability is plotted as a percentage of mock-infected 
cells, and error bars represent the standard deviation of each triplcate set. 
N.B. 100% of cells were infected, as determined by immunofluorescence.
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Figure 3.14:  The response of w3, CPI+, CPI- and VDC-infected cells  
  to non-viral apoptosis inducers.
A549 cells were infected with PIV5-w3, PIV5-CPI+. PIV5-CPI- and rPIV5-
VDC at an MOI of 50. 18h later (or 36h later for STS treatment), cells were 
treated with FasL/CHX (A), TNF-a/CHX (B) or STS (C).  At various times 
post-treatment, cell viability was measured in triplicate by wst-1 assay. 
Mean viability is plotted as a percentage of mock-infected, untreated cells 
and error bars represent the standard deviation of each triplicate set. 
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Figure 3.15: Expression of PIV5/V (w3) inhibits Akt activation.
Naive  A549 cells or cells expressing PIV5/V (w3) or PIV5/V 
(CPI-) were treated with IFN-a or IFN-g overnight. Cells were 
harvested, subjected to SDS-PAGE and immunoblotted.
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Figure 3.16:  PIV5/V and Akt do not co-immunoprecipitate.
293T cells were transfected with expression plasmids for PIV5/V (w3), Akt or 
PIV5/V plus Akt. 24hrs later, soluble antigen extracts were prepared, and V and 
Akt were immunoprecipitated using antibodies to Akt or V5. Immunoprecipitated 
protein complexes were subjected to SDS-PAGE and immunoblotted for the 
presence of V and Akt.
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Figure 3.17:  Activation of Akt in PIV5 infected cells.
(A) A549 monolayers were infected with FLUAV (rUd), SeV (strain Z) 
and PIV5-w3, in the absence of serum, at an MOI of 10. Cells were 
harvested at various times post-infection, subjected to SDS-PAGE 
and immunoblotted for phospho-Akt, viral proteins and actin.  (B)
A549 cells were infected with PIV5-w3, PIV5-CPI+, PIV5-CPI- or rPIV5-VDC 
at an MOI of 10 in the absence of serum. 12h, 24h and 36h later, cells were 
harvested, subjected to SDS-PAGE and immunoblotted for phospho-Akt, viral 
proteins and actin. The P degradation product, P*, is marked with an asterisk.
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Figure 3.18: The kinetics of PI3K/Akt activation by FLUAV are   
  cell-type dependent.
MDCK, A549, MRC-5, HFFF, Hep2, 1321N1 or Vero cells were mock-
infected or infected with rUd wt FLUAV virus at an MOI of 5. At various times 
post-infection (hours post-infection; hpi), cells were harvested, subjected 
to SDS-PAGE and immunoblotted for Akt activation and NS1 expression.
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Figure 3.19: rUd-Y89F is unable to activate PI3K.
MDCK, A549 or MRC-5 cells were mock-infected or infected 
with rUd wt or rUd-Y89F virus at an MOI of 10. At various times 
post-infection, cells were harvested, subjected to SDS-PAGE 
and immunoblotted for Akt activation and NS1 expression.
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Figure 3.20: rUd-Y89F is attenuated in A549 and MRC-5 cells
Triplicate A549 (A) or MRC-5 (B) monolayers were infected 
with rUd wt or rUd-Y89F at an MOI of 0.001 in the presence 
of trypsin. At various times post-infection, the supernatant was 
removed and titrated by plaque assay on MDCK cells. Error 
bars represent the standard deviation of each triplicate set.
MRC-5
A549
Figure 3.21: FLUAV infection causes apoptosis at high MOI.
A549 monolayers were infected with rUd wt at an MOI of over 100. 
A time-lapse video of infected cells was produced from 8-24hrs 
post-infection (supplied on disc). Shown are two stills from the 
video: (A) shows cells at 12h, (B) shows the same cells 12h later.
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Figure 3.22:  PI3K activation in NS1-expressing A549 cells does  
  not protect cells from non-viral apoptosis inducers.
A549 cells stably expressing  NS1 wt or NS1-Y89F were mock-treated or 
treated with FasL (A), FasL/CHX (B), TNF-a (C), TNF-a/CHX (D) or STS 
(E). At various times post-treatment, cell viability was measured in triplicate 
by wst-1 assay. Mean viability is plotted as a percentage of untreated cells 
and error bars represent the standard deviation of each triplicate set. (F) 
Naive A549 cells or cells stably expressing NS1 wt or NS1-Y89F were 
cultured in the presence or absence of serum.  Lysates were subjected 
to SDS-PAGE and immunoblotted for Akt activation and NS1 expression.
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Figure 3.23:  Effect of PI3K activation by NS1 on IAV-induced cell  
  death.
   
Triplicate MDCK (A), A549 (B) or MRC-5 (C) monolayers were infected 
with either rUd wt and rUd-Y89F, or rWSN wt and  rWSN-Y89F at an MOI 
of 35. Cell viability was measured in triplicate at various times post-infection 
using  wst-1.  Mean viability is plotted as a percentage of mock-treated cells 
and error bars represent the standard deviation for each set of triplicates. 
N.B. 100% of cells were infected, as determined by immunofluorescence.
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Figure 3.24:  rUd-Y89F does not induce more apoptosis 
  than rUd wt.
MDCK, A549 and MRC-5 cell  monolayers were infected with rUd 
wt or rUd-Y89F at an MOI of 5. Cells were harvested at various 
times post-infection, subjected to SDS-PAGE and immunoblotted. 
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Figure 3.25:  PI3K activation by NS1 does not protect cells from 
  non-viral apoptosis inducers.
A549 and MRC-5 cels were mock-infected or infected with rUd wt or rUd-
Y89F at an MOI of 35. After 12 hrs, cells were mock-treated or treated with 
FasL (A), FasL/CHX (A549 only)(B),TNF-a (C), TNF-a/CHX (D) or STS 
(E). At various times post-treatment, cell viability was measured in triplicate 
by wst-1 assay. Mean viability is plotted as a percentage of mock-infected, 
untreated cells and error bars represent the standard deviation of triplicate 
sets. N.B. 100% of cells were infected, as determined by immunofluorescence.
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AB
Figure 3.26:  Use of LY294002 to inhibit PI3K activation by NS1   
  may give misleading results.
A549 (A) and MRC-5 (B) cells were mock-treated with DMSO or treated with 
25uM LY294002 for 1h, then mock-infected or infected with rUd wt or rUd-
Y89F at an MOI of 35 in the presence of DMSO or LY294002. At various 
times post-infection, cell viability was measured in triplicate by wst-1 assay. 
Mean viability is plotted as a percentage of mock-infected/DMSO-treated 
cells and error bars represnt standard deviation for each triplicate set. 
N.B. 100% of cells were infected, as determined by immunofluorescence.
0 10 20 30 40 50
0
20
40
60
80
100
Mock + DMSO 
rUd wt + DMSO 
rUd-Y89F + DMSO 
Mock + LY 
rUd wt + LY 
rUd-Y89F + LY 
%
 C
el
l v
ia
bi
lit
y
Time (hours post-infection)
0 10 20 30 40 50
0
20
40
60
80
100
120
Mock + DMSO 
rUd wt + DMSO 
rUd-Y89F + DMSO 
Mock + LY 
rUd wt + LY 
rUd-Y89F + LY 
%
 C
el
l v
ia
bi
lit
y
Time (hours post-infection)
MRC-5
A549
phospho-p53
phospho-Akt
actin
NS1
p53
- 4 6 8 10 12 24 4 6 8 10 12 24
rUd rUd-Y89F
actin
phosho-Akt
NS1
p53
phospho-p53
N
ai
ve
N
S
1
N
S
1-
Y
89
F
A
B
Figure 3.27:  Akt activation by NS1 affects p53 
  expression and activation.
(A) A549 monolayers were infected with rUd wt or rUd-Y89F 
at an MOI of 10. Cells were harvested at various times post-
infection and immunoblotted. (B) 1321N1 cells stably expressing 
PR8 NS1or PR8 NS1-Y89F were harvested and immunoblotted.
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Figure 3.28:  PI3K/Akt activation by NS1 has no effect on  
  FasL expression.
  
A549 monolayers were infected with rUd wt or rUd-Y89F at an MOI of 10. 
Cells were harvested at various times post-infection and immunoblotted. 
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Figure 3.29:  rUd-Y89F causes more apoptosis than rUd wt 
  in neutrophils.
Triplicates of A549 cells (A) or freshly-isolated neutrophils (B) were infected with 
rUd wt or rUd-Y89F at an MOI of 50. Apoptotic cells were quantified by annexin-V/PI 
staining and flow cytometry, and calculated as a proportion of the cell population.
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Figure 3.30: PI3K activation by NS1 has no effect on IFN  
  production.
A549 cells were infected with rUd wt or rUd-Y89F at an MOI of 10. 
At 12, 24, 36, 48 and 60 hrs post-infection, the culture supernatant 
was collected. The amount of IFN present was estimated using 
a cell-based IFN assay. Titrations were carried out in triplicate. 
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Figure 3.31: PI3K activation by NS1 has no effect on 
  NF-kB activation.
Triplicate monolayers of A549 cells stably expressing firefly luciferase 
under the control of an NF-kB-responsive promoter were infected 
with rUd wt or rUd-Y89F at an MOI of 10. Cells were treated 
with TNF-a for 6hrs as a positive contol. At various times post-
infection, cells were harvested and the amount of luciferase present 
was quantified. Mean luciferase activity is plotted and error bars 
represent standard deviation of each set of triplicates (A). Duplicate 
lysates were subjected to SDS-PAGE and immunoblotted (B).
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Figure 3.32: PI3K activation by NS1 does not have a significant  
  effect on ISRE activation.
A549 cells stably expressing luciferase under the control of an ISRE were mock-
infected or infected with rUd wt or rUd-Y89F at an MOI of 5.  (A) At various 
times post-infection, cells were lysed and luciferase activity was measured (in 
duplicate). Error bars represent standard deviation for duplicate set. Identically 
treated cells were also harvested at the same times post-infection, subjected to 
SDS-PAGE and immunoblotted. (B) Cells were infected as in (A). 6 hrs prior to 
harvesting, cells were treated with IFN-a (104 units/ml). Cells were harvested 
at 8 and 12hrs post-infection and assayed for luciferase activity in duplicate. 
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Figure 3.33: PI3K activation by NS1 does not have a   
  significant effect on ISG  expression.
A549 cells were mock-infected or infected with rUd wt or rUd-
Y89F at an MOI of 5. 8hrs later, cells were mock-treated 
or treated with IFN-a (103units/ml). 16h later, cells were 
harvested, subjected to SDS-PAGE and immunoblotted.
p-Akt
Table 3.1: NS1 mutations introduced into rUd and their biological effects.
Figure 3.34: NS1 mutations introduced into rUd.
The nature and position of amino acid substitutions resulting from mutation in the 
NS segment are shown. Cellular interactors of NS1 whose binding is affected by 
these mutations are shown in grey. 
Modified from Hale et al., 2006 by Dr. D. Jackson.
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rUd-184-8(P)
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Kochs  et al., 2007
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infection
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Twu et al., 2007
Kochs  et al., 2007
Destabilises the NS1:CPSF30  interactionrUd-103/106
rUd-P162/4/7A
Shin et al., 2007
Unable to activate PI3K
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Hale et al., 2006
Hale., 2007
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Figure 3.35:  PI3K activation, NS1 expression and induction of  
  apoptosis in cells infected with different rUd NS1  
  mutants.
A549 (A) or MRC-5 (B) cells were infected with  rUd wt, rUd-Y89F, 
rUd-P164/7A, rUd- P162/4/7A, rUd-D99, rUd-R38A, rUd-123/4, rUd-
184-8(P), rUd-184-8(L) or rUd-103/106 at an MOI of 5. 24h later, 
cells were harvested, subjected to SDS-PAGE and immunoblotted.
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Figure 3.36:  Rate of cell death following infection with 
  rUd NS1 mutants.
MDCK (A) or A549 cells (B) were infected with the full panel of rUd 
NS1 mutant viruses (rUd wt, rUd-Y89F,  rUd-P164/7A, rUd- P162/4/7A, 
rUd-D99, rUd-R38A, rUd-123/4, rUd-184-8(P), rUd-184-8(L) and rUd-
103/106) at an MOI of 35.  At various times post-infection, cell viability 
was  measured in triplicate by wst-1 assay. Mean viability is plotted 
and error bars represent standard deviation for each triplicate set. (C) 
MRC-5 cells were infected with a selection of  the panel of rUd NS1 
mutants (rUd wt, rUd-Y89F, rUd-P164/7A, rUd-P162/4/7A and rUd-
184-8(P)) at an MOI of 35.  At various times post-infection, cell viability 
was measured in triplicate by wst-1 assay. Mean viability is plotted and 
error bars represent standard deviation for each triplicate set. N.B. 
100% of cells were infected, as determined by immunofluorescence.
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Figure 3.37:  Caspase activity and apoptosis in cells infected   
  with rUd NS1 mutant viruses.
A549 (A) or MRC-5 (B) cells were infected with  rUd wt, rUd-Y89F,  rUd-
P164/7A, rUd- P162/4/7A, rUd-D99, rUd-R38A, rUd-123/4, rUd-184-
8(P), rUd-184-8(L) or rUd-103/106 at an MOI of 35. Cells were harvested 
24h later and caspase-3 and -7 activity was quantified in duplicate by 
Caspase-Glo 3/7 luciferase assay. Mean luciferase activity is plotted 
and error bars represent standard deviation for duplicates.  (C) MDCK 
cells were mock-infected or infected with rUd wt, rUd-Y89F, rUd-164/7A, 
rUd-P162/4/7A or rUd-184-8(P) at an MOI of 35. At 20h post-infection, 
cells were fixed and stained with acridine orange. Apoptotic nuclei were 
visualised  using a fluorescence microscope with a fluorescein  filter. 
N.B. 100% of cells were infected, as determined by immunofluorescence.
C
Figure 3.38:  PI3K activation by serum does not prevent   
  apoptosis induction by rUd-184-8(P).
A549 cells were mock-infected or infected with rUd wt, rUd-Y89F or rUd-
184-8(P) at an MOI of 35. After the inital virus adsorption period (1h), virus 
inoculum was removed and replaced with serum-free DMEM or DMEM 
supplemented with 10% foetal calf serum. Cell viability was measured by 
wst-1 assay 36hpi (A) or cell lysates were immunoblotted at 24hpi (B). 
N.B. 100% of cells were infected, as determined by immunofluorescence.
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Figure 3.39:  rUd NS1 mutants induce different levels of IFN.
A549 cells were infected with  rUd wt, rUd-Y89F,  rUd-P164/7A, rUd- 
P162/4/7A, rUd-D99, rUd-R38A, rUd-123/4, rUd-184-8(P), rUd-184-8(L) 
or rUd-103/106 at an MOI of 5. At 12h and 24h post-infection culture 
supernatants were removed  and the amount of IFN present was titrated in 
triplicate in a cell-based IFN assay. Mean relative IFN production is  plotted 
and  with error bars to show standard deviation for each set of triplicates. 
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Figure 3.40:  Rate of cell death following infection with    
  rUd NS1 mutants in cells deficient in the IFN   
  response.
A549 naive and A549/BVDV/NPro cells were infected with the full panel of rUd 
NS1 mutant viruses (rUd wt, rUd-Y89F,  rUd-P164/7A, rUd- P162/4/7A, rUd-D99, 
rUd-R38A, rUd-123/4, rUd-184-8(P), rUd-184-8(L) and rUd-103/106) at an MOI 
of 35.  At 36hpi, cell viability was  measured in triplicate by wst-1 assay. Mean 
values are plotted and error bars represent standard deviation for each triplicate 
set. N.B. 100% of cells were infected, as determined by immunofluorescence.
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4 DISCUSSION
4.1 Sensitisation of cells to apoptosis inducers
4.1.1 CHX promotes TNF-α and FasL-induced apoptosis
This study examined the sensitivity of A549 and MRC-5 cells to a number of
apoptosis inducers. A549 cells were resistant to TNF-α and FasL-induced apoptosis
but became sensitised to these treatments in the presence of CHX. This has been
reported previously (Kreuz et al., 2001, Micheau et al., 2001, Ogura et al., 2008,
Fulda et al., 2000, Mitsiades et al., 2000, Arscott et al., 1997), and indicates that
resistance to TNF-α and FasL is mediated by a labile inhibitor. cFLIP, cIAPs and anti-
apoptotic Bcl-2 family members have all been implicated in TNF-α and FasL
resistance (Schoemaker et al., 2002, Wang et al., 1998a, Wang et al., 1999a, Stehlik
et al., 1998, Chu et al., 1997, Ichikawa et al., 2005, Zou et al., 2004, Notarbartolo et
al., 2004, Gordon et al., 2007, Yemelyanov et al., 2006, Chang et al., 2002, Irmler et
al., 1997, Micheau et al., 2002, Sekine et al., 2008, Ruemmele et al., 2002). In
addition, CHX has been reported to downregulate TNFR1 expression in A549 cells
by promoting its cleavage from the cell surface (Ogura et al., 2008): it has been
suggested that TNF-α sensitivity of a particular cell-type is dictated by the ratio of
TNFR1 to cFLIP expression. The ability of FasL to cause apoptosis in MRC-5 cells
without the need for CHX treatment suggests that these cells may express low levels
of anti-apoptotic proteins.
As described in the Introduction, DRs activate NF-kB signalling to upregulate anti-
apoptotic genes (Kreuz et al., 2001, Micheau et al., 2001, Ogura et al., 2008). In
support of this, sensitisation of A549 cells to TNF-α by CHX was found to correlate
with abrogation of NF-kB-dependent gene expression. Unlike TNF-α however, FasL
treatment did not activate NF-kB signalling (Figure 3.3), so FasL-resistance in A549
cells is unlikely to be mediated by NF-kB-dependent gene expression. The
contribution of Fas-mediated NF-kB activation to apoptosis resistance may vary
between cell-lines: while NF-kB mediates Fas-resistance in eosinophils and T cells
(Qin et al., 2002), resistance in thyroid carcinoma cell-lines is NF-kB-independent
(Mitsiades et al., 2006). Since FasL did not activate NF-kB signalling in this study,
resistance to FasL in A549 cells must be mediated by an additional anti-apoptotic
signalling pathway. Indeed, cFLIP expression can be induced in an NF-kB-
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independent manner (Duverger et al., 2004). Furthermore, FasL can activate MAPK
signalling, and activation of this pathway prevents Fas-mediated apoptosis in Jurkat
T cells (Holmstrom et al., 1998, Barnhart et al., 2004, Ahn et al., 2001).
4.1.2 IFN pre-treatment potentiates FasL-induced apoptosis
Both IFN-α and IFN-γ potentiated FasL-induced apoptosis in A549 cells. IFN
treatment is thought to upregulate expression of pro-apoptotic ISGs such as the Fas
receptor and procaspases (Tomita et al., 2003, de Veer et al., 2001, Wen et al.,
1997, Lee et al., 2000b, Ahn et al., 2002, Spets et al., 1998, Xu et al., 1998).
Although IFN-α and IFN-γ upregulate Fas receptor expression to similar extents in 
human fibrosarcoma cells (Der et al., 1998a), results obtained here indicated that
IFN-γ is much more efficient than IFN-α at sensitising A549 cells to FasL-mediated
apoptosis. This has been reported previously: Reinhold and colleagues
demonstrated that IFN-γ, but not IFN-α, sensitised a range of melanoma cell-lines to
anti-Fas agonist antibody (Ugurel et al., 1999).
Non-classical IFN signalling pathways may participate in IFN-γ/FasL synergy in some
cell types: IFN-γ sensitises vascular smooth muscle cells to Fas-mediated apoptosis
by stimulating Fas receptor trafficking to the cell surface in a PI3K-dependent manner
(Rosner et al., 2006). Furthermore, it has been reported that IFN-γ/FasL synergy in 
A549 cells is JAK-dependent but STAT1-independent (Kurdi and Booz, 2007). In
support of a role for PI3K/Akt in IFN-γ/FasL synergy, IFN-γ, but not IFN-α, activated
Akt in A549 cells (Figure 3.5). However, PI3K inhibition by LY294002 treatment did
not affect IFN-γ/FasL-induced apoptosis, indicating that PI3K signalling was not
responsible for FasL potentiation by IFN-γ. Moreover, in direct contradiction with
Kurdi and Booz, IFN-γ/FasL synergy was found to require STAT1, and as such, could
be blocked by PIV5/V (Figure 3.10). While this study used FasL to stimulate the Fas
receptor, Kurdi and Booz used an anti-Fas antibody used by Kurdi and Booz (Kurdi
and Booz, 2007): FasL and anti-Fas agonist antibody have been reported to
stimulate different signalling pathways (Thilenius et al., 1997). Using anti-Fas
antibody may therefore not give an accurate representation of Fas-mediated
apoptosis in some situations. An additional factor contributing to contradictions
between this and previous work may be the different methods used to knock-down
STAT1; this will be discussed later, in Section 4.2.2.
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Neither IFN-α nor IFN-γ were able to sensitise A549 cells to TNF-α-induced
apoptosis. This is despite reports that IFN and TNF-α can synergistically induce
apoptosis through upregulation of the TNF-α receptor in some cell types (Frankel et
al., 2006, Kimura et al., 2003, Kulkarni et al., 2006, Manna et al., 2000, Sasagawa et
al., 2000, Suk et al., 2001). The ability of IFN-γ to potentiate FasL but not TNF-α-
induced apoptosis in A549 cells may be due to the association of STAT1 with
TNFR/TRADD, but not the Fas receptor, to inhibit TNF-α-induced NF-kB activation
(Wang et al., 2000b). In support of this, IFN-γ has been reported to inhibit TNF-α-
induced apoptosis in murine myoblasts by promoting NF-kB-dependent cIAP1
expression (Tolosa et al., 2005). IFN treatment limits STAT1:TRADD association by
shunting STAT1 into the JAK/STAT signalling pathway, alleviating NF-kB inhibition
(Pajak and Orzechowski, 2007, Wang et al., 2000b). IFN-γ treatment in A549 cells 
may therefore make cells more resistant to TNF-α by enhancing NF-kB activity.
The resistance of A549 cells to TNF-α and FasL-induced apoptosis, may have
implications for their response to NK cell and CTL cytotoxicity during in vivo virus
infections. Sensitisation of cells to FasL by IFN-γ suggests that IFN produced during
virus infection may indirectly aid virus clearance by promoting FasL-mediated NK cell
cytotoxicity. In vivo, IFNs can also modulate NK cytotoxicity independently of
Fas/FasL pathways. NK cell cytotoxicity is augmented by IFN-α treatment through
elevated perforin expression (Kaser et al., 1999, Liang et al., 2003) while IFN can
render hepatocytes resistant to CTL cytotoxicity by promoting expression of
granzyme B inhibitors (Willberg et al., 2007). Cytokine synergism may also be
important during disease development as IFN-γ/TNF-α synergy has been implicated
in the destruction of pancreatic β-cells in vitro and development of autoimmune
diabetes in vivo (Suk et al., 2001, Kim et al., 2007).
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4.2 Apoptosis modulation by PIV5/V
4.2.1 PIV5/V expression limits apoptosis
In A549 cells, expression of PIV5/V(w3) was found to limit apoptosis induced by
FasL/CHX and TNF-α/CHX. In accordance with the pro-apoptotic functions of STAT1
(see Introduction), this effect was due to STAT1 depletion in A549/PIV5/V cells;
PIV5/V(CPI-), which is unable to target STAT1 for proteasome-mediated
degradation, was completely unable to inhibit apoptosis by the same inducers.
STAT1 can inhibit expression of NF-kB-dependent pro-survival genes through a
direct association with the p65 NF-kB subunit (Kramer et al., 2006). In addition,
STAT1 interacts with TNFR1/TRADD to inhibit TRADD/RIP/TRAF2 complex
formation and prevent downstream NF-kB activation (Wang et al., 2000b, Pajak and
Orzechowski, 2007, Wesemann and Benveniste, 2003). STAT1 can also positively
regulate apoptosis through enhancement of p53-dependent transcription and
inhibition of Mdm2 expression (Townsend et al., 2004). Consequently, it has been
suggested that STAT1 levels determine whether TNF-α treatment induces cell death
or cell survival in a particular cell-line. Indeed, TNF-α treatment of STAT1-null cells
led to enhanced NF-kB activation and subsequent resistance to apoptosis in previous
studies (Wesemann and Benveniste, 2003, Kumar et al., 1997). While TRADD is not
involved in NF-kB activation downstream of Fas and TRAIL receptors (Imamura et
al., 2004), STAT1 and TRADD interact even in quiescent cells (Pajak and
Orzechowski, 2007, Wesemann and Benveniste, 2003); STAT1 may therefore inhibit
basal NF-kB activity even in cells treated with FasL and TRAIL. However, STAT1-
dependent expression of pro-apoptotic genes was not responsible for the anti-
apoptotic effect of PIV5/V(w3) here, as new protein synthesis was abrogated in cells
treated with TNF-α/CHX and FasL/CHX. The role of STAT1 in FasL/CHX and TNF-
α/CHX-induced apoptosis is therefore likely to involve transcription-independent
mechanisms (see Introduction). Interestingly, a transcription-independent role for
NF-kB in cell death may exist. The NF-kB2/p100 precursor contains a death domain
that permits its recruitment to death receptors, where it induces apoptosis (Wang et
al., 2002d, Hacker and Karin, 2002). NIK, the enzyme responsible for NF-kB2/p100
processing and removal of its death domain, is required for Fas and TNF-α-mediated
NF-kB activation (Malinin et al., 1997). It follows then that STAT1 may prevent NIK
activation through its interaction with TRADD; in doing so, STAT1 may prevent NF-
kB2/p100 processing, resulting in accumulation of NF-kB2/p100 and apoptosis.
Conversely STAT1 depletion, as seen in A549/PIV5/V(w3) cells, may increase NIK
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activity, reducing NF-kB/p100 levels and preventing NF-kB2/p100-induced apoptosis.
The direct association between STAT1 and p53 (Townsend et al., 2004) also hints
that STAT1 may modulate p53 expression and activity by promoting its post-
translational modification.
TNF-α/CHX induced similar levels of apoptosis in MRC-5 and MRC-5/PIV5/V cells.
This may indicate that in MRC-5 cells, PIV5/V(w3) exerts its effects on apoptosis by
modulating gene expression, not through transcription-independent mechanisms. In
support of this, MRC-5 cells expressing PIV5/V(w3) were less sensitive to FasL-
induced apoptosis (in the absence of CHX) than MRC-5 naïve cells. Here, NF-B
activity may be increased by STAT1 depletion in MRC-5/PIV5/V(w3) cells, resulting
in expression of anti-apoptotic proteins. It would be interesting to determine whether
the reverse is true: STAT1 overexpression in MRC-5 cells may sensitise them to
TNF-α-induced apoptosis by preventing NF-kB-dependent gene expression.
PIV5/V(w3) also limited STS-induced apoptosis in both A549 and MRC-5 cells. Since
CHX treatment is not required for STS-induced cell death, this effect may be due to
transcription dependent and/or transcription-independent mechanisms. Interestingly,
in A549 cells, PIV5/V(CPI-) expression also reduced STS-induced apoptosis (albeit
less efficiently than PIV5/V(w3); the effects of PIV5/V on STS-induced apoptosis
therefore appear to be less dependent on STAT1 depletion than TNF-α/CHX and
FasL/CHX. This is perhaps not surprising as STAT1 plays a predominant role in DR-
mediated apoptosis due to its recruitment to TNFR/TRADD. However, STS treatment
may indirectly affect STAT1-dependent transcription through inhibition of PKC-δ
(Gschwendt et al., 1995, Seynaeve et al., 1994): PKC-δ is required for STAT1 serine
phosphorylation (DeVries et al., 2004, Uddin et al., 2002) and its inhibition by STS
may impair STAT1-dependent transcription independently of PIV5/V expression.
4.2.2 PIV5/V expression prevents IFN-γ/FasL synergy
In addition to its effects on TNF-α, FasL and STS-induced apoptosis, PIV5/V
expression also inhibited IFN-γ/FasL synergy. STAT1 degradation was required for 
this effect, since PIV5/V(w3), but not PIV5/V(CPI-), could prevent IFN-γ/FasL-
induced cell death. IFN-γ/FasL-induced apoptosis was also inhibited by MuV/V.
While MuV/V targets STAT1 for degradation (Kubota et al., 2001, Yokosawa et al.,
2002), MuV/V also disrupts association of STAT1 with the IFN receptors (Kubota et
al., 2002); the effect of MuV/V on IFN-γ/FasL is presumably a function of these two 
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properties. In A549/PIV5/V(w3) and A549/MuV/V cells, IFN-γ-treatment may be
unable to upregulate pro-apoptotic ISG expression due to STAT1 depletion/inactivity.
This is in stark contrast to a report that JAK1 inhibition, but not STAT1 knockdown by
siRNA, blocks IFN-γ/Fas-mediated apoptosis in A549 cells (Kurdi and Booz, 2007).
The writers of this study proposed that the pro-apoptotic effects of IFN-γ occurs 
downstream of JAK1 activation via a non-canonical pathway, independent of STAT1.
A possible reason for this discrepancy is the inefficiency of siRNA knockdown in the
study by Kurdi et al: while siRNA reduced IFN-γ-induced STAT1 levels, basal levels
of STAT1 were still detectable and may have been sufficient to activate ISG
expression. Since no STAT1 could be detected in A549/PIV5/V(w3) cells following
IFN-γ treatment (Figure 3.10C), expression of PIV5/V may represent a more efficient
method for STAT1 knockdown than siRNA. Another possible reason, mentioned in
section 4.1.2, is the differential stimulation of signalling pathways by FasL and anti-
Fas agonist antibody (Thilenius et al., 1997).
Paramyxoviruses target STATs to antagonise IFN signalling (see Section 1.3.1.2).
Apart from the observation that MuV/V promotes apoptosis in transformed cells
through STAT3 degradation (Ulane et al., 2003), the contribution of STAT
degradation by paramyxoviruses to apoptosis regulation has been largely unstudied
until now. Results obtained in this study indicate that the ability of PIV5/V to target
STAT1 for degradation appears to confer an additional advantage to the virus by
limiting apoptosis induction. This occurs either through inhibition of pro-apoptotic ISG
expression or through interference with STAT1 interactions with apoptosis regulators.
Limiting apoptosis induction may have implications for the ability of PIV5 to establish
persistent infections.
4.2.3 PIV5/V expression inhibits Akt activation
Many viruses activate PI3K/Akt signalling to prevent or delay host cell apoptosis
(Bitko et al., 2007, Dawson et al., 2003, Lee et al., 2001, Zhang et al., 2002, Peters
et al., 2008) and recent reports suggest that PI3K and Akt play important roles during
paramyxovirus infection (Peters et al., 2008, Sun et al., 2008a). While the previous
section found that PIV5/V expression could inhibit apoptosis through its effects on
STAT1, it was also investigated whether PIV5/V could inhibit apoptosis through
PI3K/Akt activation. Surprisingly, PIV5/V(w3) expression in A549 cells was actually
found to inhibit Akt activation following IFN treatment. This supports a suggestion that
V may prevent Akt activation by the L protein during PIV5 infection (Luthra et al.,
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2008). In contrast to A549/PIV5/V(w3), A549/PIV5/V(CPI-) exhibited similar levels of
Akt activation to naïve cells, suggesting that STAT1 degradation is required for Akt
inhibition by PIV5/V. Further evidence for this was obtained during PIV5 infection:
PIV5-CPI- and PIV5-VΔC, which do not cause STAT1 degradation, induced Akt
activation earlier and to a greater extent than PIV5-w3 and PIV5-CPI+ (Figure
3.17B). PIV5/V(w3) may therefore prevent upregulation of an ISG involved in
promoting Akt activation. While this study makes no attempt to identify the protein
responsible for this effect, several candidate ISGs exist. The chemokine CCL5 and
its receptor CCR5 are both upregulated by IFN (Kitaya et al., 2007, Plskova et al.,
2006, de Veer et al., 2001): PI3K is activated downstream of CCL5/CCR5
association (Ignatov et al., 2006, Huang et al., 2008a, Tyner et al., 2005). The RhoC
GTPase is also upregulated by IFN (Der et al., 1998a) and activates PI3K/Akt (Ruth
et al., 2006), presumably through direct interaction with the p85 subunit of PI3K in the
same manner as other Rho family members (Tolias et al., 1995, Zheng et al., 1994b).
While no evidence for V:Akt association was obtained in this study, such an
interaction has been reported by He and colleagues (Sun et al., 2008a). They
proposed an unsubstantiated model whereby V interacts with Akt to limit Akt-
dependent NF-kB activation by the PIV5 L protein (Figure 4.1, Luthra et al., 2008). V
may therefore inhibit Akt activation by two distinct mechanisms: by preventing
production of an Akt-activating ISG and through direct association with Akt. Indeed,
PIV5/V(w3) expression reduced phospho-Akt levels even in the absence of IFN
treatment; while this may represent inhibition of constitutive STAT1-dependent gene
expression (see Introduction), it could also be due to direct inhibition of Akt. It would
be interesting to determine which parts (if any) of V are responsible for Akt binding,
and whether a hierarchy of Akt, mda-5 and STAT1 inhibition functions exists:
interaction with Akt may render V unable to bind STAT2, DBB1 or mda-5. If a direct
interaction is required for Akt inhibition, this interaction presumably requires amino
acid residues in its N-terminus since V(w3) and V(CPI-) differ by six amino acids in
their N-termini. Further experiments are also required to determine whether V can
inhibit Akt-dependent NF-kB activation.
It is interesting to note that inhibition of Akt activation by PIV5/V did not promote
apoptosis since PIV5/V expression actually limited apoptosis induced by a range of
treatments. This indicates that viruses may modulate PI3K/Akt signalling for
apoptosis-independent reasons. For example, IL-6 expression and release, which is
regulated by PI3K/Akt, is blocked by PIV5/V (Lee et al., 2006, Qian et al., 2009, Tang
Figure 4.1:  Model for activation of AKT in PIV5-infected cells and the roles  
  of AKT in PIV5 replication. 
AKT plays a critical role in phosphorylation of P, which is an essential component of the viral 
polmerase. Luthra et al. proposed that L activates AKT by causing phosphorylation of AKT. 
Activated AKT contributes to the activation of the expression of cytokines such as IFN-β 
and IL-6 as well as phosphorylation of P. Since V blocks expression of IFN-β and IL-6 and 
reportedly interacts with AKT, they speculate that V can block the activation of NF- B through 
its interaction with AKT. Modified from Luthra et al., 2008.
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et al., 2007a, Young et al., 2006). V expression also slows the cell cycle (Lin and
Lamb, 2000); this may occur through Akt inhibition since Akt promotes cell cycle
progression in a number of ways (see Introduction). In addition, Akt and
downstream mTORC1 are also required for enhancement of ISG translation (Kaur et
al., 2008a, Kaur et al., 2008b, Lekmine et al., 2003): while V enhances host and viral
protein synthesis by limiting PKR activation (Gainey et al., 2008a), V-mediated Akt
inhibition may limit ISG expression to antagonise the IFN response.
4.2.4 Induction of IFN and apoptosis during PIV5 infection
The PIV5-w3, PIV5-CPI+, PIV5-CPI- and rPIV5-VΔC strains of PIV5, which express
V proteins with different biological properties, differed in their ability to induce IFN.
rPIV5-VΔC was the best inducer while PIV5-w3 was the poorest, in accordance with
a previous study (Poole et al., 2002). PIV5-CPI+ and PIV5-CPI- viruses induced
significant levels of IFN in infected cells, despite the ability of their V proteins to
inhibit mda-5 activity (Childs et al., 2007, Andrejeva et al., 2004, Poole et al., 2002).
This may be explained by reports that paramyxoviruses activate RIG-I, but not mda-5
signalling (Kato et al., 2006, Loo et al., 2008); since PIV5 is unable to block RIG-I
signalling (Andrejeva et al., 2004, Childs et al., 2007), these viruses will still induce
IFN. One obvious question is raised by these observations: why do paramyxoviruses
actively inhibit mda-5 activity if paramyxovirus infection predominantly signals
through RIG-I? It may be that PIV5 activates both mda-5 and RIG-I, but only RIG-I
activity can be detected in infected cells due to mda-5 inhibition by V. In support of
this, rPIV5-VΔC, whose V protein is unable to inhibit mda-5 signalling due to a C-
terminal truncation (Poole et al., 2002, He et al., 2002a), induces large amounts of
IFN: rPIV5-VΔC may be activating both RIG-I and mda-5 signalling. Comparisons of
IFN induction by different virus strains may additionally be complicated by the
presence of defective interfering (DI) particles in virus stocks. DIs lack one or more
functions required for genome replication or synthesis/assembly of virus particles and
can therefore replicate only in the presence of a replication-competent (“helper”)
virus. DIs are potent inducers of IFN and apoptosis, presumably because they are
able to efficiently produce the inducer of IFN/apoptosis but are unable to antagonise
these responses (Johnston, 1981, Sekellick and Marcus, 1982, Aoki et al., 2001,
Strahle et al., 2006, Fuller and Marcus, 1980b, Fuller and Marcus, 1980a, Strahle et
al., 2007). DIs are difficult to correct for, as virus titres obtained by plaque assay are
representative of the number of non-defective (plaque-forming) particles, but not DIs.
Estimates of DI numbers in a particular virus stock can be obtained from the ratio of
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haemagglutinin titre to plaque-forming units; however, in this experiment the levels of
DIs in virus stocks were unknown. The large amounts of IFN induced by rPIV5-VΔC 
could therefore be due to the presence of large amounts of DIs.
PIV5-CPI-, but not PIV5-CPI+, induced significant amounts of apoptosis in A549
cells. While PIV5-CPI- and PIV5-CPI+ induced similar levels of IFN, PIV5-CPI- is
unable to block STAT1 signalling, so IFN produced during PIV5-CPI- infection can
upregulate pro-apoptotic genes and promote apoptosis. Accordingly, in
A549/BVDV/NPro and A549/PIV5/V cells, which are unable to produce or respond to
IFN respectively, PIV5-CPI- and PIV5-CPI+ viruses cause a similar amount of cell
death. Somewhat surprisingly, rPIV5-VΔC, which is reported to be apoptogenic (Sun
et al., 2004), did not cause cell death in A549 naïve cells, despite inducing large
amounts of IFN. In IFN-defective A549/BVDV/NPro and A549/PIV5/V cells however,
rPIV5-VΔC induced significant apoptosis. These results suggest that the large
amount of IFN produced during rPIV5-VΔC infection induced an antiviral state in
naïve cells: rPIV5-VΔC is unable to antagonise the IFN response, so the virus is 
unable to replicate efficiently and is unable to cause cell death. In contrast, the
antiviral state is not established in A549/BVDV/NPro and A549/PIV5/V cells so
rPIV5-VΔC can replicate efficiently, resulting in apoptosis induction. The ability of
PIV5 to induce cell death therefore seems to depend on the balance between
limitation of virus replication by the host cell, and the ability of the virus to circumvent
host cell responses to enhance its replication. Since A549/BVDV/NPro cells are
IRF3-deficient, rPIV5-VΔC-induced cell death did not require IRF3; this is a surprising
result since IRF3 is a requirement for apoptosis induced by dsRNA, reovirus,
Bunyamwera virus, NDV and SeV (Heylbroeck et al., 2000, Peters et al., 2008,
Weaver et al., 2001, McAllister and Samuel, 2008, Kohl et al., 2003, Holm et al.,
2007). This indicates the existence of IRF3-independent pathways of apoptosis
induction by PIV5. IRF3-independent modes of apoptosis induction may also be
activated by infection with other viruses: while Bunyamwera virus is still able to
induce significant cell death in cells with low levels of IRF3 expression (Kohl et al.,
2003).
PIV5-w3 was unable to induce apoptosis in IFN-competent or IFN-compromised
cells; this indicates that this virus may not produce significant amounts of the viral
inducer of apoptosis. Work by Parks and colleagues revealed that the 6 amino acid
differences between the shared P/V N-terminus of PIV5-w3 and PIV5-CPI- are
responsible for differences in viral RNA production and subsequent PKR activation
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(Gainey et al., 2008a). During PIV5-w3 infection, Gainey et al. suggest a model by
which P/V gene products decrease activity and increase fidelity of the viral
polymerase, thereby limiting production of aberrant viral RNA to prevent activation of
antiviral responses. In contrast, the P/V gene products from PIV5-CPI- are unable to
do this, so PIV5-CPI- induces IFN and apoptosis (Gainey et al., 2008a). In fact, the
three amino acid differences between the PIV5-w3 and PIV5-CPI+ P/V proteins are
sufficient to affect RNA production by these viruses (Timani et al., 2008). Both PIV5-
CPI+ and PIV5-CPI- are therefore unable to limit viral RNA synthesis. This would go
some way to explaining why PIV5-CPI+ and PIV5-CPI- induce similar levels of IFN
and apoptosis and why both viruses induce more IFN/apoptosis than PIV5-w3
(Figures 3.12 and 3.13). Interestingly though, ectopic expression of V(w3) could only
partially prevent PIV5-CPI- or PIV5-CPI+ induced cell death in this study. This may
indicate that while V(w3) expression levels in A549/PIV5/V are sufficient to deplete
STAT1, they are insufficient to limit viral RNA production by PIV5-CPI- and PIV5-
CPI+. In conclusion, there may be at least four factors dictating induction of IFN and
apoptosis by PIV5 infection: the ability of the V protein to target STAT1 for
degradation, the ability of V to bind and inhibit mda-5, the numbers of DIs in virus
stocks and the ability of V to limit viral RNA production.
Despite observations that PIV5/V(w3) can inhibit apoptosis when stably expressed in
cell-lines, apoptosis induction by FasL/CHX, TNF-α/CHX and STS was not
significantly affected in PIV5-infected cells. PIV5-CPI- and PIV5-VΔC-infected cells
did not go into apoptosis faster with these inducers than cells infected PIV5-w3 and
PIV5-CPI+ (Figure 3.14), despite differences in STAT1 expression between these
cells. IFN induced during virus infection may be affecting apoptosis induction, so it
would be interesting to repeat this experiment in IFN-deficient cells.
4.2.5 An additional role for mda-5 inhibition by PIV5/V?
In addition to limiting IFN induction, inhibition of mda-5 by paramyxovirus V proteins
may have additional, as yet uncharacterised effects in the host cell. mda-5 was first
identified as a tumour-suppressor and may play an important role in apoptosis
regulation (Kovacsovics et al., 2002, Cocude et al., 2003, Kang et al., 2002). During
apoptosis, mda-5 is cleaved by caspases; this results in liberation of the C-terminal
helicase domain from the N-terminal CARDs (the presence of CARDs may also be
an indicator of role for mda-5 in apoptosis). The helicase domain subsequently
translocates to the nucleus, where it accelerates apoptosis-induced DNA degradation
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(Kovacsovics et al., 2002, Barral et al., 2007). MAVS, the mda-5 downstream
interactor (Kawai et al., 2005), is also involved in apoptosis; it acts downstream of
RIG-I to promote IRF3-mediated apoptosis during virus infection (Heylbroeck et al.,
2000, Weaver et al., 2001, Rintahaka et al., 2008, McAllister and Samuel, 2008,
Holm et al., 2007, Zhang and Samuel, 2008). Since mda-5 also activates IRF3, mda-
5 and RIG-I may perform similar but non-redundant roles in promoting IRF3-
dependent apoptosis in response to infection with different types of viruses. In
addition, the mda-5/MAVS complex recruits FADD and RIP1 to induce IFN
(Balachandran et al., 2004, Michallet et al., 2008); FADD and RIP1 may activate
apoptotic pathways through DISC formation and activation of the caspase cascade. It
would be of interest to determine whether mda-5 inhibition by paramyxovirus V
proteins also has implications for host cell apoptosis induction. Preliminary
experiments reveal that PIV5-CPI-, which inhibits mda-5 but is unable to promote
STAT1 degradation, prevents mda-5 cleavage during apoptosis, but this may be due
to inhibition of caspase-activation rather than a direct effect of V:mda-5 interaction
(data not shown). The effects of V expression and mda-5 inhibition on dsRNA/virus-
induced apoptosis remain to be investigated.
4.3 Effects of BVDV/NPro and HCV/NS3/4A on apoptosis
In addition to PIV5/V, the effects of the viral IFN antagonists BVDV/NPro and
HCV/NS3/4A on apoptosis induction were investigated in this study. Ectopic
expression of BVDV/NPro rendered A549 and MRC-5 cells IRF3 deficient but this
was found to have no effect on TNF-α, FasL or STS-induced apoptosis. This is
somewhat surprising since IRF3 is well-described as a positive regulator of apoptosis
(Holm et al., 2007, McAllister and Samuel, 2008, Peters et al., 2008). However, PIV5-
CPI- and rUd-184-8(P), viruses that cause significant amounts of apoptosis in naïve
A549 cells, are unable to cause apoptosis in A549/BVDV/NPro. IRF3 therefore
appears to be required for induction of apoptosis during virus infection: this is
supported by previous studies which suggest that IRF3 acts downstream of RIG-
I/MAVS to stimulate apoptosis in response to viral RNA (McAllister and Samuel,
2008, Holm et al., 2007, Peters et al., 2008, Weaver et al., 2001, Heylbroeck et al.,
2000, Kohl et al., 2003). Expression of BVDV/NPro presumably inhibits dsRNA- and
virus-induced apoptosis, but is unable to affect cell death following treatment with
other inducers.
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HCV/NS3/4A clips MAVS away from the outer mitochondrial membrane and prevents
MAVS oligomerisation to inhibit IFN induction (Baril et al., 2009, Li et al., 2005b, Foy
et al., 2005). Like IRF3, MAVS is important in IFN-independent induction of apoptosis
by virus infection (Heylbroeck et al., 2000, Weaver et al., 2001, Rintahaka et al.,
2008, McAllister and Samuel, 2008, Holm et al., 2007, Zhang and Samuel, 2008).
NS3/4A has been reported to both promote and inhibit apoptosis (Nomura-Takigawa
et al., 2006, Fujita et al., 1996b, Tanaka et al., 2006, Deng et al., 2006, Ishido and
Hotta, 1998). In this study, NS3/4A expression neither promoted nor inhibited
FasL/CHX or STS-induced apoptosis in A549 cells but did reduce cell-death in
response to TNF-α/CHX treatment. This supports a report that hepatocytes stably
expressing NS3/4A were resistant to TNF-α, but not Fas-mediated apoptosis (Frelin
et al., 2006). Like BVDV/NPro, HCV/NS3/4A may play a more predominant role in
inhibiting IRF3-mediated apoptosis in response to dsRNA and virus infection.
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4.4 PI3K activation by IAV/NS1
4.4.1 Kinetics of PI3K/Akt activation in IAV-infected cells
The kinetics of PI3K/Akt during IAV infection varied considerably according to cell-
type. While IAV infection activated Akt during the first 8-12hpi in all cell-types tested,
Akt activation lasted for different lengths of time. In canine kidney MDCK (widely
used in IAV research) and Vero (simian kidney) cells, activation of Akt was extremely
transient while A549, MRC-5 and HFFF cells displayed prolonged Akt activation. The
reasons for these differences are unknown, but may represent varying virus
replication rates between cell-types. Alternatively, it may reflect apoptosis induction:
apoptosis induces caspase-mediated cleavage and inactivation of Akt (Asselin et al.,
2001, Jahani-Asl et al., 2007, Rokudai et al., 2000). MDCK cells go into apoptosis
rapidly following IAV infection (destruction of the monolayer is seen by 24hpi) while
MRC-5 cells do not die rapidly during IAV infection (Figure 3.23). A positive feedback
loop may exist: phosphorylated (active) Akt is more resistant to caspase cleavage
than unphosphorylated (inactive) Akt (Jahani-Asl et al., 2007) so may be able to
prolong cell-survival thus preventing further caspase cleavage. However, a role for
PI3K activation in delaying apoptosis is refuted by other data obtained in this study.
Because accurate, direct measurement of PI3K activity is technically demanding
(Hawkins et al., 2006), many studies, including this one, rely on phosphorylation of
Akt as a marker of PI3K activation. The kinetics of PI3K activation during IAV
infection may differ from those indicated by Ser473 phosphorylation of Akt. For
instance, there may be a significant temporal delay between PI3K and Akt activation,
and additional cellular factors may be involved in prolonging/shortening the period of
Akt phosphorylation. In addition, Akt can be activated independently of PI3K following
insulin receptor activation (Luan et al., 2009). Besides Ser473 (the marker used in
this study), there also appears to be plethora of other modifications that affect Akt
catalytic activity. For instance, Akt is phosphorylated at Thr308 and activated in a
PI3K-dependent manner (Walker et al., 1998). In addition, tyrosine phosphorylation
of Akt, at Tyr474 (and possibly also Tyr315 and Tyr326), is also required for its
catalytic activity (Chen et al., 2001b, Conus et al., 2002). These tyrosine
modifications are mediated by Src kinases in a manner that may or may not be PI3K-
independent (Chen et al., 2001b, Conus et al., 2002). There appears to be crosstalk
between these modifications, as mutation of either Ser473 or Tyr474 markedly
reduces Thr308 phosphorylation and kinase activity (Conus et al., 2002). While
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Thr308 phosphorylation of Akt during IAV infection has previously been shown (Hale,
2007), tyrosine phosphorylation of Akt downstream of the NS1:PI3K interaction has
not yet been demonstrated. To further confuse the issue, Akt can also regulate its
own activity through autophosphorylation at Thr72 and Ser246: mutation of these
sites significantly reduces its kinase activity (Li et al., 2006c). Akt activation may
therefore occur during IAV infection independently of NS1-mediated PI3K activation,
and Akt catalytic activity can not necessarily be inferred by Ser473 phosphorylation
detection alone.
4.4.2 NS1-mediated PI3K activation and host cell apoptosis
Results obtained in this study indicated that PI3K activation during IAV infection does
not mediate anti-apoptotic signalling. While introduction of the Y89F mutation into
both Udorn and WSN backgrounds rendered IAV unable to bind PI3K and activate
Akt (Figure 3.19, Hale, 2007, Hale et al., 2006), infection of epithelial and fibroblast
cell-lines with these mutant viruses did not cause significantly more apoptosis than wt
virus. In fact, neither wt nor Y89F viruses were able to cause rapid apoptosis in A549
and MRC-5 cells: despite being extremely sensitive to apoptosis inducers, a
significant proportion of MRC-5 cells were still viable up to 60hpi. Additionally, even
though PI3K and Akt are reported to mediate their anti-apoptotic roles, at least in
part, through activation of NF-kB (Bortul et al., 2003, Reddy et al., 2000, Suzuki et
al., 2008), no difference in activation of an NF-kB reporter system by rUd and rUd-
Y89F could be detected (Figure 3.31).
These findings contradict several previously-published studies which assign PI3K
activation by NS1 an anti-apoptotic role during IAV infection (Ehrhardt et al., 2007,
Shin et al., 2007a, Zhirnov and Klenk, 2007). A number of factors may contribute to
these differences. Previous work has focused on apoptotic responses of MDCK and
CV-1 cells (Ehrhardt et al., 2007, Shin et al., 2007a, Zhirnov and Klenk, 2007), while
experiments here were carried out in A459 and MRC-5 cells which are human
alveolar epithelial and lung fibroblast cells respectively, and may more accurately
reflect IAV infection in vivo.
Zhirnov and Klenk demonstrated that infection with a delNS1 virus caused
significantly more apoptosis than wt virus and attributed this effect to Akt activation
(Zhirnov and Klenk, 2007). However, given the multifunctional nature of NS1,
knocking out the entire NS1 protein may have a number of effects on apoptosis that
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are independent of its PI3K activation function. In contrast, the rUd-Y89F virus
appears to be a much more specific tool for studying the role of PI3K activation
during IAV infection since other functions of NS1 appear to be intact (Hale, 2007).
Two studies report that pharmacological inhibition of PI3K in IAV-infected cells using
LY294002 correlated with an increase in PARP cleavage and caspase-9 activation
(Zhirnov and Klenk, 2007, Ehrhardt et al., 2007). However, LY294002 is widely
regarded as a promiscuous inhibitor and directly affects activity of a significant
number of other kinases, including the PI3K downstream targets mTOR and GSK-3,
at the concentrations required to inhibit PI3K (Bain et al., 2007, Brunn et al., 1996,
Gharbi et al., 2007, Davies et al., 2000). Moreover, one study has expressly
recommended that LY294002 no longer be used in PI3K cell-based assays (Bain et
al., 2007). Additionally, LY294002 and LY303511 (a structural analogue of LY294002
that is unable to inhibit PI3K (Ding et al., 1995, Vlahos et al., 1994)) have been
demonstrated to inhibit NF-kB activity, cytokine induction and cell proliferation
independently of its effects on PI3K, and its use has previously given misleading
results in innate immunity studies (Kim et al., 2005, Hazeki et al., 2006, Kristof et al.,
2005). LY294002 and LY303511 can also promote apoptosis induced by
chemotherapeutic agents by enhancing H2O2 production (Poh and Pervaiz, 2005)
and sensitise cells to TRAIL-mediated apoptosis by inducing DR oligomerisation
(Poh et al., 2007). Receptor multimerisation is also required for sensitisation to Fas-
mediated apoptosis (Stel et al., 2007), so LY294022 may sensitise cells to other DR
ligands, independently of its effects on PI3K. In support of this, Figure 3.26
demonstrated that LY294002 treatment of rUd-Y89F-infected cells (in which PI3K/Akt
is not activated) induced more apoptosis than either rUd-Y89F infection or LY294002
alone. Wortmannin and PI-103 are alternative commercially available PI3K inhibitors,
but while they are more specific for PI3K than LY294002, these inhibitors also have
non-PI3K targets (Bain et al., 2007, Fan et al., 2006).
Pi3K/Akt activation has previously been shown to protect cells from FasL (Ivanov et
al., 2002), anti-Fas antibody (Hatano and Brenner, 2001, Moumen et al., 2007, Osaki
et al., 2004), TNF-α (Pastorino et al., 1999, Burow et al., 2000, Hatano and Brenner,
2001, Imose et al., 2003) TNF-α/CHX (Suzuki et al.), TRAIL (Oka et al., 2006,
Alladina et al., 2005, Lane et al., 2007) and STS treatment (Wan et al., 2002,
Goswami et al., 1999, Liu et al., 2008a, Shao et al., 2008, Wang and Damania,
2008). In addition, Ehrhardt et al. reported that transfection of NS1 into MDCK cells
limited STS-induced apoptosis. They concluded that PI3K/Akt activation was
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responsible for this effect because Akt activation was observed in NS1-expressing
cells. However, the multi-functional nature of NS1 means that apoptosis could be
affected independently of Akt. In this study, activation of PI3K by NS1 was found not
to protect cells from non-viral apoptosis inducers (Figures 3.22 and 3.25). In direct
contradiction with Ehrhardt et al., stable NS1 expression in A549 cells did not render
them more resistant to apoptosis induced by STS. TNF-α/CHX and FasL/CHX-
induced apoptosis was similarly unaffected. Since NS1 expression levels were lower
in these cells than during IAV infection (data not shown), high amounts of NS1 may
be required to block apoptosis. However, rUd infection was also unable to protect
A549 or MRC-5 cells from FasL, TNF-α or STS-induced apoptosis. Moreover, there
was no difference between rUd wt and rUd-Y89F-infected cells in sensitivity to these
apoptotic stimuli. These data indicate that the primary function of PI3K activation
during IAV infection is not to protect infected cells from apoptosis.
Interestingly, infection with either rUd wt or rUd-Y89F sensitised cells to FasL- and
TNF-α-induced apoptosis. This effect is probably due to global inhibition of protein
synthesis by IAV; NS1 has been shown to inhibit cellular pre-mRNA processing and
nuclear export (Fortes et al., 1994, Qiu and Krug, 1994). The ability of IAV to inhibit
translation therefore appears to have disadvantages to the virus: infected cells may
become more sensitive to the cytotoxic effects of NK cells and CTLs due to down-
regulation of anti-apoptotic proteins. A549 cells stably expressing PR8/NS1 or
PR8/NS1-Y89F were not sensitised to FasL and TNF-α however: PR8/NS1 is unable
to bind CPSF30 to inhibit cellular mRNA processing (Das et al., 2008, Kochs et al.,
2007) In addition, other viral proteins may be more important than NS1 for protein
synthesis inhibition; for example, the viral polymerase interacts directly with cellular
RNA polymerase II (Engelhardt et al., 2005), possibly to promote its degradation
(Rodriguez et al., 2007).
4.4.3 NS1-mediated PI3K activation and p53
p53 activation by Ser15-phosphorylation was observed at late times during rUd wt
infection, and appeared to correlate with a decrease in Akt phosphorylation. This is
consistent with previous studies that report p53 activation by IAV (Technau-Ihling et
al., 2001, Turpin et al., 2005, Zhirnov and Klenk, 2007). Zhirnov and Klenk
demonstrated similar kinetics of Akt and p53 activation, and in addition,
demonstrated that a delNS1 virus was unable to activate p53 (Zhirnov and Klenk,
2007). This indicated that NS1 is the viral factor responsible for p53 activation and
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implied that activation of Akt and p53 were inversely linked. However, in this study,
p53 activation was also seen during infection with rUd-Y89F, indicating that this is not
the case: NS1 appears to activate PI3K/Akt and p53 independently. Indeed, an
interaction between NS1 and p53 has been reported (Luke et al., 2005). This said
however, PI3K/Akt activation by NS1 regulates PI3K-independent NS1-mediated p53
expression and activation. rUd-Y89F-infected cells exhibited increased levels of p53
expression than rUd wt-infected cells (Figure 3.27), consistent with PI3K/Akt-
mediated down-regulation of p53 gene transcription (Chun-gen Xing, 2008) and
stabilisation of the p53 inhibitor Mdm2 (Feng et al., 2004, Mayo and Donner, 2001,
Ogawara et al., 2002). In addition, p53 phosphorylation at Ser15 was more
pronounced at 24hpi following rUd-Y89F infection than with rUd wt. While this effect
may be due to an increase in total p53 levels, it may also represent an ability of
PI3K/Akt to limit p53 activation. Indeed, PI3K has been shown to inhibit p53
activation by inhibiting its phosphorylation at Ser6 (Filiz et al., 2008). The ability of
NS1 to limit p53 activity and expression through PI3K activation does not necessarily
correlate with cell survival however. Apoptosis induced by delNS1 virus is not
accompanied by significant p53 activation, and experiments in human lung cells with
a regulated p53 gene demonstrated that IAV-induced cell death is independent of
p53 expression (Zhirnov and Klenk, 2007). The authors suggested that p53 activation
observed late in IAV infection is instead a secondary product of p53-independent
apoptotic events.
4.4.4 NS1-mediated PI3K activation may prevent apoptosis in neutrophils
IAV-infected cells are susceptible to phagocytosis by neutrophils and macrophages
in vitro and in vivo; phagocytosis inhibits virus replication and aids IAV clearance
(Fujimoto et al., 2000, Shiratsuchi et al., 2000, Hashimoto et al., 2007, Watanabe et
al., 2002, Watanabe et al., 2004, Tate et al., 2008, Fujisawa et al., 1987, Fujisawa,
2001). Phagocytic responses may be important in determining IAV pathogenicity as
inhibition of phagocytosis augments mortality in IAV-infected mice (Watanabe et al.,
2005b) and a moderately virulent IAV strain becomes severely virulent in the
absence of an efficient neutrophil response (Tate et al., 2008). Moreover, infection
with highly pathogenic H5N1 and 1918 pandemic strains is associated with rapid and
excessive neutrophil and alveolar macrophage recruitment to the lungs (Tumpey et
al., 2005, Perrone et al., 2008). It has been suggested that neutrophils function as a
vehicle for IAV replication and systemic spread (Zhao et al., 2008, Ratcliffe et al.,
1992). Furthermore, PI3K plays an important role in promoting neutrophil survival in
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response to granulocyte-macrophage colony stimulating factor (GM-SCF), TLR
ligands and hypoxia, through upregulation of Mcl-1 expression (Leuenroth et al.,
2000, Al-Shami et al., 1997, Al-Shami and Naccache, 1999, Yasui et al., 2002,
Epling-Burnette et al., 2001, Klein et al., 2000, Francois et al., 2005). IAV may
activate PI3K to prolong neutrophil survival, thereby promoting virus replication and
dissemination. NS1 from the 1918 strain of IAV hyperactivates PI3K through an
interaction with Crk/CrkL (Heikkinen et al., 2008). It is possible then that excessive
PI3K activation (and subsequent neutrophil survival and chemotaxis) is responsible
for the virulence of these strains and severity of disease symptoms in humans.
While rUd wt infection in neutrophils induced apoptosis (in agreement with previous
reports: Engelich et al., 2001, Colamussi et al., 1999), rUd-Y89F induced significantly
more apoptosis than rUd wt. These data support a role for NS1-mediated PI3K
activation in neutrophil survival. However, these results should be considered
preliminary, as PI3K activation by these two viruses has not yet been investigated in
neutrophils. In addition, it has been suggested IAV infection in neutrophils is abortive
and that these cells are unable to produce infectious virus (Cassidy et al., 1988), so
further studies are required to examine IAV replication and PI3K/Akt activation in
neutrophils.
4.4.5 NS1-mediated PI3K activation does not modulate the IFN response
PI3K is required for complete IRF3 phosphorylation and maximal IRF3 transcriptional
activity (Ehrhardt et al., 2006, Sarkar et al., 2004). In addition, PI3K can negatively
regulate IFN induction by inhibiting NF-kB (Aksoy et al., 2005) and p53 activation
promotes IFN secretion from virus-infected cells (Munoz-Fontela et al., 2008).
However, NS1-mediated PI3K activation does not appear to be involved in
modulation of IFN induction in A549 cells since rUd wt and rUd-Y89F-infected cells
produced similar levels of IFN in this study. Additionally, there was no difference in
NF-kB activation in rUd wt or rUd-Y89F-infected cells. Since PI3K-mediated inhibition
of NF-kB activity and IFN-β expression has so far only been observed in DCs (Aksoy
et al., 2005), NS1 may preferentially inhibit IFN production in these cells. DCs are
potent inducers of IFN-α/β expression during IAV infection (Cella et al., 1999,
Feldman et al., 1994) and NS1 could activate PI3K in these cells to efficiently limit
initiation of the IFN response in vivo.
122
NS1-mediated PI3K activation was not able to regulate ISRE activation or ISG15
expression (Figures 3.32 and 3.33). This is in accordance with previous reports that
PI3K inhibition is unable to affect type I IFN induced gene transcription (Thyrell et al.,
2004, Hjortsberg et al., 2007, Uddin et al., 1997). Indeed, rUd-Y89F is attenuated in
MDCK cells that are unable to respond to IFN (Hale, 2007), so the facilitatory role of
PI3K in virus replication is independent of IFN signalling, at least in MDCK cells.
However, while PI3K activation by NS1 does not affect ‘classical’ IFN signalling, it
may promote expression of a subset of ISGs independently of the ISRE. It has
recently been reported that PI3K/Akt activity is required for STAT1 phosphorylation
and STAT1-dependent expression of the chemokine CCL5 in A549 cells infected with
IAV (Huang et al., 2008b). The authors did not specify whether tyrosine or serine
phosphorylation was affected, but type I IFNs can induce CCL5 gene transcription
through a STAT1-dependent, but ISGF3-independent, pathway (Cremer et al., 2002),
suggesting that PI3K/Akt may promote STAT1 serine phosphorylation. In support of
this, PI3K/Akt promotes PKC-δ-mediated STAT1 serine phosphorylation in response
to IFN-γ (Nguyen et al., 2001, Deb et al., 2003, Uddin et al., 2002). Additional work is
required to determine whether PI3K activation by NS1 can promote transcription from
non-ISRE STAT1-responsive promoters.
4.4.6 Mutations in NS1 alter IFN and apoptosis induction by IAV
While rUd-Y89F did not to cause more apoptosis than wt virus, recombinant IAVs in
which the entire NS1 protein has been deleted (delNS1 viruses) are reported to
induce large amounts of apoptosis (Zhirnov et al., 2002, Zhirnov and Klenk, 2007,
Stasakova et al., 2005). While efforts to recover a rUd-delNS1 virus have been
unsuccessful, a range of other rUd NS1 mutants have been produced in our
laboratory. These viruses express NS1 mutations reported to interfere with binding to
dsRNA and the cellular proteins PI3K, PKR and CPSF30. In addition, a virus
expressing NS1 with a C-terminal truncation was isolated; this virus lacks most of the
NS1 effector domain. Cell viability studies of cells infected with these mutant viruses
revealed that two were notable in their induction of A549 cell death: rUd-Δ99 and 
rUd-184-8(P) (Figure 3.36 and 3.37). Induction of apoptosis appeared to be
inversely correlated with NS1 stability: rUd-184-8(P)-infected A549 and MRC-5 cells
only express low levels of NS1 protein. Similarly, NS1 was not detected in rUd-Δ99-
infected cells. Further studies carried out by D. Jackson revealed expression levels of
other virus proteins were similar between rUd-Δ99-, rUd-184-8(P)- and rUd wt-
infected cells: NS1 expressed by rUd-Δ99 and rUd-184-8(P) is therefore likely to be
Figure 4.2:  The position of mutated residues in the NS1 effector domain   
  monomer and dimer structures. 
(A) The monomer structure of the NS1 effector domain. Tyr89 is highlighted in red, Pro162, 
Pro164 and Pro167 are highlighted in green and residues 184-188 are shown in blue. Two 
proposed dimer structures of the NS1 effector domain are shown in (B) and (C). The monomers 
in each dimer are coloured magenta and green. Both cartoon and surface representations 
are shown, with Tyr89 highlighted in red. Images were prepared with PyMol (Protein Data 
Bank files 3D6R (A & C) and 2GX9 (B). 
A
B
C
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unstable in the cell. Neither rUd-Δ99 nor rUd-184-8(P) infection activated PI3K/Akt.
However, this was not the reason for apoptosis induction by these viruses, as
activation of PI3K by serum was unable to prevent apoptosis in rUd-184-8(P)-
infected cells (Figure 3.38).
The rUd-P164/7A virus, in which residues that are also reported to be important for
PI3K binding are mutated (Shin et al., 2007a), did not induce significant cell death.
This provides further evidence that NS1-mediated PI3K activation does not perform
an anti-apoptotic role. These results contradict an observation by Shin et al. that a
PR8 virus carrying the P164/7A mutation was much more apoptogenic than wt (Shin
et al., 2007a). While this contradiction could be explained by the different virus
backgrounds affecting the P164/7A phenotype, closer analysis of the primer
sequences used by this group revealed that they may have generated a with
mutations of three (P162/4/7A), rather than two (P164/7A), proline residues. To
investigate this hypothesis, a rUd-P162/4/7A virus was also produced: this virus
induced more cell death, caspase activation and nuclear fragmentation than both wt
and rUd-P164/7A in all three cell-lines tested (Figures 3.36 and 3.37; data not
shown). In addition, while Shin et al. reported that PR8-P164/7A exhibited
attenuated growth characteristics, rUd-P164/7A displays a plaque phenotype very
similar to wt virus. In contrast, rUd-P162/4/7A gave a small plaque phenotype when
titrated on MDCK cells (D. Jackson, unpublished observations). These data indicate
that the apoptogenic PR8 virus produced by Shin et al. likely expressed a P162/4/7A
mutation, and not P164/7A as was reported (Shin et al., 2007a). These prolines are
found in a turn region in the NS1 monomer (Figure 4.2A) and are presumably
required for proper NS1 folding and function. The introduction of three (or even two)
proline to alanine substitutions may have effects for the whole NS1 structure and
may abrogate multiple functions of NS1. Tyr89 does not appear to form a structural
role in the structure of the NS1 effector domain (Figure 4.2A) and the Y89F mutation
is a conservative change so is unlikely to affect the overall structure of NS1. While
the effector domain of Udorn NS1 is thought to exist as a monomer (R. Russell,
unpublished observations), the effector domains of NS1 from other IAV strains are
thought to dimerise. Two structures of the NS1 effector domain homodimer have
been proposed (see Figure 4.2), with dimer interfaces comprising of either helix-helix
(Hale et al., 2008a) or strand-strand interactions (Bornholdt and Prasad, 2006).
Analyses of these structures reveal that Tyr89 is exposed for p85 binding in both
conformations and does not appear to be involved in dimer formation: the residue is
either exposed within a cleft formed at the dimer-interface (Figure 4.2B, Bornholdt
124
and Prasad, 2006) or exposed at the edge of the dimer (Figure 4.2C, Hale et al.,
2008a). In addition, work carried out by B. Hale has shown that NS1-Y89F displays
identical subcellular localisation to NS1 wt and is still able to interact with RIG-I (Hale,
2007), indicating that the overall structure and multiple functions of NS1 are unlikely
to be affected by this mutation. Given that pharmacological PI3K inhibitors non-
specifically inhibit PI3K activity (Section 4.4.2) and the P164/7A and P162/4/7A
mutations may not specifically abrogate PI3K binding, recombinant viruses
expressing the NS1-Y89F mutation appear to be a much better tool for the study of
NS1-mediated PI3K activation.
It was interesting to note that viruses expressing the R38A, 123/4, 184-8(L) and
103/106 mutations did not induce significant amounts of apoptosis in A549 cells
(Figures 3.36 and 3.37). Introduction of an R38A mutation into a Ud NS1
background completely abrogates the ability of NS1 to bind dsRNA (Wang et al.,
1999d): the primary function of dsRNA binding NS1 is reported to be sequestration of
dsRNA away from OAS/RNaseL to prevent induction of the antiviral state (Min and
Krug, 2006). The inability of the rUd-R38A virus to cause cell death indicates that
NS1-mediated OAS/RNaseL regulation does not contribute to apoptosis inhibition by
NS1, despite the pro-apoptotic roles of OAS/RNaseL (see Introduction). The 123/4
mutation abrogates direct binding to, and inhibition of, PKR (Min et al., 2007).
Interestingly, a recombinant rUd virus expressing this mutation was previously shown
to exhibit enhanced viral RNA synthesis early in infection (Min et al., 2007), perhaps
suggesting that NS1 can prevent induction of apoptosis by limiting aberrant RNA
synthesis. The NS1:CPSF30 interaction is required to inhibit processing of cellular
mRNAs and is reported to be disrupted by the 184-8(L) and 103/106 mutations
(Noah et al., 2003, Kochs et al., 2007, Das et al., 2008, Twu et al., 2006). However,
rUd viruses expressing 123/4, 184-8(L) and 103/106 mutations did not induce more
apoptosis than wt virus. It should be noted however that binding studies between
these mutant rUd NS1 proteins and their cellular binding partners have not yet been
carried out. Interactions between each of the mutant NS1s and cellular proteins are
currently being investigated to aid the characterisation of these mutant viruses.
These studies will identify those mutations that are specific for any one binding
function, and identify those mutations that have non-specific effects on cellular
protein binding due to disruption of the overall NS1 structure.
delNS1 viruses have been shown to induce more apoptosis than wt viruses in IFN-
competent, but not IFN-deficient Vero cells (Zhirnov et al., 2002). Any inhibitory
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effects of NS1 on apoptosis are therefore likely to be a direct result of IFN
antagonism. Indeed, rUd-184-8(P) is a potent inducer of IFN as well as apoptosis in
A549 and MRC-5 cells (Figure 3.39; data not shown), and is unable to cause cell
death in A549/BVDV/NPro (IRF3-deficient; Figure 3.40) or A549/PIV5/V cells
(STAT1-deficient; data not shown). rUd-184-8(L) also induced significantly more
IFN than wt virus, in accordance with a previous report (Noah et al., 2003), but this
does not render the virus more apoptogenic. It is likely that other functions of NS1-
184-8(L) are still intact and are acting to limit the antiviral state. rUd-184-8(P) may
induce more IFN than rUd-184-8(L) either because NS1-184-8(P) is unstable, thus
unable to mediate its other functions, or because this virus produces DIs that induce
IFN and apoptosis (see section 4.2.4).
4.4.7 Potential roles for PI3K in the IAV life cycle
Previous studies have demonstrated an important role for PI3K activation in virus
replication. Pharmacological PI3K inhibition inhibits IAV growth (Ehrhardt et al., 2006)
while the rUd-Y89F virus has previously been found to be attenuated in MDCK cells
(Hale et al., 2006). This study has demonstrated that rUd-Y89F is also attenuated in
A549 and MRC-5 cell-lines, indicating that PI3K activation by NS1 is also essential
for efficient virus replication in human lung cells. However, as stated above, PI3K
activation does not perform an anti-apoptotic role in these cells, so PI3K must
enhance virus replication at another stage in the IAV life cycle.
4.4.7.1 PI3K and virus entry
Observations that wortmannin could only reduce IAV titre when administered at early
stages (less than 4hpi) in infection (Ehrhardt et al., 2006) suggested a role for PI3K
during an early step of the virus replication cycle. Moreover, a reduction in IAV
protein synthesis was observed in A549 cells treated with wortmannin, but this effect
was not due to global inhibition of cellular transcription or translation and was not due
to impaired viral polymerase activity (Ehrhardt et al., 2006). Instead, wortmannin
appeared to inhibit virus uptake at a stage prior to endosomal transport (Ehrhardt et
al., 2006); the authors suggested that PI3K may regulate interaction with clathrin-
coated pits, as virus particles appeared to remain at the cell border in wortmannin-
treated cells. It is difficult to see how NS1-mediated PI3K activation could regulate
virus entry however, as current dogma states that NS1 is not present in the virus
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particle and as such, is only produced following viral RNA transcription and
translation (Krug and Etkind, 1973, Lazarowitz et al., 1971).
4.4.7.2 PI3K and selective translation of viral mRNA
Expression of viral proteins is slower during rUd-Y89F infection than rUd wt (D.
Jackson, unpublished observations). An additional study has reported reduced viral
RNA and protein synthesis following PI3K inhibition (Shin et al., 2007b). While these
observations may be consistent with impaired virus entry, they may also indicate a
role for PI3K activation by NS1 in promotion of viral translation. As described in the
Introduction, PI3K/Akt can selectively enhance translation through the activities of
mTORC1: PI3K/Akt/mTORC1 activation causes the phosphorylation and inhibition of
p70 S6K and 4E-BP1 to stimulate mRNA translation (Kaur et al., 2008a, Kaur et al.,
2008b, Lekmine et al., 2003). Some viruses, particularly DNA viruses, activate this
pathway to enhance their replication (reviewed in Buchkovich et al., 2008); for
example, the HPV E7 protein and adenoviral proteins E4-ORF1 and E4-ORF4
activate mTORC to promote protein translation (Oh et al., 2006, O'Shea et al., 2005).
NS1 has already been attributed a role in selectively enhancing viral mRNA
translation (de la Luna et al., 1995, Enami et al., 1994, Hatada et al., 1990).
However, the effect of NS1 on translation is thought to be mediated by interactions
between NS1 and the 5’UTR of viral RNA, eIF4GI (the large subunit of eIF4F),
PABP1, and possibly hStaufen (de la Luna et al., 1995, Enami et al., 1994, Aragon et
al., 2000, Burgui et al., 2003). Furthermore, it has been demonstrated that viral
mRNA translation is insensitive to rapamycin, an mTOR inhibitor, and occurs even
when eIF4E, the target of 4E-BP1, has been functionally impaired (Burgui et al.,
2007). NS1 may be able to regulate translation in an mTORC-independent manner
however: there may be a link between PI3K activation and p58IPK, a PKR inhibitor
that is activated during IAV infection (Melville et al., 1999, Lee et al., 1990, Lee et al.,
1992). p58IPK appears to play an important role in virus replication: IAV mRNA
translation is impaired in fibroblasts from p58IPK(-/-) mice (Goodman et al., 2007). It
would be interesting to determine whether activation of p58IPK during IAV infection
occurs downstream of PI3K/Akt.
4.4.7.3 PI3K, cytokine production, cytotoxicity and chemotaxis
NS1 plays an important role in limiting inflammation and establishment of T-cell
responses during IAV infection. Upon contact with virus antigen, DCs undergo
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maturation; this upregulates cell surface receptors involved in antigen presentation to
T-cells (including MHC class II molecules) and a range of proinflammatory cytokines
and chemokines. In addition to inhibiting IFN induction, NS1 limits expression of a
significant number of other cytokines involved in DC maturation, migration and T-cell
activation, independently of its ability to globally inhibit protein synthesis (Fernandez-
Sesma et al., 2006). DCs infected with a delNS1 virus secreted significantly higher
amounts of IL-6, IL-8, IL-12, MIP-1β, CCL5 and TNF-α than those infected with wt
virus (Fernandez-Sesma et al., 2006). PI3K activation may be important for inhibition
of cytokine expression: IL-12, a cytokine that enhances NK cell and CTL cytotoxicity
(Kobayashi et al., 1989), is negatively regulated by PI3K (Kamda and Singer, 2009,
Fukao et al., 2002) while PI3K inhibits IL-6 and TNF-α production in monocytes
(Kramer et al., 2009). NS1-mediated PI3K activation may play an additional role in
downregulating FasL-mediated NK cell and CTL cytotoxicity. FasL expression is
downregulated by PI3K through p53 activation and FOXO inhibition (Ciechomska et
al., 2003, Hsu et al., 2004a). While no difference in FasL expression was observed in
A549 cells infected with rUd wt or rUd-Y89F (Figure 3.28), PI3K may play a more
predominant role in regulation of FasL expression in NK cell and CTLs.
The role of PI3K/Akt in chemotaxis is an area of intensive study (reviewed by Van
Haastert and Devreotes, 2004, Merlot and Firtel, 2003). Experiments in the
Dictyostelium discoideum amoeba revealed that, in response to chemoattractants,
PI3Ks rapidly collect at the leading edge of the cell while PTEN accumulates at the
sides and the rear (Devreotes and Janetopoulos, 2003, Iijima and Devreotes, 2002,
Funamoto et al., 2002). The result is a local concentration of PIP3 at the leading
membrane followed by recruitment of PH domain-containing proteins and pseudopod
formation. While the upstream and downstream proteins involved in PI3K-mediated
chemotaxis remain to be determined, Akt appears to be involved in mediating
downstream signals since Akt-null cells display aberrant chemotaxis in response to
cAMP (Meili et al., 1999). It appears that macrophage and neutrophil chemotaxis is
also PI3K/Akt-dependent (Li et al., 2000, Hirsch et al., 2000, Sasaki et al., 2000,
Servant et al., 2000, Wang et al., 2002a, Weiner et al., 2002). If PI3K activation were
to promote cell chemotaxis during IAV infection, it may have implications for systemic
spread of the virus (Zhao et al., 2008, Ratcliffe et al., 1992).
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4.4.7.4 PI3K and sodium transport
Recent work has demonstrated a potential role for NS1-mediated PI3K activation in
sodium transport in human airway epithelial cells. PI3K can activate the downstream
kinase SGK1, which promotes increased expression and activation of epithelial
sodium channels (Vasquez et al., 2008, Lang et al., 2003, Lang et al., 2006).
Collaborative work between our laboratory and S. Wilson (University of Dundee) has
revealed that SGK1 may be activated during IAV infection, and that infection of
human airway epithelial cells with rUd wt, but not rUd-Y89F, activates these sodium
channels to stimulate sodium transport.
4.5 Outlook
4.5.1 Implications for oncolytic therapy
Although IFN was initially hoped to be a “miracle drug” for cancer treatment due to its
pro-apoptotic properties, in practice, its use is far more limited: it is currently used in
the treatment of malignant melanoma, renal cell cancer and some types of lymphoma
and leukaemia (Bryan, 2008). While loss or down-regulation of JAK/STAT signalling
has been implicated in IFN resistance (Wong et al., 1997, Sun et al., 1998, Dron and
Tovey, 1993, Sakamoto et al., 1998), it is not always a major factor in the resistance
of tumours to IFN treatment (Choi et al., 2003). For example, activation of PI3K/Akt
renders some tumour cells insensitive to IFN: a direct correlation between Akt
activation and IFN-β sensitivity has been demonstrated in human colorectal cancer
cells (Lei et al., 2005). Additionally, in some cell types, IFN-treatment can actually
make cells more resistant to apoptosis, presumably through activation of NF-kB cell
survival signals (Pajak and Orzechowski, 2007, Tamai et al., 2006, Tanaka et al.,
2005a). The significant degree of cross-talk between IFN and PI3K in the induction of
apoptosis indicates that treatment with IFN and PI3K/Akt inhibitors may prove an
effective form of combination therapy. Further investigation into activation of
additional, non-classical pathways by IFN may highlight novel targets for anti-tumour
drugs.
The synergistic effect of IFN on pro-apoptotic cytokine action also has implications
for anti-cancer therapy. DR ligands represent an area of potential anti-tumour agents
currently being investigated (reviewed in Ashkenazi and Herbst, 2008). TNF-α is
effective in the treatment of soft tissue sarcomas (Grunhagen et al., 2006), while
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FasL has demonstrated significant efficacy against a range of tumour cells. Soluble
TRAIL or TRAIL-R agonistic antibodies appear to exhibit potent anti-tumour activity
with minimal cytotoxic effects on normal cells (Ashkenazi et al., 1999, Chuntharapai
et al., 2001, Ichikawa et al., 2001, Lawrence et al., 2001). Treatment with IFN in
conjunction with these DR agonists may vastly improve their efficiency. Alternatively,
resistant tumour cells could be specifically sensitised to these DR-mediated therapies
by selective induction of IFN in these tumours. A possible mechanism for achieving
this would be targeting of IFN-inducing viruses to tumour cells; IFN could then
upregulate expression of DRs at the cell surface and render these cells more
sensitive to subsequent treatment with DR agonists. In fact, since IFN has been
shown to induce apoptosis in established tumour cell-lines, IFN induction alone may
be sufficient to induce apoptosis in these cells (Chawla-Sarkar et al., 2001, Chen et
al., 2001a, Morrison et al., 2001, Thyrell et al., 2002). Since delNS1 viruses replicate
efficiently in IFN-deficient cells (Garcia-Sastre et al., 1998, Egorov et al., 1998), they
may be used to target those tumours that are IFN-resistant (Muster et al., 2004).
PIV5 with mutations in the P/V gene may have a similar use: a virus carrying the P/V
gene of PIV5-CPI- displays oncolytic potential in human prostate cancer cells that are
defective in IFN production (Gainey et al., 2008b). The use of paramyxoviruses and
influenza viruses as vehicles for the delivery of genetic material has been described
(Lorence and Reichard, 2006, Li et al., 1993), so recombinant PIV5 and IAV lacking
the V and NS1 genes respectively could be used due to their ability to induce large
amounts of IFN and apoptosis (Sun et al., 2004, Zhirnov et al., 2002, He et al.,
2002a, Stasakova et al., 2005).
delNS1 viruses may be able to target other tumour types, not just those that are
defective in the IFN response. NS1 mutants defective in PI3K activation can be used
to specifically target tumour cells with constitutively active PI3K/Akt. PR8delNS1
replicates to high titres in cells overexpressing oncogenic Ras and has significant
oncolytic properties in these cells, but not in non-malignant cells (Bergmann et al.,
2001). Ras promotes PR8delNS1 replication either through inhibition of PKR
(Bergmann et al., 2001, Mundschau and Faller, 1992), or by promoting PI3K
activation (Rodriguez-Viciana et al., 1994, Rodriguez-Viciana et al., 1996), both
properties are knocked out in the PR8delNS1 virus. In addition, because delNS1virus
induces apoptosis independently of p53 (Zhirnov and Klenk, 2007), it may be an
effective oncolytic agent for tumour cells that are defective in p53-dependent
pathways.
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Many tumour cells express FasL at their cell surfaces; this represents a mechanism
of immune evasion during tumour development, since these cells can actively induce
Fas-mediated apoptosis in FasL-sensitive lymphocytes (Strand et al., 1996, Shurin et
al., 1998, Muschen et al., 2000, O'Connell et al., 1996, Hahne et al., 1996, Niehans
et al., 1997, Kawasaki et al., 2000). In addition, levels of soluble FasL are elevated in
serum from patients suffering from large granular lymphocytic leukaemia and NK cell
lymphoma (Tanaka et al., 1996). Since PI3K/Akt activation can negatively regulate
FasL expression through inhibition of FOXO transcription factors (Suhara et al.,
2002, Tang et al., 1999, Uriarte et al., 2005), activation of PI3K, possibly through
NS1 expression, may downregulate FasL expression and secretion. This may
prevent induction of lymphocyte apoptosis by tumour cells, or limit FasL serum levels
in NK cell lymphoma patients, both of which may alleviate some symptoms of these
diseases.
4.5.2 Implications for anti-viral drugs
Replication of both PIV5 and IAV is impaired in the presence of PI3K and Akt
inhibitors (Ehrhardt et al., 2006, Hale et al., 2006, Sun et al., 2008a). Given that small
molecule inhibitors of PI3K and Akt are being developed for use as anti-inflammatory
and anti-cancer drugs (Yap et al., 2008, Collins, 2009), they may also have important
uses as anti-viral drugs. While inhibitors of cellular PI3K signalling pathways may be
less sensitive to drug resistance than virus-specific targets, due to the wide range of
biological functions mediated by PI3K in the cell, PI3K inhibitors may have toxic side-
effects. Inhibition of PI3K/Akt activation by IAV and PIV5 may be an attractive
approach: preliminary screens have been carried out (in collaboration with N.
Westwood, University of St Andrews) to identify potential small molecule inhibitors of
the NS1:p85 interaction. If hyperactivation of PI3K by NS1 is responsible for the
virulence of 1918 and avian IAV strains, small molecule inhibitors of the NS1:p85 and
NS1:Crk/CrkL interactions may be of pivotal importance in the treatment of these
infections.
131
4.6 Conclusions
An important function of the IFN response is to establish a pro-apoptotic state in
virus-infected cells. PI3K (and its downstream target, Akt) is an important regulator of
both the IFN and apoptosis antiviral responses and this study sought to further
investigate the crosstalk between IFN, PI3K and apoptosis. PIV5 and IAV are
negative-sense single-stranded RNA viruses that encode multifunctional proteins in
order to maximise the coding capacity of their genomes. The PIV5/V and IAV/NS1
proteins are well-studied as antagonists of the IFN response and both proteins are
reported to modulate PI3K signalling. Less well-studied is the role of these proteins in
apoptosis regulation: the ability of these proteins to inhibit apoptosis induction was
investigated. PIV5/V was found to limit cell death in response to a number of
apoptosis inducers in a manner that required its STAT1-degradative activity. In
addition, PIV5/V expression inhibited Akt activation. Apoptosis induction and Akt
activation by PIV5 strains expressing V proteins with different biological properties
was also investigated. IAV/NS1 binds directly to PI3K to stimulate its activity, and this
is reported to mediate anti-apoptotic signalling during IAV infection. However, a virus
expressing an NS1 unable to bind PI3K did not induce more apoptosis than wt virus.
NS1 expression and PI3K activation, either in a stable cell-line or during virus
infection, was also unable to protect cells from pro-apoptotic stimuli. NS1-mediated
PI3K activation similarly had no effect on IFN production or ISG expression in
infected cells. In contrast, viruses that express other NS1 mutations were able to
induce large amounts of IFN and apoptosis. These viruses were unable to cause
apoptosis in cells deficient in the IFN response, indicating that NS1 may limit
apoptosis induction through its IFN antagonist function. This work may have
implications for anti-cancer and anti-viral therapies.
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